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Summary   
In this thesis mass spectral and chromatographic techniques were developed and 
applied to identify and characterise numerous novel platinum(II) and (IV) 
compounds designed as anticancer agents. 
In a novel method for the synthesis of cis-oxalato(trans-ℓ-1,2-
cyclohexanediamine)platinum(II) or oxaliplatin these techniques could be applied 
to differentiate between the molecular complex and the autoionised analogue (viz. 
Ptdach22+Ptox22-). In another novel synthetic method for the same compound the 
ligand exchange reactions at various temperatures could be investigated and 
kinetic curves obtained served to illuminate the chemistry involved, indicating the 
role of small amounts of water in the essentially non-aqueous solvent systems dmf 
and isoamyl alcohol respectively.  These allowed ligand exchange without 
resulting in hydrolyses even up to 85°C.   
The ionisation rate of divalent platinum halide complexes was determined for 
various amine ligands as well as N-S chelate ligands.  A comparison of these 
could suggest why N-S complexes have poor anticancer action.  Ionisation was 
not only studied for neutral molecular species but also for monocationic ones.  
Relationships could be found with stereochemical aspects of the chelates used. 
By investigating results of EV-CAD studies thermodynamic data could be obtained 
which indicated that bond strength decreases from chloro to iodo analogues 
although extent of ionisation in aqueous solution, i.e kinetic stability, is the reverse. 
Products formed by the reaction of NO2 gas with Platinum(II) compounds could be 
identified and separated which greatly contributed to the understanding of the 
chemistry involved in the formation of mononitro platinum(IV) complexes.  Some of 
these proved to have exceptional anticancer properties. 
Studies of the interaction of thiol containing biomolecules were performed as a 
function of time.  The results contributed to the understanding of the action of the 
anticancer agents.  
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Chapter 1:   
Background and Introduction 
1.1 Background 
The development and first-order application of novel platinum anticancer agents 
has been the focus of the NMMU Research Unit for Platinum Group Metals since 
2003.  In collaboration with Shimoda Biotech and utilising its subsidiary Platco 
Technologies, this research has led to the granting of 3 international patents 
pertaining to the synthesis of the 3rd generation platinum anticancer drug, 
oxaliplatin.1,2,3 
The aim of the research was to synthesize novel compounds after careful 
consideration of the effects of certain parameters on the solid state and solution 
chemistry of the compounds in order to correlate these with their anticancer 
action.  These parameters include aspects such as stereochemistry, kinetics, 
biomolecule interactions and the configuration of ligands around the central 
platinum atom.  The synthetic work including synthesis of ligands, preparation of 
complexes, improvement of synthetic methods, purification and first order 
characterisation were done by post graduate students (MSc and PhD students in 
Inorganic chemistry).  Since this is an interdisciplinary research effort, a post 
graduate student in the Biochemistry Department studied the anticancer action of 
the compounds on 4 different cancer cell lines.  In addition, sophisticated 
analytical techniques such as capillary liquid chromatography and mass 
spectrometry were required to assist in the identification and characterisation of 
these compounds - especially with reference to those properties relating to their 
anticancer action, such as the formation of in-solution species and the 
determination of ligand exchange rates.  These latter aspects were the focus area 
of the author of this thesis.  The work was performed at the Shimoda Biotech 
Laboratory in Plettenberg Bay.   
In this thesis, therefore, the role of the latter aspects will be dealt with in greater 
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detail including the elucidation of basic structure, identification of “in-solution” 
species, their chemistry in aqueous solution at various temperatures and their 
interaction with certain species present in serum.  Where novel synthetic 
procedures were utilised analytical methods were required to ensure the highest 
degree of compound purity. 
1.2  Introduction 
Cancer – a historical perspective 
Cancer, so named by the Greek physician Hippocrates (460-370BC), has afflicted 
humans throughout recorded history.  It is no surprise that from the dawn of 
history physicians have written about cancer.  Some of the earliest evidence of 
cancer is found among fossilised bone tumours of human mummies in ancient 
Egypt, and ancient manuscripts.  Bone remains of mummies have revealed 
growths suggestive of the bone cancer, osteosarcoma.  The oldest description of 
cancer (although the term cancer was not used) was discovered in Egypt and 
dates back to approximately 1600 B.C.  The Edwin Smith Papyrus, or writing, 
describes 8 cases of tumours or ulcers of the breast that were treated by 
cauterisation, with a tool called "the fire drill”.  The writing says about the disease, 
"There is no treatment”.4 
In the year 2000, malignant tumours were responsible for 12 per cent of the nearly 
56 million deaths worldwide from all causes.  In many countries, more than a 
quarter of deaths are attributable to cancer.  In 2000, 5.3 million men and 4.7 
million women developed a malignant tumour and more than 6 million died from 
the disease.  In 2005, 7.6 million people died of cancer out of 58 million deaths 
worldwide.  Based on projections, the World Health Organisation (WHO) predicts 
that cancer deaths will continue to rise with an estimated 9 million people dying 
from cancer in 2015, and 11.4 million in 2030.5 
What is cancer? 
Cancer develops when cells in a part of the body begin to grow out of control.  
Although there are many kinds of cancer, they all start because of out-of-control 
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growth of abnormal cells.  Normal body cells grow, divide and then die in an 
orderly fashion.  During the early years of a person's life, normal cells divide more 
rapidly until the person becomes an adult.  After that, cells in most parts of the 
body divide only to replace worn-out or dying cells and to repair injuries.  Because 
cancer cells continue to grow and divide, they are different from normal cells.  
Instead of dying, they outlive normal cells and continue to form new abnormal 
cells.  Cancer cells develop because of damage to DNA.  This substance is in 
every cell and directs all its activities.  Most of the time when DNA becomes 
damaged the body is able to repair it.  In cancer cells, the damaged DNA is not 
repaired.  People can inherit damaged DNA, which accounts for inherited cancers.  
Many times though, a person’s DNA becomes damaged by exposure to something 
in the environment, such as ultraviolet radiation. 
Chemotherapy 
Different methods are available for the treatment of cancer.  Surgery, radiotherapy 
and chemotherapy are the 3 conventional approaches to cancer treatment.  
Chemotherapy can be defined as the treatment of a disease by means of 
chemicals that have a specific toxic effect upon the disease producing 
microorganisms (antibiotics) or selectively destroy cancerous tissue (anticancer 
therapy).   
Platinum in cancer chemotherapy  
Among the numerous chemotherapeutic agents used today, platinum anticancer 
drugs are unique in that they employ an inorganic coordination complex as the 
active entity.  This is demonstrated by the example of cisplatin or cis-
diamminedichloroplatinum(II) which was discovered in 1844 and subsequently 
became known as Peyrone’s chloride after its inventor Michele Peyrone.  It played 
an important role in the elucidation of geometrical isomerism by Werner and 
enabled Chernyaev to postulate the ‘trans-effect’ theory.6,7,8,9 
In 1965, a group led by Barnet Rosenberg published an article in Nature entitled 
“Inhibition of Cell Division in Escherichia Coli by electrolysis products from a 
Platinum Electrode”10.  They had been studying the effect of an applied electric 
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field on bacterial cell division and had noted that cell division had been halted 
without inhibiting the bacterial growth.  During the next 4 years they performed 
exhaustive tests involving a plethora of control experiments to assign a 
mechanism to the observed effect and identify the active agent.  Factors such as 
ultraviolet light, temperature, pH, dyes, osmotic pressure and magnesium 
excess/deficiency were all thoroughly evaluated together with oxidising agents 
such as hypochlorite (ClO-), chlorite (ClO2-), chlorate (ClO3-), perchlorate (ClO4-), 
hydrogen peroxide (H2O2), hydroxylamine (NH2OH) and persulphate (S2O82-).  
During this time, they discovered that the active compound actually contained 
platinum and that it was in fact cisplatin, which had formed from the reaction of the 
platinum electrode in an acidic medium in the presence of chloride and ammonium 
ions.11  Today cisplatin is one of the most widely used chemotherapeutic drugs.  
The structure of cisplatin is given in Figure 1.1 
NH3
NH3
Cl
Cl
Pt
 
Figure 1-1: Structure of cisplatin showing the square planar configuration.   
The action of cisplatin 
In attempting to elucidate the relationship between structure and function for 
cisplatin it was noticed that the geometric isomer, transplatin, did not have the 
same efficacy.11  This finding led to closer examination of the structure of the 
molecule.  Cisplatin has a square planar geometry containing a central platinum(II) 
atom surrounded by two chloride atoms and two ammonia moieties in a cis 
configuration.  It is generally believed that the anticancer action of cisplatin is due 
to its ability to bind to DNA where it interferes with normal transcription and/or 
DNA replication mechanisms.12   
As cisplatin is administered intravenously, it is transported in the bloodstream 
throughout the body.  DNA is present within the nucleus of the cells and in order 
for the drug to reach the DNA it has to pass through the cell membrane and into 
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the cytosol.  The high intercellular chloride concentration (100 mM) suppresses 
the exchange of the chloride leaving groups for water molecules.  Cisplatin thus 
reaches the outer surface of cancer cells (and normal cells) as a neutral molecule.  
Trans - membrane diffusion is thought to take place passively although facilitated 
(active) transport mechanisms may contribute to cellular uptake.13   Within the 
cells, chloride concentrations are much lower (≈4 mM) and ionisation takes place 
so that one or both of the chlorine atoms are replaced by water molecules to form 
highly reactive monoaqua and diaqua species viz. [Pt(NH3)2(OH2)Cl]+ and 
[Pt(NH3)2(OH2)2]2+.6  Less reactive hydroxo species may also be formed, 
Pt(NH3)2(OH)Cl.  The further formation of the dihydroxy species Pt(NH3)2(OH)2, is 
unlikely under physiological conditions.6 
Pt(NH3)2Cl2 + H2O  [Pt(NH3)2(OH2)Cl]+ + Cl-  (eq 1.1) 
[Pt(NH3)2(OH2)Cl]+ + H2O  [Pt(NH3)2(OH2)2]2+ + Cl-  (eq 1.2) 
The cytotoxicity of cisplatin is thought to stem from its interaction with cellular 
or mitochondrial DNA in the form of platinum-DNA-protein cross-links, 
platinum-DNA monoadducts, and intra-/interstrand di-adducts.  Initially 
monofunctional adducts are formed but these react further to produce inter- 
and intra-strand cross links.12  DNA binding occurs chiefly to the N7 atoms of 
purine nucleobases i.e. guanine and adenine.6  This binding of cisplatin to 
DNA induces structural distortions in the double helix.  Such distortions inhibit 
the DNA replication process and it is generally thought that futile attempts to 
repair cisplatin-DNA adducts may finally end up in the triggering of apoptosis 
or programmed cell death.12  
Before reaching the DNA, however, cisplatin first has to pass through the 
cytosol or intracellular solution.  Within the cytosol many potential platinum 
binding sites are also available including DNA, RNA and sulfur containing 
enzymes (metallothionein) and peptides (glutathione).  The amount of 
cisplatin that actually binds to nuclear DNA is estimated to be less than 1% of 
the amount entering the cell, with the majority ending up bound to proteins 
and other biomolecules.12 
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One of the most important scavengers of cisplatin is probably the tripeptide 
glutathione (GSH), which is present in cells at a concentration of 0.5-10 mM.  
Glutathione and other thiols (cysteine) bind rapidly and irreversibly to 
platinum.  Interaction with these nucleophiles renders the platinum complex 
inactive or detoxified, as these complexes are thermodynamically inert.14  The 
deactivated platinum-GSH adducts are excreted from the cell by the glutathione 
S-conjugate pump.12  The non-specific toxic effects produced by binding to non-
DNA targets may contribute to the mechanism of cytotoxicity of cisplatin in 
cancer cells.  For example, the reaction of cisplatin with several proteins is 
known to block their enzymatic functioning.15  A representation of cisplatin entry 
into the cell and the possible intracellular reactions is given in Figure 1.2.   
NH
NH
O
O
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O
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SH
OH
NH3
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Cl
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Figure 1-2:  Schematic representation of cell-wall transport of cisplatin and possible  
 reactions in the cell.12,16,17 
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Platinum(II) with its 5d8 e-configuration has a number of properties making it 
suitable for its role as transition metal complex.  Firstly it exhibits relatively slow 
ligand exchange rates.  This is as a function of the high covalent character in its 
bonding as well as the high crystal field stabilisation energy associated with 5d8 
and 5d6 systems (platinum(II) and (IV) respectively).  Secondly the ‘soft’ Lewis 
acid platinum has a great affinity for ligands with ‘soft’ donor atoms especially 
nitrogen and sulfur, while having a lower affinity for hard donor atoms such as 
oxygen. 
Following the discovery of cisplatin and its application as a chemotherapeutic 
agent several drawbacks emerged.  These include severe toxicity (nephrotoxicity, 
neurotoxicity and emetogensis); poor solubility; narrow spectrum of activity as well 
as the development of cisplatin resistance.  These drawbacks have led to the 
search for other antitumour active platinum complexes with improved 
pharmacological properties.12  Three main approaches are being followed: 
(1) decreasing the reactivity of the platinum complexes used in order to decrease 
toxic side-effects and detoxification processes; (2) design compounds with a 
different transport mechanism that may increase the efficacy of the drug and 
possibly help to evade certain resistance mechanisms; and (3) design of platinum 
complexes with DNA interaction structurally different from cisplatin, in order to 
circumvent resistance mechanisms related to DNA repair/tolerance.12  This has 
proven challenging.  Of the thousands of platinum compounds synthesized during 
the last 4 decades, only about 30 have entered clinical trials.18  These compounds 
can be divided into 4 structurally distinct groups. 
Type 1: Mononuclear square planar platinum(II) compounds containing either two 
monodentate or one bidentate ligand which functions as the non-leaving group 
and two monodentate or one bidentate anionic group which acts as the leaving 
group.  The orientation of the groups is cis, similar to the original cisplatin 
complex.  This type of complex has certainly received the most attention with 
examples including cisplatin and carboplatin, cis-diammine(1,1-
cyclobutanedicarboxylato)platinum(II).  These complexes follow the structure-
activity relationships developed by Cleare and Hoeschele19 , 20  in that they are 
uncharged complexes possessing a cis-configuration of relatively strongly bonded 
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leaving groups and a non-leaving group of ammines. 
Type 2: Compounds similar to Type 1 but with a trans orientation.  In recent years, 
several trans-platinum compounds have been reported to possess promising 
antitumour activity and can be divided into the following subgroups.21   Trans-
platinum(II) complexes with planar ligands; trans-platinum(II) complexes with 
iminoether ligands; and trans-platinum(II) complexes with aliphatic amine ligands.  
Type 3: The kinetically more inert platinum(IV) compounds have been evaluated 
recently in the quest to develop oral anticancer agents.  The first platinum(IV) 
compound of promise was bis(acetato)amminedichloro(cyclohexylamine)-
platinum(IV) (JM216, satraplatin).  This complex was sufficiently stable kinetically 
to resist therapeutic deactivation in the acidic medium of the stomach and could 
thus be taken orally.  It is believed that the active DNA-binding species is the 
platinum(II) species, produced by reduction of the platinum(IV) ‘parent’ drug.22  
Other advantages of these complexes include provision of axial ligand sites at 
which their lipophilicity can be further amended and their toxicity reduced (a 
consequence of their kinetic inertness). 
Type 4: During the last 20 years, a new class of platinum compounds was 
developed, viz. multinuclear platinum complexes, which are characterised by having 
two or more platinum centres per molecule.  The first of such complexes was 
developed by Nicholas Farrell and co-workers in 1988, and consisted of two cisplatin 
moieties tethered together by a linking alkyldiamine chain.  Later, transplatin 
derivatives were employed analogously and work on trinuclear complexes was 
initiated.  Since then, many polynuclear platinum complexes have been synthesised 
varying in the number of platinum centres, DNA-binding sites per centre and the 
configuration around each centre.12  One of these compounds, BBR 3464, trans-
{bis[trans-diamminechloro-platinum(II)(µ-1,6-hexanediamine)]}diammineplatinum(II) 
tetranitrate, exhibited greater potency and lower toxicity than cisplatin and is currently 
undergoing clinical development. 23 
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Figure 1-3:  Examples of platinum compounds that are used as AC agents or have been 
evaluated for possible therapeutic application.  
Following a thorough literature survey of platinum containing anticancer 
compounds, seven factors were identified as being pertinent to the activity of 
known anticancer agents.  These can be summarised as follows and the specific 
factors of each will be discussed hereafter.  (1) Configuration around the platinum 
atom; (2) lipophilicity; (3) stereochemistry; (4) kinetics; (5) biomolecule 
interactions; (6) mode of DNA binding; (7) inhibition of STAT function; (8) 
biodistribution and (9) cellular localization.  
1.3  Fundamental  aspects of cl inical ly act ive 
plat inum compounds 
1.3 .1 Cis  vs  t rans  conf igurat ion 
Due to the inactivity of transplatin, the trans isomer of cisplatin, early research into 
platinum drug development was mainly focused on derivatives with a cis configuration 
i.e. one bidendate or two monodendate non-leaving groups (usually consisting of a 
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simple amine or ammonia) and one bidendate or two monodendate leaving groups.  
This is evident from the fact that of the thousands of platinum compounds screened 
for anticancer activity since 1971, only about 30 have entered clinical trials and 
among them only carboplatin and oxaliplatin (both having a cis configuration) have 
received world wide approval so far.24  The diminished activity of transplatin was 
thought to be due to its rapid ionisation in water.  When compared to cisplatin it was 
found that transplatin underwent aquation 4 times faster and would thus be more 
susceptible to reaction with cellular constituents – further decreasing the likelihood of 
transplatin reaching the DNA.25  However recent studies have revealed that not all 
trans compounds have diminished activity.  When planar ligand26 iminoethers27 and 
branched amines 28  are used or when used in platinum(IV) or multinuclear 
complexes,25 some of the latter have shown greater efficacy and lower toxicity than 
cisplatin.23 
Based on the currently approved platinum drugs it would appear as if active 
compounds are mostly of the cis configuration (cisplatin, carboplatin, oxaliplatin 
and nedaplatin).  However, the time span between a new drug candidate testing 
positive in a cell line test and finally reaching the market can be protracted.  
Current research shows that the nature of the ligands and the oxidation state of 
the central platinum are as important as the configuration. 
1.3 .2 L ipophi l ic i ty 
In order to reach the DNA, platinum molecules must pass through the cell and 
nuclear membranes.  As these membranes consist of hydrophobic lipid bilayers, 
passive diffusion would favor a more non-polar molecule.29  It has been found that 
cytotoxicity can be raised by increasing the non-polar nature of axial ligands in 
platinum(IV) complexes and this is probably due to greater accumulation of 
platinum in the cell,  which is a result of improved permeation.30   
1.3 .3 Stereochemistr y 
When comparing the guanine-guanine platinum adducts (d(GpG)Pt) formed by 
cisplatin and oxaliplatin, it was found that the major difference was the protrusion 
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of the dach moiety into the major groove of the DNA for the oxaliplatin adducts.31  
This can explain why platinum adducts with the dach ligand were more effective 
inhibitors of replication and transcription than cis-diamine adducts.32  Platinum-
DNA adducts with significant steric hindrance may also play a role in overcoming 
resistance due to ‘tolerance’ of conventional cisplatin-DNA adducts.  If we again 
look at cisplatin vs oxaliplatin we find that cisplatin depends upon the proteins of 
the mismatch repair (MMR) pathway for maximal toxicity.  Certain cell lines used 
for anticancer testing are deficient in MMR and are resistant to cisplatin.  These 
cell lines are often not resistant to oxaliplatin and this could be attributed to the 
fact that MMR proteins are unable to bind correctly to oxaliplatin-DNA adducts due 
to the steric hindrance of the dach group.33,34,35 
Stereochemical crowding is an important parameter in decreasing the ligand 
exchange rate or reactivity of a platinum coordinated complex.  By crowding the 
nitrogen ligands with alkyl substituents it becomes difficult to coordinate with the 
platinum.  These alkyl-crowding groups could also present a physical barrier to 
donation by large sulfur atoms present in biological fluid.  This has been 
accomplished with the platinum(II) compound ZD0473.36  The crystal structures of 
ZD0473 cis-amminedichloro(2-picoline)-platinum(II) and its analogue cis-
amminedichloro(3-picoline)platinum(II) were reported and showed that the pyridine 
ring was tilted by 102.7° with respect to the PtN2Cl2 square plane in the former and 
only by 48.3° in the latter.  This effectively placed the 2-picoline ring of ZD0473 
directly over the square plane, which would hinder an axial approach of the platinum 
metal from above thereby slowing down the rate of substitution.6,37  Indeed, studies 
showed that the rate of ionisation of the Cl- ligand trans to NH3 (cis to 2-picoline) was 
about five times slower than cisplatin and two to twelve times slower than the 3-
picoline analogue (due to less steric hindrance in the latter complex).6,36,37 
Cl
Cl
H3N
N
Pt
CH3
Cl
Cl
H3N
N
PtCH3
 
Figure 1-4:  Structure of cis-amminedichloro(2-methylpyridine)platinum(II) (ZD0473 or 
picoplatin) (left) and its analogue cis-amminedichloro(3-
methylpyridine)platinum(II) (right).  
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Decreased stereochemical crowding can also result in decreased anticancer 
activity.  This is in contrast to the former but stems from the notion that the 
presence of at least one hydrogen atom on the coordinating amines is necessary 
for activity.  This hydrogen is suspected of stabilising the resulting platinum-DNA 
adducts through hydrogen bonding.19   
The diagram in Figure 1-4 indicates that the ‘crowding’ CH3 group of 2-picoline is 
not on the coordinating nitrogen but rather on the adjacent carbon.  To harness 
stereochemical crowding in the design of a suitable platinum coordination complex 
it would seem possible that bulky ligands can be used to avoid detoxification by 
thio compounds, but the crowding should not be directly on the coordinating 
amines.  A compromise should thus be sought with regard to stereochemical 
crowding.  
1.3 .4 Kinet ics  
The ligand exchange rate of the coordinated platinum complex determines the 
reaction kinetics of the drug and thus directly influences the efficacy thereof.  An 
exchange rate that is too fast results in the platinum being exposed to biological 
thiol entities such as metallothionein proteins, methionine or glutathione.  Once 
bound to any of these compounds the drug is no longer available for interaction 
with the DNA and can be considered detoxified.  On the other hand a ligand 
exchange rate that is too slow would result in the drug being inert and although 
being available for DNA interaction, reaction would be unlikely.  An intermediate 
exchange rate is thus desirable.   
Ligand exchange reactions in square planar platinum(II) complexes largely occur 
via a 5-coordinate trigonal bipyramidal intermediate, by an associative process 
(SN2) although a dissociative mechanism (SN1) may be favoured with bulky 
ligands .  Ligand exchange is usually governed by the ‘trans-effect’ rule i.e.  the 
capacity of a coordinated ligand to labilize a ligand trans to it.  The normal order of 
trans-directing nucleophiles is:  
thioethers >SC(NH2)2 >NO2- ~I- ~SCN- >Br- ~Cl- >amines ~ NH3~OH-~H2O. 
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The above sequence is based on the kinetics of the reaction of these complexes 
with pyridine.38  From this sequence it is clear that sulfur donor ligands will readily 
displace other ligands commonly found in blood plasma (chloride, amines or 
water) and it is for this reason that they are used to demetallate mercury and lead 
from a biological system.  Evidence for this is apparent in the results of urine 
analysis where it has been shown that a proportion of cisplatin is excreted bound 
to sulfur.38  However, as stated above, the sequence is based on the kinetics of 
reaction of these complexes with pyridine and as such there are a number of 
exceptions to the rule.  These exceptions become important when trying to 
optimize ligand exchange rates in drug development and are discussed briefly 
below. 
• The cis-effect tends to dominate when the coordinating ligands have a weak 
trans-effect. 39   This is usually the case for compounds of the form 
Pt(NH3)2Cl2.  According to the trans-effect series, Cl- > NH3; however, it is 
found that Cl- is labilized in preference to NH3 as is evident in the ionisation 
of cisplatin. 
• The nature of the co-ligands also plays an important role as it has been 
found that the presence of electronegative co-ligands (nitrogen and oxygen) 
can decrease the trans directing strength of a sulfur donor ligand.  This is 
due to an increase in the effective nuclear charge on the platinum centre 
reducing its pi-backbonding capability toward the sulfur nucleophile.  Such 
properties are referred to as biphillic.39 
• In sterically hindered systems the nucleophilicity sequence is also changed.  
This is evident in the case of ZD0473 (See1.3.3) where the formation of a 5-
coordinate intermediate results in slower kinetics.   
• Bidendate leaving groups tend to have slower kinetics than monodendate 
leaving groups (chelate effect) as can be seen when comparing the 
ionisation rates of carboplatin and cisplatin.  Studies have shown that the 
rate of aquation of carboplatin was a hundred times slower than that of 
cisplatin and this had been attributed to the enhanced stability of the 
chelated weak acid, 1,1-cyclobutanedicarboxylate.40 
The above factors can act in combination to complicate any predictions based on 
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the nucleophilicity series. 
The oxidation state of the platinum also plays a major role in the reaction kinetics 
as the six coordinate platinum(IV) is much more inert than the four coordinate 
platinum(II).  This is due to the higher effective nuclear charge and greater crystal 
field stabilisation energy of the former.  This attribute was exploited in the 
development of JM216, a platinum(IV) drug which has 2 carboxylate groups in the 
axial positions.  The more inert nature of the platinum(IV) ensures that it was less 
susceptible to detoxification by thiols.  As it is also less likely to undergo aquation, 
the drug can be taken orally and is currently undergoing clinical trails. 
1.3 .5 Biomolecule  interact ion 
Although the precise mechanism underlying antitumour action of platinum drugs is 
not completely understood, they are known to bind DNA primarily by forming 
bifunctional adducts.  The anticancer activity of cisplatin and its analogues can be 
attributed to a unique type of 1,2-GG or AG intrastrand cross link with platinum 
crosslinking N7 atoms of neighbouring purine residues of DNA.41  However before 
the platinum can find its GN7 target it has to pass through the bloodstream, cell 
membrane and the intracellular solution or cytosol.  During this passage the 
platinum drug may come into contact with numerous biological compounds.  
Those containing class B nucleophiles such as sulfur atoms are especially 
important as they can form very stable complexes with platinum.  This detoxifying 
effect not only removes the drug, but binding of platinum to certain thiol containing 
proteins is thought to be the reason for the toxic side effects.   
The two most significant groups of biomolecules encountered by platinum in the 
cell are DNA nucleobases (primary target) and sulfur containing compounds. 
1.3 .5 .1 P lat inum – DNA interact ion 
Elucidation of the basic structure of DNA by Watson and Crick, in 1953, stands as 
a milestone in the development and understanding of genetics.  In order to 
appreciate aspects involved in the formation of platinum-DNA adducts we need to 
briefly look at the fundamentals of the DNA structure.  The DNA in the nucleus of 
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all eukaryotic cells consists of two strands coiled into a double helix and packed 
into a compact form by coiling around histone proteins.  Each strand consists of 
nitrogenous bases (purines: guanine (G), adenine (A) and pyrimidines: cytosine 
(C), thymine (T)) linked to a sugar-phosphate backbone (see Figure 1-5).  The 
strands run in opposite directions with complimentary bases linked by hydrogen 
bonding: guanine pairs with cytosine and adenine with thymine.8  There are thus a 
number of nitrogen atoms available to the platinum(II) for binding.  The order of 
preference depends upon a number of factors such as the basicity of the donor 
atom, interligand interactions and steric factors. 42   These steric factors are 
exacerbated in the case of double stranded DNA where some of the donor sites 
are involved in intermolecular hydrogen bonding.43  The potential binding sites for 
platinum(II) on DNA are indicated in Figure 1-5. 
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Figure 1-5: Possible binding sites for platinum(II) on the bases of single-stranded DNA.  
In double-stranded DNA, only GN7 and AN7 are accessible from the solvent.  
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A list of the factors favoring or hindering possible platinum interaction for each of 
the candidate nitrogen atoms was summarised by Jaganath44 (Table 1.1.) 
Table 1-1: Factors disfavouring platinum(II) coordination through various purine and 
pyrimidine nucleobase N-donor sites in double stranded DNA. 
Nucleoside Site pKaa Commentsb 
Guanine N1 9.2 
I. Protonated at physiological pH 
II. Involved in H-bonding within DNA helix 
III. Steric hindrance by exocyclic amine at C2 
 
N2c 
  
 N3  
I. Observed only with excess platinum8 
II. Site is sterically hindered45 
 N7 2.2 I. Potential steric hindrance by 6-oxo group 
Adenine N1 3.6 
I. Involved in H-bonding within DNA helix 
II. Steric hindrance by exocyclic amine N6 
 N3  I. Site is sterically hindered45 
 N7 -1.6 I. Steric hindrance by exocyclic amine N6 
 
N6 c 
 I. Pt adducts rarely observed8 
Cytidine N3 4.3 I. Involved in H-bonding within DNA helix 
 N4 16.7 
I. Only observed in a N3-N4 chelate with 
Platinum(IV)8 
Thymidine N3 9.6 
I. Protonated at physiological pH 
II. Involved in H-bonding within DNA helix 
a
 pKa values were taken from Martin46,47 
b
 Comments adapted from Martin unless otherwise indicated48 
c Exocyclic amine  
From the evaluation above it appears as if two of the sites are better favoured for 
platinum(II) interaction i.e. these sites are not protonated, exposed to solvent, are 
uninvolved in Watson-Crick hydrogen bonding and suffer minimal steric hindrance.  
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They are the N7 atoms of guanine and adenine. 
In order to compare the two nitrogen donors, space-filling models and charge 
distribution values were obtained as shown in Figure 1-6. 
               
 Adenine  
           
 Guanine  
Figure 1-6: Space-filling models and charge distribution values for adenine and guanine.  
The first difference visible in the diagrams above is that the GN7 atom suffers less 
stereochemical crowding than the AN7 atom facilitating approach by a platinum 
complex. 
From the charge distribution diagrams we can see that the negative charges on 
the two atoms adjacent to the N7 atoms differ significantly.  Those adjacent to the 
guanine base were higher than those of adenine, resulting in a greater potential 
for induction (electron transfer) by platinum(II).   
As indicated by the pKa value of guanine (pKa 2.2), the bond formed with platinum 
will be stronger than that of adenine (pKa 1.6), leading to a stronger platinum-
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nitrogen bond. 
Once a platinum(II) complex is bonded to the N7 atom of either guanine or 
adenine, hydrogen bonding can occur between the nearby O6 atom of guanine 
and the platinum compound.  By contrast, there will be repulsion from the protons 
on the exocyclic NH2 of adenine.  This is demonstrated in Figure 1.7. 
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Figure 1-7: Cis-platinum complex binding at G vs. A: the preference for G can be 
explained by hydrogen bonding.  
The arguments presented above are supported by the fact that competitive binding 
assays under in vivo conditions have shown that GN7 binding of a cis-platinum(II) 
complex occurs in preference to AN7 binding.  These studies also evaluated various 
sulfur containing bio molecules present in the cytoplasm and showed that the 
preferred sequence was in fact glutathione (thiol) > guanine N7 > methionine 
(thioether) > adenine N7.49  The interaction of sulfur donors with platinum is discussed 
below.  
1.3 .5 .2 P lat inum sul fur  interact ion 
The trans-labilizing potential of sulfur donors in square planar platinum(II) complexes 
is well known.  Due to this large nucleophilicty, sulfur-containing molecules such as 
diethyldithiocarbamate (ddtc), sodium thiosulphate (sts) and thiourea (tu) are often 
employed as so-called ‘rescue’ or ‘protecting’ agents.50  These are often administered 
simultaneously or shortly after administration of the platinum complex and are 
believed to minimize binding to detoxifying sulfur nucleophiles in the body and may 
also prevent platinum-protein binding, thus diminishing toxicity.14   
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There are two kinds of sulfur donors based upon the thermodynamic stability of 
their platinum(II) complexes.  Firstly, thioethers and sulfoxides, which are known 
for their σ-donor pi-acceptor capability and, secondly, thiols and compounds like 
thiourea, which essentially act via σ-donor pi-donor action.  The latter group forms 
more thermodynamically stable complexes with platinum(II) than the former.  The 
reason for this is that the thiol sulfur can very readily be deprotonated by the very 
‘soft’ 5d transition metal platinum, in effect changing it from a neutral to a 
monoanionic one with all the covalent ‘equipment’ available to satisfy the 
nephelauxetic character of platinum(II).  Thioethers however, can be regarded as 
virtually neutral sulfur atoms having a lower order of donicity. 
Intermolecular competition studies have shown that platinum-thioether bonds can 
be reversed and changed to Pt G-N7 bonds, which although formed more slowly, 
are thermodynamically preferred.14  However platinum thiol bonds were found to be 
essentially irreversible.  This is in accordance with the sequence presented above. 
Based on the much larger size of the sulfur atom (see Figure 1-8), it becomes 
apparent that stereochemical crowding of the platinum center will slow down 
interaction with sulfur donor molecules.  As interaction proceeds via the formation 
of a trigonal bipyramidal complex, the smaller N7 of guanine (see Figure 1-6) will 
be less affected by this crowding.  Figure 1-8 shows the space filling and charge 
distribution diagram of cysteine as an example.  
                     
Figure 1-8: Space-filling model and charge distribution values for cysteine.  
There are two examples of how the presence of biothio-compounds can actually 
assist in the function of platinum chemotherapeutic complexes.  Firstly, orally 
administered platinum(IV) complexes can be reduced to their active platinum(II) 
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counterparts in-vivo, as in the example of JM216.  This activation is possible as sulfur 
donors such as glutathione, cysteine and methionine are in fact biological reducing 
agents.  Secondly, thioether binding, mentioned previously, may protect complexes 
from irreversible deactivation arising from attack by thiols.  In addition, it is now also 
believed that platinum-sulfur interactions may serve as a drug reservoir for DNA 
platination, thus affording an additional pathway towards this end.51  
1.3 .6 Mode of  DNA b inding 
The cytotoxicity in platinum chemotherapy is largely attributed to DNA intercalation 
as has been shown in cisplatin and carboplatin.31  In the case of cisplatin, binding is 
dependant upon ionisation of the first chloride leading to the formation of the cation 
[Pt(NH3)2(OH2)Cl]+.  It is thought that electrostatic interaction with the polyanionic 
DNA precedes covalent boding.6  Loss of the second chloride leads to formation of 
bifunctional adducts with the DNA.6  This process occurs more slowly for carboplatin 
and oxaliplatin, due largely to the slower ionisation rates (both have a bidendate 
dicarboxylate leaving group as opposed to the two monodendate chloro atoms of 
cisplatin).  The dach ligand of oxaliplatin was also found to retard bifunctional 
adduct formation due to steric interactions with the DNA.32   
The adduct profile of cisplatin (as depicted in Figure 1-9) includes 1,2-GpG 
intrastrand cross-links (60-65%) and 1,2-ApG intrastrand cross-links (20-25%).  
Minor adducts such as intrastrand 1,3-GpG (~2%) and interstrand cross-links 
(<1%) have also been observed.12,6 
 
 Figure 1-9: Types of cisplatin-DNA adducts and their frequency of formation.3,4 
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There is much debate over which of the above adducts are responsible for the 
activity of cisplatin.6,12  Support for the abundant 1,2-GpG adducts came from 
findings that the nucleotide excision repair (NER) system, an important DNA repair 
pathway, repaired 1,3-intrastrand adducts more efficiently than 1,2-intrastrand 
adducts.12  In addition, the 1,2-GpG adduct proved to be the most inhibitory lesion 
of DNA polymerases involved in DNA replication. 52   The argument that the 
intrastrand rather than the interstrand lesions were responsible for cytotoxicity was 
supported by observations that trans-diamminedichloroplatinum(II), which formed 
interstrand cross-links more efficiently and rarely formed intrastrand lesions, was 
considerably less cytotoxic.53 
Several multinuclear platinum complexes have also been evaluated in the search 
for novel anticancer agents.23  The feature that most distinguishes multinuclear 
complexes from cisplatin and other mononuclear platinum complexes, is their 
ability to form long-range adducts that span several base pairs.54  (See Figure 
1-10). 
  
     (Pt ,Pt) Interstrand Cross-link      (Pt, Pt) Intrastrand Cross-link  
Figure 1-10: Schematic showing long-range inter- and intrastrand binding modes 
possible for binuclear DNA-binding complexes.15 
Most notable of these is BBR3464.  It was shown that the 1,4-interstrand cross-
links formed by this highly active trinuclear platinum complex were not removed by 
NER suggesting that they might persist longer and so contribute to the 
cytotoxicity.55 
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1.3 .7 Inhibi t ion of  STAT funct ion 
DNA intercalation is not the only mechanism by which platinum chemotherapy 
drugs kill cancer cells.  Recently the platinum(IV) compounds CPA7 and IS3 295 
were shown to perform the same function through disruption of cellular signaling 
mechanisms.56,57  The signaling mechanisms involved are complex and beyond 
the scope of this work, but to understand the action of the platinum compounds in 
this process we need to briefly look at the fundamentals involved.   
Normal STAT function 
In order for cells to respond to their environment, external stimuli must be received 
and transmitted to the nucleus.  This results in activation of genes that lead to 
specific biologic responses.  STAT proteins are normal constituents of cells, the 
acronym standing for signal transduction and translation.  Although there are 
several STAT proteins, STAT3 activity is frequently up regulated in many human 
tumours. 
Many cytokines, lymphokines, and growth factors signal through a related super 
family of cell surface receptor tyrosine kinases that are associated with activation 
Janus kinases (JAKs).  The process begins with a growth factor or cytokine 
binding to their specific receptors on the cell membrane.  This results in the 
activation of enzymes called tyrosine kinases, which in turn cause tyrosine 
phosphorylation of the STAT protein.  This in turn causes phosphotyrosine 
interactions between two STAT monomers and the formation of dimers.  
Dimerisation activates the STAT proteins.  In the translation phase, the STAT 
protein migrates to the nucleus, where it binds to promoter elements on the DNA 
molecule, leading to expression of target genes.  The process is summarised in 
the Figure 1-11. 
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Figure 1-11: Outline of the key steps in the JAK STAT pathway.58  
Disrupted STAT function in cancer cells 
Cancer cells utilise a mechanism whereby tyrosine kinases that are not associated 
with specific receptors can activate STAT proteins directly.  The resultant STAT 
proteins are in a state of constant activation, thereby bypassing the normal finely 
tuned control mechanisms and causing a malfunction in the cellular signaling 
apparatus. 59   One of the effects of these "constitutive" STAT proteins is the 
inhibition of p53 gene expression.  The p53 protein is involved in the 
‘maintenance’ of the DNA.  When mutations are found the levels of p53 rise and 
bind to specific segments of the DNA, which activate or inactivate certain genes 
involved with cell growth.  If the cell cannot repair the defects, p53 initiates 
apoptosis, or programmed cell death.60  A second effect is on the process of 
angiogenesis.  In order for a tumour to continue to grow, it must also continue to 
develop new capillaries to provide nutrients and oxygen.  The most potent 
angiogenesis-inducing signal is vascular endothelial growth factor (VEGF).  
Studies have shown that STAT3 is a direct transcriptional activator of the VEGF 
gene.61  A third result of STAT3 up-regulation is the promotion of the expression of 
genes that act to inhibit apoptosis.62 
Platinum STAT interaction 
It has been shown that IS3 295 interacts with STAT3 thereby inhibiting the protein 
binding to its DNA target.  The activity is thought to be as a result of 
conformational changes in the STAT3 protein or due to irreversible binding of IS3 
295 to STAT3.57  Studies have shown that unlike the classical DNA alkylating 
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agents such as cisplatin and oxaliplatin, there is very little evidence that IS3 295 
denatures the STAT3 target area (consensus binding oligonucleotide sequence or 
hSIE) on the DNA.57 
Turkson et al.56 found that the novel platinum(IV) compounds, CPA1, CPA7, and 
platinum(IV) tetrachloride blocked STAT3 activity in vitro at low micromolar 
concentrations.  In malignant cells that harbour constitutively activated STAT3, 
CPA-1, CPA-7, and platinum(IV) tetrachloride inhibited cell growth and induced 
apoptosis.  By contrast, cells that do not contain persistent STAT3 activity were 
only marginally affected by these compounds. 
1.3 .8 Biodist r ibut ion and cel lu lar  local isat ion 
As desirable as hydrophilicity is in getting the drug to dissolve in water, so 
hydrophobicity is required for the enhancement of cross membrane transport by 
passive diffusion.  Aqueous solubility can be increased by changing the 
monodentate chloro ligands with oxygen rich carboxylates, such as oxalate or 
malonate.  However this change not only increases the solubility but also alters 
the kinetics and advantages gained in the form of increased solubility may be lost 
due to an increase in the inertness of the complex.  Another way of gaining 
solubility is by oxidation of platinum(II) to platinum(IV).  The enhanced solubility of 
such a complex, coupled with the inertness conferred by the higher oxidation 
state, would facilitate its distribution in the body and make it amenable to oral 
administration.   
The exact mechanism of trans membrane movement is not yet fully understood, 
with evidence in favour of both passive diffusion and facilitated diffusion or active 
transport.  It has been shown that by increasing the lipophilic nature of the 
complexes, cellur uptake is increased and resistance due to decreased platinum 
accumulation is circumvented.63   
1.3 .9 Targeted drug del iver y 
The severe toxic side effects associated with the use of cisplatin and other platinum 
anticancer agents is directly attributable to their indiscriminate cellular action, where 
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no distinction is made between healthy and cancerous cells.  Consequently research 
efforts have focused on finding ways of forcing the drugs to preferentially target 
cancerous cells over healthy cells.  There have basically been five different 
approaches to this problem and these are discussed briefly below. 
(1)  Passive tumour targeting based on the EPR effect 
As a result of compromised vasculature, tumours are often hyperpermeable to 
macromolecules.  Combined with a lack of effective lymphatic drainage, also 
common in tumours, accumulation of such macromolecules can take place.  This 
‘enhanced permeability and retention effect’ (so-called EPR effect) can lead to 
increased drug concentration within the tumour tissue if the therapeutic agent is 
coupled to a macromolecular carrier, or packed inside a nano-sized particle. 64  
Platinum based applications that exploit the EPR effect include liposomal formulations 
of cisplatin (SPI-77 and lipoplatin)65,66 and polymer drug delivery systems in which the 
active drug is linked to a polymeric carrier while circulating in the blood to be released 
at the target.  An example of the latter is AP5280 which consists of a platinum(II) 
diamine linked to N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer via an N,O-
chelating unit.  Intercellular release of the drug is thought to occur as a result of 
proteolytic cleavage of the short peptide bridge linking the drug to the polymer, or 
through release of the platinum from the chelating ligand via ionisation. 67 
(2)  Receptor mediated targeting 
Tumour associated receptors on the outer surface of cancerous cells present a 
unique target for drug delivery.  By tailoring the drug to have high affinity for such 
receptors the drug can be endocytosed (taken up) by specific cells.  Receptors 
associated with cell growth and division, are often over expressed on tumours, 
thus providing obvious targets for cancer therapy.  Many platinum compounds with 
receptor-specific appended ligands have been prepared including drugs targeted 
to oestrogen receptors, folic acid receptors and oncofoetal protein receptors.67 
(3)  Enzymatically activated prodrugs 
A number of enzymes are found in highly increased concentration around tumour 
tissue.  Selective generation of a cytotoxic drug from an inactive prodrug is 
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feasible with antibody-directed enzyme prodrug therapy (ADEPT), or with prodrug 
monotherapy (PMT).  This involves a single administration of the prodrug, which is 
activated locally to yield the active drug.64  In one in vitro study the compatibility of 
platinum compounds towards β-glucuronidase-based prodrug therapy was 
investigated. 68   Instantaneous cleavage of the β -glucuronic bond in the 
glucuronyl-platinum conjugate was observed upon addition of β-glucuronidase 
resulting in the release of platinum(II)(dach)(4-hydroxybenzylmalonate) and 
glucuronic acid.  See Figure 1-12.  
 
Figure 1-12: Reagents and conditions: Deuterated phosphate buffer (pH 7.2), b-
glucuronidase, 37 ºC.68  
(4)  Compounds targeted towards cellular DNA 
Cellular DNA is the single most studied target for platinum antitumour drugs and 
many platinum drug designs have sought to exploit this interaction.  One avenue 
explored, sought to introduce a positive charge on the platinum drug thereby 
increasing its affinity for the polyanionic phosphate backbone of the DNA. 69  
Another method involved tethering different types of DNA targeting ligands to 
platinum complexes such as oligonucleotides, intercalators and DNA-groove 
binders.70,71 
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(5)  Platinum prodrugs with an acidic pH optimum 
Solid tumours are often hypoxic due to an insufficient blood supply.  They 
draw their energy mainly from glycolysis, which results in production of large 
amounts of lactate accompanied by the release of protons.  Both lactate and 
H+ are transported into the interstitial fluid therefore the intracellular pHi and 
the extracellular pHe are decreasing with increasing tumour size.72  A high 
concentration of H+ outside the tumour cells is a problem for weakly basic 
drugs as protonation leaves them more lipophobic and less likely to penetrate 
the cell membrane.  
1.3 .10 Plat inum resistance 
Treatment of cancer by platinum chemotherapy is characterised by resistance, 
both acquired and intrinsic.  Platinum resistance decreases the efficacy of the 
agents necessitating the use of higher or more prolonged doses with the 
accompanying increase in toxicity.  By understanding platinum resistance new 
drug designs attempt to circumvent the mechanisms involved.  These 
mechanisms can be divided into 2 broad categories viz. classical resistance 
mechanisms and newer molecular based resistance factors.73   
Classical resistance mechanisms include factors such as blood flow and drug 
delivery; the extracellular environment; drug uptake; drug efflux; drug 
detoxification; drug binding; DNA repair; decreased DNA mismatch repair; 
reduced apoptotic response and apoptosis inhibitors.  Selected examples are 
given below: 
The tumour extracellular environment is often acidic while the tumour 
intracellular pH is neutral to alkaline.74,75  A pH gradient with extracellular pH < 
intracellular pH favors the uptake of weak acids74 and cisplatin uptake is markedly 
increased at low extracellular pH. 
A correlation has been found between the reduced drug uptake of cisplatin in 
resistant cell lines and an increase in the rigidity of cell membranes with high 
sphingomyelin and cholesterol content. 76 77   This increase in rigidity could 
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potentially alter either passive drug diffusion or activity of membrane transport 
systems. 
Copper competes with cisplatin for uptake into cells, but also reduces cisplatin 
efflux, and may increase cisplatin net accumulation and cytotoxicity. 78  
Overexpression of the copper-transporting P-type adenosine triphosphatase 
ATP7B is associated with poor outcome in cisplatin-treated patients with 
esophageal cancers 79  and squamous cell cancers of the head and neck, 80 
suggesting that ATP7B-associated platinum efflux could potentially contribute to 
clinical platinum resistance.   
Drug detoxification has been linked to increased intracellular glutathione (GSH) 
concentrations, which may cause resistance81 , 82 , 83 , 84 , 85  by binding/inactivating 
cisplatin, enhancing DNA repair, or reducing cisplatin-induced oxidative stress.86 
Platinated DNA damage repair is primarily executed by the nucleotide excision 
repair (NER) system ERCC1 and related genes.87,88  Overexpression of ERCC1 is 
associated with reduced efficacy of platinum based therapy in ovarian cancer.89 
A summarised overview by David Stewart73 of the current understanding of platinum 
resistance, including the newer molecular factors is given Table 1-2. 
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Table 1-2: Summarised overview of the current understanding of platinum resistance.73 
Mechanism  Contributing factor  
Impaired blood flow/drug delivery ↑ Tissue pressurea ↑ Plasma fibrinogenb ↑ Blood viscosityb 
 
↓ Blood pressuree ↓ RBC deformabilityb 
 
 
Extracellular matrix/other factors ↑ Tissue pressurea/↓ diffusion ↑ γ-Glutamyltransferase  
 ↑ Fibronectin ↑ Type IV collagen ↑ Laminin 
 
Decreased drug uptake ↑ Cell membrane rigidity ↑ Sphingomyelin ↑ Cholesterol 
 
↑ NaClc ↑ KClc ↑ Mannitolc 
 ↑ Extracellular pH ↑ Protein binding  
 ↓ Copper transporter CTR1 ↑ Copper ↓ CaCl2c 
 ↓ Uptake concurrently of several factors Concurrent ↓ expression several transporters ↓ γ-Catenin 
 
Defective endocytosis/formation of endocytic recycling 
compartment 
↓ Small GTPases (rab5, rac1, rhoA) 
which regulate endocytosis  
 
Increased efflux ↑ Cu transporters ATP7A, -7B ↓ CuCl2c ↑ Intracellular pH 
 
↑ MRP2/cMOAT/GSH-X pumpd ↑ MRP1d ↑ p-Glycoproteind 
 
↑ MVP/LRPd Abnormal sorting into exosomal pathway ↑ Sequestration intracelluarly 
 
Increased detoxification ↑ GSH ↑ GSTd ↑ GST-pi/GST-pi SNPse 
 ↑ γ-Glutamylcysteine synthase ↑ γ-Glutamyltransferase ↑ GSH peroxidase 
 ↑ Glutamate cysteine ligase ↑ GSH reductase ↑ Catalase 
 ↑ Dihydrodiol dehydrogenase ↑ Superoxide dismutase ↑ Metallothioneinsd,e 
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Mechanism  Contributing factor  
Decreased drug binding ↑ Proton pumps ↑ Intracellular pH ↑ Extracellular pH 
 ↑ In cell cycle G1/ ↓ in G2/M ↑ Histone methylation  
 
Increased DNA repair ↑ Nucleotide excision repair system (ERCC1 and XPF) ↑ XPAe ↑ BRCA1e 
 
Host ERCC1/XPD SNPse, ↑ Topoisomerase-II ↑ REV1 
 
↑ Base excision repair (DNA polymerase-βd, -zeta, and 
-eta) ↑ Homologous recombination repair 
↑ DDB2 (damaged-DNA-binding-
protein-2 
 ↑ DNA damage recognition protein HMG1   
 
Increased tolerance of DNA damage ↓ DNA postreplicational mismatch repair ↓ hMLH1, hMSH2, hMSH6d ↓ Non-homologous end-joining 
repair 
 
Decreased pro-apoptotic factors Down-regulation/↓ expression (p53, p53-binding-protein-2, Bax, Fas, caspases 8, 9, other) ↓ Activation (Fas, caspase 9) 
P53 mutation (with 
overexpression of a non-
functional protein)d,e 
 Mitochondrial abnormalities P53 deletion  
 
Increased apoptosis inhibitors ↑ Bcl-2d,e ↑ Bcl-xLd,e ↑ Bfl-1/A1 
 ↑ Survivin Hypoxia (via ↑ Bcl-xL) ↑ FLIP 
 ↑ Xiap ↑ IAP-2 ↑ COX-2d,e 
 
Altered mitochondria ↑ Fatty acid use for O2 consumption ↑ Mitochondrial-uncoupling-protein-2 ↑ No. mitochondria 
 ↓ Membrane potential   
 
Increased chaperones ↑ HSP27d ↑ HSP90-β ↑ HSP70 
 ↓ GRP78   
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Mechanism  Contributing factor  
 
Altered cell signaling pathways ↑ E-cadherin ↑ EGF/EGFR Catenins: ↑ α & β / ↓ γ 
 ↑ Heregulin/ ↑ p21WAF1/CIP1 ↑ Her-2/neud PTEN loss 
 ↑ PI3K ↑ AKT ↑ mTOR 
 
↑ MAPK signaling cascaded ↑ p110α ↑ Hyaluronan-CD44 
 ↑ c-Myc/c-Fos/c-Jun activation ↑ /Mutated ras ↑ c-cot 
 ↑ STAT1/STAT3/JAK2 ↑ PDE2 ↑ PKC-iota 
 ↑ Protein phosphatases 2A & 4 SRPK1 inactivation ↓ SAPK/JNK activation 
 ↓ p38 kinase activation ↓ IP3R1 ↓ HGF 
 
Transcription factors, cell cycle related 
factors, checkpoint kinases, etc. ↑ YB-1 ↑ CTF2 ↑ ATF4 
 ↑ ZNF143 ↑ mtTFA ↑ Ets-1 
 ↑ Zipper transcriptional factor ↑ AP-2 ↑ SKP2 
 
↑ NF-kappaBd ↑ Cyclin D1  
 ↓ Chk1 ↓ Chk2  
 ↓ Telomerase mRNA expression ↓ Telomere length ↓ Telomerase activity 
 
Gene arrays: differential expression ↑ FN1 ↑ TOP2A ↑ LBR 
 ↑ ASS ↑ COL3A1 ↑ STK6 
 ↑ SGPP1 ↑ ITGAE ↑ PCNA 
 ↑ MDR1 ↑ MRP1 ↑ MRP2 
 ↑ CD55 ↑ PGK1 ↓ Caveolin 1 
 
Proteomic analyses: differential 
expression ↑ HSP60/HSP90/heat-shock cognate 71 kDa protein ↑ Calmodulin ↑ Calumenin 
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Mechanism  Contributing factor  
 ↑ Peroxiredoxins PRX 2/PRX 6 ↑ GST ↑14-3-3 
 ↑ Voltage-dependent anion-selective channel-1   
 
Miscellaneous ↑ Ribosomal proteins RPS13, RPL23 Altered sphingolipid pathway Altered ganglioside expression 
 Chromosomal abnormalities ↑ Splicing factor SPF45 ↑ Serum LDHd,e 
 
↑ Glucose utilizationf ↑ Lactate productionf ↑ LDH-5e,f 
 ↑ Golgi apparatus ↓ Microsatellite D6S1581 ↓ Pyruvate kinase M2 
a
 Paradoxically associated with improved cisplatin efficacy and patient survival. 
b
 Thought to be important for drugs in general, but not directly tested with platinums. 
c
 Alter platinum cellular uptake and efficacy when added in vitro. 
d
 Effect not seen consistently across all studies, or opposite effect seen in some studies. 
e
 Demonstrated in clinical studies. 
f
 Despite cells with low intracellular and extracellular pH having decreased platinum efflux and increased platinum uptake, binding and efficacy. 
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1.4  Aims and objectives of this thesis 
The primary focus of this thesis is on the analytical aspects related to the 
synthesis, characterisation and evaluation of novel platinum anticancer 
compounds.   
By studying the analytical aspects of the various classes of compounds a link was 
sought between anticancer activity, based on classical cell line bio assay tests and 
a specific characteristic, such as ionisation rate or susceptibility to attack by small 
sulfur compounds (GSH or Met).  Hence, analysis and examination of the novel 
compounds synthesised during this project were brought into perspective by 
comparison with the known anticancer agents: cisplatin, carboplatin and 
oxaliplatin.  The ESI experiments performed in this thesis thus serve as model for 
the reactivity of the complexes in solution in terms of selectivity, stability, ligand 
exchange rate and represent a method to observe transient catalytic 
intermediates.  More specifically the following topics were addressed: 
• Characterisation of target species and identification of all major species 
present in synthesis samples.  This task was primarily performed by direct 
infusion of aqueous or solvent-based sample solutions into the MS.  
However direct infusion analysis of impure samples did not provide the 
necessary semi quantitative information required and was also incapable of 
distinguishing between ionisation species and gas phase association 
species.  In these cases LC-MS was used to first separate the individual 
species prior to identification of each.  Subsequently, the analysis was 
transferred to LC-UV, which enabled better detection of inorganic salts, 
neutral species and simplification of the analysis when large numbers of 
samples were handled. 
• Identification of the specific “in-solution” species formed during 
solvation/solvolysis.  By monitoring the solutions over time and at various 
temperatures information could be obtained on the reaction pathways and 
the rate at which reactions occurred for specific species.  The effects of 
different solvents, ligands and leaving groups could be directly compared.   
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1.4 .1 Out l ine  of  work presented in  each chapter .  
• Chapter 1 gives an introduction to the field of platinum complex 
chemotherapy by examination of the parameters pertinent to basic drug 
design.  Literature that is relevant to the subject matter is cited and the 
direction of current research is examined. 
• All experimental procedures are detailed in Chapter 2.  In many cases 
specific and unique analytical methods had to be developed in order to 
measure the species present in the various reactions.  The chapter serves 
as a reference with each of these methods clearly described.  Discussions 
in the later chapters are thus not cluttered with analytical details, distracting 
the reader from the specific subject under examination.  This chapter also 
incorporates an elementary background on the use of electrospray 
ionisation MS and its application in the field of metalloligand research.  The 
technology is demonstrated by way of actual samples analysed during the 
course of this study. 
• In Chapter 3 parameters were optimised for the synthesis of oxaliplatin via 
novel routes, through the use of microscale reactions.  In order to optimise 
parameters such as reaction time, temperature, solvent and reagent ratios, 
microscale reactions were undertaken.  This enabled the rapid evaluation of 
numerous parameters whilst utilising minute quantities of expensive 
platinum starting material.   
• Evaluation of a series of novel N-S non leaving groups is discussed in 
Chapter 4. Synthetic procedures are evaluated and comparisons are 
drawn between the characteristics of these and known anticancer 
agents 
•  Chapter 5 details the synthesis, characterisation and preliminary 
evaluation of mononitro platinum(IV) complexes.  The archetypal 
mononitro compound CPA7 has been shown to be STAT active i.e. 
having a novel anticancer action that is significantly different to DNA 
platination.  Some of the novel compounds synthesised during this 
study has shown excellent in vitro anticancer activity.  
• In Chapter 6 selected compounds were reacted with several small 
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biomolecules to evaluate platinum biomolecule interaction. A DNA 
surrogate was used to compare DNA binding efficiency while 
susceptibility to attack by small thio molecules was also evaluated and 
compared to known anticancer agents. 
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Chapter 2:   
Experimental 
2.1 Introduction 
The physical methods utilised to characterise the molecular structure and to 
elucidate the chemistry involved in the synthesis of the different types of platinum 
complexes, will be fully described in this chapter.  The experimental procedures 
herein have been set out according to their utilisation in later chapters.  This 
ensures that the reader can revert back to this chapter for a full description of each 
procedure.  Consequently subheadings in this chapter (see sub heading 2.4) are 
related to the later chapters.  In Chapter 3, investigations into the reactions used 
to produce novel synthetic methods for cis-oxalato(trans-ℓ-1,2-
cyclohexanediamine)platinum(II) i.e. oxaliplatin will be discussed. 
Extensive use was made of electrospray ionisation mass spectrometry (ESI-MS) 
and the following section provides some background to the utilisation of this 
technique in the field of metalloligand research. 
2.2 General  background to ESI-MS and i ts  
appl ication in metal lol igand research 
Electrospray ionisation can be defined as the process whereby ions in solution are 
transferred into the gas phase and subsequently subjected to mass spectrometric 
analysis.  
The electrospray process is ‘soft’ relative to various other ionisation techniques 
and yields predominantly intact molecular ions through adduct formation (H+, 
NH4+, Na+ or HCOO-). There are three characteristics that render ESI ideally 
suited to mass spectrometric analysis: 
• The mass spectrum obtained is a close reflection of the actual “in solution” 
state of the molecules. 
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• Multi charging of the analyte molecule enables the mass to charge (m/z) 
ratio to be lowered to within the mass range of benchtop quadrupole and ion 
trap MS systems, enabling the analysis of high molecular mass compounds 
such as biopolymers (proteins and DNA) 
• The electrospray process requires analytes to be in solution and is thus 
ideally suited to the coupling of separation techniques such as high 
pressure liquid chromatography (HPLC) and capillary electrophoresis (CE). 
First developed over 80 years ago the electrospray process involves the creation of a 
fine aerosol of highly charged micro droplets in a strong electric field. It has found 
application in fuel atomization, electrostatic painting, drug delivery and rocket 
propulsion.90 Utilisation of the ESI process for MS was introduced by Yamashita and 
Fenn91 in 1984. Fenn shared the Nobel Prize in Chemistry in 2002 with Tanaka who 
introduced another MS ionisation technique - MALDI. A very similar, independent 
development was reported at about the same time by Aleksandrov and co-workers.92 
The concept of creating gas phase ions using electrospray and analysis of these ions 
by mass spectrometry was proposed much earlier (1968) by Dole.93 However his 
experiments were focused on neutral polymers such as polystyrene and the results 
were not convincing. Since 1984 the development of ESMS has seen unprecedented 
growth in a wide range of applications, soon surpassing the number of yearly 
publications using older techniques such as FAB. See Figure 2.1. 
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Figure 2-1: Popularity of ESI-MS and FAB, as measured by papers published. 94 
Popularity of the FAB technique peaked in the early 1990’s at the point when 
ESI instruments were commercialised. 
The potential of ESI for obtaining and studying gas phase metal complexes was 
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realised soon after the method had been introduced, with reports appearing by 
Kebarle and co workers94,95,96,97 and Chait and coworkers98  in 1990. Previously 
the mass spectral analysis of transition metal complexes was limited to a select 
few types (metal carbonyls and acetylacetonates). This limitation resulted from 
both the low thermal stability of transition metal complexes and the lack of 
ionisation methods that produce gaseous ions with sufficiently low internal energy 
to prevent fragmentation in the ionisation source.99 In 1991 Poon et al.100 used ESI 
to investigate the mass spectra of three platinum anticancer agents, cisplatin, 
iproplatin and tetraplatin. Before ESI the methods used for platinum drug detection 
included radiochemical labeling with 195mPt, X-ray fluorescence (XRF), proton induced 
X-ray emission (PIXIE), inductively coupled plasma (ICP) and flameless atomic 
absorption (FAA). All of these methods have some drawbacks such as the short half-
life of the 195mPt radionucleotide, poor sensitivity and matrix problems. Most 
importantly however they only provide information on the total platinum levels in the 
biological samples. The use of HPLC with UV or electrochemical detection can 
possibly identify platinum species present after column separation. However none of 
these techniques can provide definitive structural information on parent drugs and 
metabolism. Such information can be obtained by 195Pt, 15N and 1H nuclear magnetic 
resonance (NMR), but relatively large and pure samples are required. Modern 
hyphenated techniques such as HPLC-NMR and HPLC-ESI-MS enable individual 
characterisation of the separated complexes eluting from the column. 
2.2 .1 The ESI  mechanism 
During the ESI process analytes in a liquid solution are transferred to the gas 
phase at atmospheric pressure and into the high vacuum region of the mass 
spectrometer. This is done by creating a fine spray of highly charged droplets in 
the presence of a strong electric field. The sample solution is sprayed from the tip 
of a stainless steel needle maintained at 3-5 kV. The highly charged droplets are 
then attracted to the MS inlet which consists (in this case) of a heated metal 
capillary (0.5 mm i.d.) at 200ºC. Nitrogen gas is blown as a sheath around the 
metal needle to aid in the desolvation of the droplets. As the droplet size 
decreases due to evaporation of the volatile solvent, the density of the electric field 
on the surface increases. The repulsion between the charges on the surface of 
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each droplet increases to the point where the surface tension is exceeded and 
ions begin to leave the droplets (Columbic explosion). These ions are directed into 
the mass analyser through a series of electrostatic ion guides. Cations or anions 
may be selected for detection. 
 
Figure 2-2: Diagrammatic representation of the electrospray ionisation (ESI) process 
taking place in the atmospheric pressure ionisation (API) source of the 
instrument.101 
2.2 .2 Out l ine  of  MS System ut i l ised in  th is  study 
Various mass analysers are available of which the quadrupole is probably the 
most common. Quadrupole mass analysers consist of 4 parallel metal rods. 
Applied between each pair of opposite and electrically connected rods are a DC 
voltage and a superimposed radio-frequency potential. As accelerated ions pass 
between the rods they are acted upon by the applied electric fields. The applied 
conditions will allow ions of a certain mass to charge ratio (m/z) to successfully 
pass between the rods while all others will follow unstable trajectories and be lost 
by collision with the rods.  
Another type of mass analyser is the quadrupole ion trap (QIT) which was first 
described by Wolfgang Paul nearly 50 years ago and for which he was awarded 
the Nobel Prize in Physics in 1989.102 This device is able to trap gas phase ions 
using applied electric fields. A QIT (often referred to simply as an ion trap) consists 
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of a ring shaped electrode with curved caps on the top and bottom. Ions are 
injected from the source, through one of the caps, and by applying a combination 
of voltages to the ring and capping electrodes, the ions can be trapped in a 
complicated three-dimensional orbit. A constant pressure of helium (ca. 0.1 Pa) is 
maintained in the trap to remove excess energy from the ions, which would 
otherwise repel each other. In the order of 300 – 1000 ions are injected directly 
into the trap in a step which takes approximately 0.5 s.90 During the next mass 
selective ejection step, the electrode potentials are manipulated in such a way that 
similar ions pass sequentially into an external detector. 
Such an ion trap system was utilised during this study. The basic outlay of the 
entire system is shown in Figure 2.3. 
 
Figure 2-3: Basic outlay of the LC-MS system utilised during this study showing the 
position of the quadrupole ion trap101 
2.2 .3 Isotopes and isotope dist r ibut ion pat terns  
The wide occurrence of polyisotopic elements in inorganic metal ion complexes 
leads to very distinct mass spectra. As a mass spectrometer separates individual 
ions with sufficient mass resolution, an ion containing a polyisotopic element will 
give rise to a number of isotope peaks in the mass spectrum. It is thus convention 
to use the so called monoisotopic mass when calculating the masses of ions. This 
is the mass of an ion of a given formula calculated using the exact weight of the 
most abundant isotope of each element, e.g. 194 (193.96) is used for platinum as 
opposed to the average mass which is 195 (195.08). Isotope peaks have a 
characteristic pattern of spacing and relative intensities depending on the masses 
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and the relative abundance of the isotopes in the ion. This envelope of peaks is 
known as the isotope pattern of an ion. Spectra of organic compounds (C, H, N, S, 
P and O), generally show rather simple isotope patterns while those of metal ion 
complexes containing polyisotopic elements (Ru, Pd, Ag, Cd, Sn and Pt), show 
much more complex isotope patterns. See Figure 2.4. 
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Figure 2-4: Isotope patterns of 3 essentially monoisotopic elements (C, H and O) versus 
3 polyisotopic elements (Pd, Cd and Pt) 
These patterns can be calculated using a binomial expansion which is performed 
automatically by the software of most MS systems enabling a theoretical isotope 
pattern to be generated. The example in Figure 2.5 shows the effect of the 
polyisotopic elements platinum and bromine on the isotope pattern of the metal ion 
complex J12.3. 
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Figure 2-5: Positive ion mass spectrum of the metal ion complex J12.3 showing the 
distinct Isotope pattern obtained due to the presence of platinum and 
bromine. 
2.2 .4 Resolut ion 
A number of features suited to the structural elucidation of platinum containing 
complexes are visible in Figure 2.5.  Firstly the detector response is such that the 
theoretical isotope abundances are reflected in the individual intensities of each 
isotope i.e. the pattern is similar.  Secondly the mass accuracy of the instrument 
shows very good correlation to the theoretical masses of the individual isotopes. 
Thirdly the resolution of the system is sufficient to separate the individual mass 
isotopes.  Resolution is the ability of the instrument to discern between ions of 
similar mass, in this case the various isotopes which differ by one Da.  The system 
utilised had the ability to improve the resolution by scanning very slowly over a 
small mass window (a process known as zoomscan).  Figure 2.6 demonstrates 
the increase in resolution obtained using this feature for the platinum ion complex 
Y21. 
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Figure 2-6: Figure demonstrating the gain in resolution due to utilisation of the 
zoomscan function 
Another feature of the specific mass spectrometer used during this study was the 
ability to obtain MS2 (MS/MS), MS3 and in some cases MS4 data. What this implies 
is that a specific ion can be selected within the ion trap.  All other ions are then 
scanned out of the trap.  The energy within the trap is increased and the selected 
ions begin to fragment.  The fragmented (daughter) ions are detected yielding an 
MS2 spectrum.  In an MS3 spectrum one of the daughter ions from the MS2 
spectrum is similarly selected, isolated and fragmented to produce further 
(granddaughter) ions.  Multiple steps of MS fragmentation provide valuable 
information relating to the structure of unknown ions.  An example of the use of MS3 
for structural elucidation of the platinum ion complex Lg49 is shown in Figure 2.7. 
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Figure 2-7: Positive ion ESI-MSn spectra of the complex trans-[Pt(β-Ala-OEt)(NH3)I2] in MeCN. 
From the top: the standard MS spectrum with no additional fragmentation energy; 
MS2 spectrum, 25% collision energy applied on the ion cluster at m/z583; MS3 
spectrum, with the m/z566 ion cluster selected, fragmented at 25% collision 
energy to yield ion clusters at m/z328 and m/z456. 
All the above factors combine to provide an instrument that is well suited to the 
structural elucidation of metal ion complexes in solution. 
2.2 .5 EV-CAD 
The ability to select and isolate specific ions for further fragmentation studies 
provides another method for the characterisation of the analytes.  In MSn studies 
sufficient energy is applied to the trap to effect the fragmentation e.g. [M+NH4]+ → 
[M-X+S]+ or [M-X+S]+ → [M-2X-H+S]+. By stepwise application of a supplementary 
RF voltage (0-5 V) to the end caps of the ion trap, the energy within the trap is 
increased.  The selected complex begins to fragment i.e. collision associated 
dissociation (CAD) occurs.  The fragmented ions (daughter ions) are then 
detected yielding an MS2 spectrum.  
The curve constructed from the amount of energy applied to the trap (X-axis) 
versus the decrease in ion abundance (Y-axis) of the specific ion cluster is known 
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as an EV-CAD curve.  E½ values are defined as the collision energy required for a 
50% drop in the relative ion abundance of the precursor complex.  Complexes with 
higher E½ values are considered more stable than complexes with lower E½ 
values.103 See Figure 2.8 for an example of EV-CAD utilisation in this dissertation. 
 
Figure 2-8 Positive ion mass spectra obtained during EV-CAD study of complex Lt16 
By plotting the amount of energy applied to obtain the fragmentation shown in the 
mass spectra in Figure 2.8, against the relative abundance of the ion clusters studied, 
EV-CAD curves are obtained.  Examples of such curves are depicted in Figure 2.9. 
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Figure 2-9:  EV-CAD plots depicting the relative collision energy required for the fragmentation 
of different ions related to the complexes Lt16, Lt16.3 and Lt16a.  
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MS2 spectrum of Sample Lt16, 
showing the selected isolated ion 
cluster [M+NH4] + at 14% CAD 
Note that no secondary fragmentation 
has occurred. 
MS2 spectrum of Sample Lt16 at 25% 
CAD Note that secondary 
fragmentation has occurred yielding 
the daughter ion [M-Cl] + at m/z447 
MS3 spectrum of Sample Lt16, 
showing the selected isolated 
daughter ion [M-Cl] + at m/z447 
Note that no tertiary fragmentation 
has occurred. 
MS3 spectrum of Sample Lt16 at 25% CAD 
(MS2) and 35% CAD (MS3) 
Note that tertiary fragmentation has 
occurred yielding the granddaughter ion 
[M-2Cl-H+H2O] + at m/z429 
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As illustrated by the curves in Figure 2.9 the amount of energy required for the 
fragmentation of the individual ion clusters varies from species to species.  For 
example a relative collision energy of 14.6% is required to fragment the [M+NH4]+ 
ion of Lt16a while 18.0% is required to fragment the [M-Br+S]+ ion of Lt16.3. 
2.2 .6 HPLC-MS 
Due to the compatibility of ESI with the solvents typically used for HPLC (water, 
methanol and acetonitrile) it is also possible to use the mass spectrometer as a very 
specific detector for HPLC.  This enables mass selective characterisation of individual 
species present in a solution.  LC-MS is currently the most utilised technique in drug 
pharmacokinetic studies where trace amounts of drug metabolites need to be 
accurately quantified at the pg – fg level in large numbers of biological samples 
(plasma or urine).  By performing a typical gradient HPLC separation (1 to 70% 
acetonitrile) utilising a reverse phase column (C8 or C18) and detecting the eluting 
compounds in positive and negative ion mode, an enormous amount of relevant data 
can be obtained in a relatively short time.  The example below (Figure 2.10 and 
Figure 2.11) demonstrates the typical LC-MS analysis of a crude synthesis sample for 
the compound Y18I2. 
 
Figure 2-10 Figure showing the chromatographic separation of the sample in MeCN with positive 
(top) and negative (lower) ion mode detection. The separation was  performed on a 
SGE C18 column (150x1.0 mm, 5 µm) at a flow rate of 120 µl/min. 
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Figure 2-11: Full scan mass spectra obtained of peak B (Y18I2) in positive (top) and 
negative (lower) ion mode together with tentative structural assignments. 
As illustrated by the chromatograms obtained, negative ion spectra are often less 
cluttered than positive ion mode spectra facilitating the interpretation and 
identification process. 
ESI-MS has been applied to the analysis of a diverse range of analytes including 
peptides and proteins, nucleic acids and their constituents, carbohydrates and 
lipids, drug metabolism and pharmacokinetics as well as inorganic and 
organometallic complexes.104 
In one of the most revolutionary experiments performed using ESI-MS it was 
found that living organisms could be ionised, transferred into vacuum, recovered 
and found to retain their viability. This was accomplished in 1995 by Siuzdak and 
colleagues105 at the Scripps institute in La Jolla California.  Here they managed to 
separate rice yellow mottle virus (RYMV) from tobacco mosaic virus (TMV).  
During the separation, following mass selection, transmission electron 
micrographs of the collected ions demonstrated preservation of the icosahedral 
RYMV capsid and the rod shape of the helical TMV.  As the capsids are stabilised 
by non covalent interactions between protein subunits, the retention of the virus 
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ultrastructures provided direct evidence that the quaternary structure of non 
covalent complexes could be conserved in the gas phase and throughout the 
mass analysis process. 
2.3  Instrumentat ion and chemicals 
2.3 .1 ESI -MS 
Measurements were carried out on an LCQ Deca instrument (Finnigan, San Jose, 
CA, USA) in either positive or negative ionisation mode.  For infusion studies the 
samples, in appropriate solvent, were directly infused at a flow rate of 10 µl/min 
using a 500 µl Unimetrics HPLC syringe and the instruments own syringe pump.  
A 50% MeCN/10 mM ammonium formate/0.06% formic acid solution was used as 
sheath liquid at a flow rate of 150 µl/min.  The tip of the fused silica capillary (i.d. 
100 µm, o.d. 190 µm) was positioned 0.5 to 1.0 mm inside the tip of the stainless 
steel sprayer capillary allowing direct contact with the analysis solution.  The 
electrospray atmospheric pressure ionisation probe was maintained in position 2.  
The parameters of the instrument were tuned utilising an infusion solution of 
Pt(dach)Cl2 in MeCN (10 µM at 10 µl/min). 
• Positive ion mode instrument settings 
The instrument parameters were tuned using the ammonium adduct [M+NH4]+ 
with the following values: nitrogen sheath gas flow rate 80 arbitrary units, nitrogen 
auxiliary gas flow rate 20 arbitrary units, sprayer voltage 3.5 kV, capillary voltage 
46.0 V, tube lens offset 55.0 V, multipole 1 offset -5.75 V, lens voltage -28.0 V, 
multipole 2 offset -10.00 V, multipole RF amplitude (V p-p) 400 V, entrance lens -
62.0 V and 100 ms maximum injection time using automatic gain control.  
•  Negative ion mode instrument settings 
The parameters of the instrument were tuned using the formate adduct 
[M+HCOO] - to the following values: nitrogen sheath gas flow rate 80 arbitrary 
units, nitrogen auxiliary gas flow rate 20 arbitrary units, sprayer voltage 5.0 kV, 
capillary voltage -12.0 V, tube lens offset 5.0 V, multipole 1 offset 5.25 V, lens 
   
49 
voltage 46.0 V, multipole 2 offset 10.00 V, multipole RF amplitude (V p-p) 400 V, 
entrance lens 38.0 V and 100 ms maximum injection time using automatic gain 
control. 
•  MSn experiments  
Fragmentation studies were carried out using an isolation width of at least 5 Da 
i.e. the ion isolation window was adjusted to allow passage of all major isotopes in 
the platinum isotope profile with a 2.5 mass unit margin on the high (198Pt) and low 
(194Pt) end of the target.  Activation amplitude and activation time were adjusted 
individually for each fragmentation within the ranges 5 - 50% for activation 
amplitude and 40 - 100ms for activation time, always resulting in maximum 
abundance of the fragment ion examined.  The transfer capillary temperature was 
kept constant at 200ºC, being the lowest temperature to provide sufficient 
desolvation.  Spectra were obtained after averaging the acquired spectra. More 
spectra were required for averaging when low concentration or dirty samples were 
analysed. 
2.3 .2 LC-MS 
The LCQ Deca mass spectrometer was connected to a Thermo Surveyor HPLC 
system consisting of a quaternary gradient pump and autosampler.  For LC-MS 
analyses, varying solvents were utilised but in each case, the solvents and 
modifiers complied with the overriding requirement of ESI-MS, in that all 
components had to be volatile.  Thus, no separations could be effected with the 
help of phosphates or sulphonic acids and no sodium, potassium or chloride salts 
could be used.  Instead, volatile buffer systems such as ammonium formate, 
ammonium acetate or diethylamine were used.  
2.3 .3 HPLC-UV 
LC separations were performed on a Waters HPLC system consisting of a WISP 
717 autosampler, 600E quaternary gradient pump and 484 variable wavelength 
UV-Vis detector.  
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2.3 .4 Column separat ions 
Various HPLC separation columns were used during this study. The specifications 
of each are listed in Table 2.1. 
Table 2-1:  HPLC separation columns used during this study. 
Supplier Phase Dimension 
YMC Hydrosphere C18 120 Å 5 µm 250 x 4.6 mm 
YMC-Pack Hydrosphere C18 120 Å 3 µm 150 x 2.1 mm 
SGE Wakosil C18 120 Å 5 µm 150 x 1.0 mm 
SGE Nucloesil C4 300 Å 5 µm 150 x 2.0 mm 
Phenomenex Gemini C18 110 Å 5 µm 30 x 2.0 mm 
Phenomenex Luna C18 (2) 100 Å 5 µm 150 x 2.0 mm 
Waters Novapak C18 120 Å 5 µm 150 x 3.9 mm 
Alltech Rocket Prevail C18 3 µm 53 x 7 mm 
Phenomenex Curosil PFP 5 µm 250 x 4.6 mm 
2.3 .5 Chemicals  used 
Chemical Supplier 
Ammonium acetate (99%) SMM Chemicals 
Acetonitrile (99.9+ %) Burdick and Jackson 
Methanol (99.9+ %) Burdick and Jackson 
Water (for GC and HPLC) Burdick and Jackson 
Dimethylformamide (99+ % for HPLC) Aldrich 
Isoamylalcohol (98.5%) Fluka 
Dichloro(1,2)diaminocyclohexane)-platinum(II) (Ptdc) Aldrich 
Cisplatin In house 
Oxaliplatin In house 
Glutathione 98% Sigma 
Methionine Aldrich 
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D, L –cysteine hydrochloride Aldrich 
2’-Deoxyguanosine 5’-monophosphate (GMP) 98% Sigma 
Phosphoric acid 99.9% 85 wt% solution in water Aldrich 
Oxalic acid 99+ % Aldrich 
Ammonium formate ≥99.0% Fluka 
Tetrabutyl ammonium hydroxide 40% in water Aldrich 
Formic acid Aldrich 
2.4  Specif ic analyt ical  methods 
2.4 .1 Methods ut i l ised in  Chapter  3  
Method M3.1 for the standardisation of tbaox in dmf 
Prior to monitoring the reaction of Pt(dach)Cl2 with tbaox to produce oxaliplatin, a 
method was required to standardise the tbaox which had been prepared in-house in 
dmf. 
Preparation of tbaox in dmf  
The tbaox was prepared by dissolving a one molar equivalent of oxalic acid (6.5g, 
52.15 mmol) in 2 molar equivalents of a 40% standardised aqueous solution of 
tbaOH (104.2 mmol). The solution was then stirred at RT until all oxalic acid had 
dissolved. The pH of the solution was then adjusted to 7.0 by further addition of 
tbaOH solution, where after water was removed under vacuum at 40ºC until a 
paste was obtained. The solid was dissolved in deoxygenated dmf (50 ml) and 
allowed to stand over mol sieve (3Å) in the dark for 24 h. The resulting ca 1 M 
tbaox solution in dmf was standardised by measuring the oxalate concentration 
using an ion pairing RP HPLC method. 
The developed method was based on the method used for the determination of 
oxalate (Impurity A) in oxaliplatin, according to the European Pharmacopoeia.106 
However, due to the sample being in dmf and not water, the method had to be 
adjusted. The wavelength was changed from 205 to 260 nm and the sample 
injection volume was decreased from 20 µl to 5 µl.  At the shorter wavelength, the 
   
52 
absorbance due to dmf made accurate quantitation of oxalate ions impossible and 
the smaller injection volume decreased the effect of peak tailing.  
• HPLC analysis 
System Waters 600E pump Waters 717 WISP autosampler Waters 486 
variable wavelength UV detector 
   Varian Galaxie Chromatography software 
Mobile phase  3.2 ml tbaOH (40%) 
   0.544 g KH2PO4 
   400 ml water 
   Adjust pH to 6.0 with 8.5% H3PO4 
   Add 100 ml acetonitrile 
Column  Waters Novapak C18 150 x 3.9 mm (5 µm) 
Detection λ  260 nm 
Flow rate   1.5 ml/min 
Injection volume 5 µl 
• Standard and control preparation 
Two oxalate stock solutions were prepared by weighing oxalic acid (ca 3.5 mg) 
into a 4 ml vial and adding enough 90% dmf (10% water) to produce a 1.00 mg/ml 
oxalic acid (11.11 mM oxalate) solution.  One solution was used to prepare the 
standard solutions while the other was used to prepare control standards.  The 
preparation of these solutions is stipulated in Table 2.2. 
Table 2-2:  Table indicating how standard and control samples were prepared for the 
analysis of [oxalate] in dmf. 
Standard oxalate stock 11.11 mM (µl) dmf (ml) water (µl) [oxalate] (µg/ml) 
Std1 200 3.42 380 48.9 
Std2 400 3.24 360 97.8 
Std3 600 3.06 340 146.7 
Std4 800 2.88 320 195.6 
Crl1 400 3.24 360 97.8 
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Standard oxalate stock 11.11 mM (µl) dmf (ml) water (µl) [oxalate] (µg/ml) 
Crl2 400 3.24 360 97.8 
• Sample preparation (triplicate) 
The sample solution (ca 1 M tbaox) in dmf (42.1 µl) was diluted to 4.0 ml with dmf 
(10.52 mM). This solution was further diluted (648 µl) to 4.0 ml with dmf to yield an 
oxalate concentration of (150 µg/ml). 
A sample concentration of 150 ug/ml oxalate thus reflects an original tbaox 
solution of 1.00 M. 
Method M3.2 for the determination of [oxalate] in 95% dmf 
This method was setup specifically to monitor the degradation of oxalate during 
typical reaction conditions. An experiment was setup to determine the degradation 
of tbaox in 95% dmf at 3 different concentrations (equivalent to the planned 
Pt(dach)Cl2: tbaox molar ratios of 1:1.5; 1:2.5 and 1:5.0) and 4 different 
temperatures (70ºC, 75ºC, 80ºC and 85ºC). For each parameter e.g. 1:1.5 at 
70ºC, samples (10) were taken over a period of 7.5 h. 
Measuring oxalate concentration monitored tbaox degradation. As dissociation of 
the tbaox into tba+ and ox2- takes place upon injection into the flow path of the 
HPLC (80% water), it was decided to monitor the concentration of the oxalate 
anions as the tba+ cations were expected to be very stable.   
• HPLC Analysis 
The same HPLC method as outlined in Method M3.1 was used. 
• Sample preparation 
A 1M tbaox solution was prepared (dmf) and this stock solution was further diluted 
to 10.52 mM using dmf. This diluted tbaox stock solution was then used to prepare 
the following sample solutions: 
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Table 2-3:  Table indicating how samples were prepared for the monitoring of tbaox 
degradation in 95% dmf. 
Ratio 
Ptdc: tbaox 
Volume 10.52 mM 
tbaox (µl) 
Volume dmf 
(µl) 
Volume water 
(µl) dmf (%) 
No. of samples 
Prepared 
1:1.5 150 1370 80 95 10 
1:2.5 250 1270 80 95 10 
1:5.0 500 1020 80 95 10 
• Degradation 
The vials (vial racks) were placed in ovens at the specified temperature. Two 
ovens were used. The first was a GC oven (70ºC on day 1 and 80ºC on day 2). 
The second oven was a standard lab oven which had been calibrated (75ºC on 
day 1 and 85ºC on day 2).  At the appropriate time the oven door was opened and 
the specific vials were removed. The oven door was not opened for more than 30s 
at a time. The removed vials were placed in a freezer at ca. -18ºC 
On the day of the analysis (15 days later) the samples were removed from the 
freezer and allowed to reach RT. A subset of selected samples was done first 
[T0 (time 0:00), T5 (time 02:30) and T9 (07:30)]. It was quickly noticed that 
very little drop, if any, in the oxalate level had occurred. Consequently only 
these three time intervals were analysed (36 samples in total). [4 temperature 
levels x 3 concentration levels x 3 time intervals = 36]. 
• Calibration 
Serial dilutions of the stock 10.52 mM tbaox were used to produce the following 
standard solutions: 
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Table 2-4:  Table indicating how standards were prepared for the analysis of [oxalate] in 
95% dmf. 
Standard Volume tbaox [10.52 mM] (µl) 
Volume dmf 
(µl) 
Volume water 
(µl) 
[oxalate] 
(µg/ml) 
1 37.5 1482.5 80 21.7 
2 75 1445 80 43.4 
3 150 1370 80 86.8 
4 250 1270 80 145 
5 500 1020 80 289 
Method M3.3 for the determination of [Pt(dach)Cl2] and [oxaliplatin] in 95% 
solvent (95% dmf or 95% iaOH) 
This method was used to monitor reagent (Pt(dach)Cl2) and product (oxaliplatin) 
levels during the course of the reaction in either 95% dmf or in 95% iaOH. 
Although essentially the same method, certain parameters had to be tailored to 
the specific solvent. For example Pt(dach)Cl2 is completely soluble in dmf but 
insoluble in iaOH. For the reaction in dmf a standardised solution of tbaox in dmf 
was utilised, while for the iaOH method, tbaox was prepared from oxalic acid and 
tbaOH in iaOH. A detailed description of each method is given below. 
The study was undertaken to monitor the rate at which Pt(dach)Cl2 was converted 
to oxaliplatin in the presence of tbaox over a 20 hour period (n=16) in 95% dmf. 
Similarly the reaction was followed over 12 h and 6 h periods (n=16) for the 
reaction in 95% iaOH.  The reactions were performed at elevated temperatures 
(70, 75, 80 and 85ºC) with varying ratios of Pt(dach)Cl2 and tbaox (1:1.5, 1:2.5 
and 1:5.0), in 95% dmf. The iaOH solvent system was monitored at slightly higher 
temperatures (75, 80, 85 and 90ºC).   
The reaction products (Pt(dach)Cl2 and oxaliplatin) were quantified using LC-MS 
(negative ion mode). A simultaneous set of experiments were performed to 
monitor the degradation of Pt(dach)Cl2 and oxaliplatin under these same 
conditions. 
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Method M3.3.1 Determination of [Pt(dach)Cl2] and [oxaliplatin] in 95% dmf 
Stock solution preparations (95% dmf) 
• Pt(dach)Cl2 in dmf (5.263 mM/2000 ppm) 
A mass of Pt(dach)Cl2 (50.23 mg Aldrich) was weighed into a 25 ml volumetric 
flask. The flask was filled to the mark with dmf. (Actual concentration 5.287 
mM/2009.2 ppm) 
• tbaox in dmf (10.52 mM) 
A tbaox solution (1.0 M) in dmf was obtained from NMMU on 26 august 2005. It 
was decided to standardise this solution by quantifying the [oxalate]. This was 
done using Method (M1) for the standardisation of tbaox in dmf. The concentration 
of the tbaox solution was determined to be 0.577 M. A 10.52 mM solution was 
prepared by diluting 911 µl to 50.0 ml (dmf). 
• oxaliplatin in 10% water 90% dmf (0.657mM/261ppm) 
A 0.657 mM/261 ppm oxaliplatin stock solution was prepared by weighing 13.0 mg 
oxaliplatin CRS into a 50 ml volumetric flask. The flask was made to the mark with 
a solution of 10% water in dmf. (Actual concentration 0.654 mM/260 ppm) 
• Internal standard in dmf (Y14.2/500 ppm) 
A series of dilutions were performed to establish the linear region for Y14.2 under 
the analytical conditions used for this study. It was determined that addition of 100 
µl of 500 ppm Y14.2 solution (dmf) to 400 µl of the reaction mixture yielded an 
internal standard concentration of 100 ppm which was well within the linear region 
for Y14.2. A 500 ppm stock solution of Y14.2 was prepared by weighing 27.3 mg 
Y14.2 into a 50 ml volumetric flask. The flask was made to the mark with dmf. 
(Actual concentration 545 ppm) 
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• Sample solution preparations 
All reactions were performed in 2 ml glass autosampler vials with Teflon lined 
septa. The reaction solutions were transferred to each vial using a calibrated auto 
pipette with the appropriate sized plastic tip. The volume of each of the stock 
solutions used is depicted in the Table 2.5.  
Table 2-5:  Table indicating how the sample solutions were prepared prior to incubation 
and analysis (95% dmf reaction). 
  
tbaox 
(10.52 mM) 
(µl) 
Ptdc 
(5.263 mM) 
(µl) 
dmf 
 
(µl) 
water 
 
(µl) 
oxaliplatin 
(0.657 mM) 
(µl) 
Total 
 
(µl) 
 Ptdc:  tbaox 
      
1 1 :1.5 37.5 50 292.5 20 - 400 
2 1 :2.5 62.5 50 267.5 20 - 400 
3 1 :5.0 125 50 205 20 - 400 
4 Ptdc degradation 
 50 330 20 - 400 
5 oxaliplatin degradation 
 - - - 400 400 
In each case (Reactions 1-5), 16 vials were similarly filled (T0 to T15), for each 
temperature level (70, 75, 80 and 85ºC). The total number of reaction vials used 
for this portion of the experiment was thus:  
5 x 16 x 4 = 320 
• Standard preparations 
Oxaliplatin 
Table 2-6:  Preparation of calibration standards for oxaliplatin (95% dmf reaction). 
 
Volume oxaliplatin stock 
(0.654 mM/260 ppm) 
(µl) 
Volume 10% water 
90% dmf 
(µl) 
[oxaliplatin] 
(µg/ml) 
Std1 80 320 52 
Std2 160 240 104 
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Volume oxaliplatin stock 
(0.654 mM/260 ppm) 
(µl) 
Volume 10% water 
90% dmf 
(µl) 
[oxaliplatin] 
(µg/ml) 
Std3 240 160 156 
Std4 320 80 208 
Std5 400 - 260 
Pt(dach)Cl2 
A diluted stock solution (250 µg/ml) was prepared by taking 250 µl of the 2000 
ug/ml stock to 2.0 ml (dmf) 
Table 2-7: Preparation of calibration standards for Pt(dach)Cl2 (95% dmf reaction). 
 
Volume Ptdc stock 
( 250 ppm) 
(µl) 
Volume dmf 
(µl) 
[Ptdc] 
(µg/ml) 
Std1 80 320 50 
Std2 160 240 100 
Std3 240 160 150 
Std4 320 80 200 
Std5 400 - 250 
• Sample reactions 
As only 2 calibrated ovens were available and the period monitored was 20 h, the 
experiment was conducted over 2 days. On day 1 temperature levels 70 and 75ºC 
were evaluated while temperature levels 80 and 85ºC were evaluated on day 2. 
In all cases (except for the oxaliplatin degradation samples) the solution containing 
the Pt(dach)Cl2 was added just before the start of the experiment. The vials were 
well shaken and transferred to Perspex vial racks which were placed in the 
equilibrated ovens. Care was taken to ensure that no fluid had collected under the 
lid. The T0 samples were removed and placed in the freezer. At the designated 
time the oven door was opened and the specific vials were removed. The oven 
door was not opened for more than 30 s at a time. The removed vials were placed 
in a freezer at ca. -18ºC. 
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The time intervals utilised for this study are given in Table 2.8. 
Table 2-8:  Sampling times utilised for reaction monitoring in 95% dmf. 
  
Time 
(min) 
Time 
(h) 
Time 
(h:min) 
70 ºC and 75ºC 
Day 1 
80 ºC and 85ºC 
Day 2 
T0 0 0.00 0 10:45 07:50 
T1 10 0.17 00:10 10:55 08:00 
T2 30 0.50 00:30 11:15 08:20 
T3 60 1.00 01:00 11:45 08:50 
T4 100 1.67 01:40 12:25 09:30 
T5 150 2.50 02:30 13:15 10:20 
T6 210 3.50 03:30 14:15 11:20 
T7 280 4.67 04:40 15:25 12:30 
T8 360 6.00 06:00 16:45 13:50 
T9 450 7.50 07:30 18:15 15:20 
T10 550 9.17 09:10 19:55 17:00 
T11 660 11.00 11:00 21:45 18:50 
T12 780 13.00 13:00 23:45 20:50 
T13 910 15.17 15:10 01:55 23:00 
T14 1050 17.50 17:30 04:15 01:20 
T15 1200 20.00 20:00 06:45 03:50 
A graphical display of the data spread is given in Figure 2.12. 
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Figure 2-12:  Graphical display of the data spread used during the 95% dmf study. 
After completion of all the reactions the reaction vials together with the standard 
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vials were removed from the freezer and allowed to equilibrate.  
To each of the vials was added 100 µl of the internal standard solution (Y14.2/500 
ppm). All vials were thoroughly shaken prior to analysis 
The analysis sequence followed is detailed in Table 2.9. 
Table 2-9:  Table stipulating the sample analysis sequence followed during the 95% dmf 
study. 
Run # Sample Run # Sample Run # Sample Run # Sample 
1 Ptdc std1 91 Ptdc std1 181 Ptdc std1 271 Ptdc std1 
2 Ptdc std2 92 Ptdc std2 182 Ptdc std2 272 Ptdc std2 
3 Ptdc std3 93 Ptdc std3 183 Ptdc std3 273 Ptdc std3 
4 Ptdc std4 94 Ptdc std4 184 Ptdc std4 274 Ptdc std4 
5 Ptdc std5 95 Ptdc std5 185 Ptdc std5 275 Ptdc std5 
6 oxaliplatin 
std1 96 
oxaliplatin 
std1 186 
oxaliplatin 
std1 276 
oxaliplatin 
std1 
7 oxaliplatin 
std2 97 
oxaliplatin 
std2 187 
oxaliplatin 
std2 277 
oxaliplatin 
std2 
8 oxaliplatin 
std3 98 
oxaliplatin 
std3 188 
oxaliplatin 
std3 278 
oxaliplatin 
std3 
9 oxaliplatin 
std4 99 
oxaliplatin 
std4 189 
oxaliplatin 
std4 279 
oxaliplatin 
std4 
10 oxaliplatin 
std5 100 
oxaliplatin 
std5 190 
oxaliplatin 
std5 280 
oxaliplatin 
std5 
11 70115T00 101 75115T00 191 80115T00 281 85115T00 
12 70125T00 102 75125T00 192 80125T00 282 85125T00 
13 70150T00 103 75150T00 193 80150T00 283 85150T00 
14 70P00 104 75P00 194 80P00 284 85P00 
15 70O00 105 75O00 195 80O00 285 85O00 
16 70115T01 106 75115T01 196 80115T01 286 85115T01 
17 70125T01 107 75125T01 197 80125T01 287 85125T01 
18 70150T01 108 75150T01 198 80150T01 288 85150T01 
19 70P01 109 75P01 199 80P01 289 85P01 
20 70O01 110 75O01 200 80O01 290 85O01 
21 70115T02 111 75115T02 201 80115T02 291 85115T02 
22 70125T02 112 75125T02 202 80125T02 292 85125T02 
23 70150T02 113 75150T02 203 80150T02 293 85150T02 
24 70P02 114 75P02 204 80P02 294 85P02 
25 70O02 115 75O02 205 80O02 295 85O02 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
86 70115T15 176 75115T15 266 80115T15 356 85115T15 
87 70125T15 177 75125T15 267 80125T15 357 85125T15 
88 70150T15 178 75150T15 268 80150T15 358 85150T15 
89 70P15 179 75P15 269 80P15 359 85P15 
90 70O15 180 75O15 270 80O15 360 85O15 
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All samples were analysed by LC-MS using a Thermo Surveyor quaternary 
HPLC and a LCQ Deca quadrupole ion trap mass spectrometer operating in 
the negative ion mode and utilising an electrospray API source.  
 System  Thermo Surveyor autosampler and quaternary HPLC 
 LCQ Deca quadrupole ion trap mass spectrometer utilising 
an Electrospray API source 
 Mode   negative ion mode 
 Mass range  m/z300-600 
 Tune file  Ptdc neg 050517 
 Capillary temperature 200ºC 
 Capillary voltage 5.0 kV 
 Probe position  4 
 Flow rate  400 µl/min 
 Column   SGE GL Nucleosil C4 2.0 x 150 mm (5 µm) 
 Mobile phase   45% acetonitrile containing 20mM ammonium formate 
 Injection volume 2 µl 
 Run time  6 min (Divert to MS from 1 to 3.2 min) 
Analytes monitored 
The MS was setup to quantify negative ions related to the reactants (m/z300 – 
600). These ions are represented in Figure 2.13. 
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Figure 2-13:  Analytes monitored during the reaction of Pt(dach)Cl2 and tbaox in 95% dmf. 
Method M3.3.2 Determination of [Pt(dach)Cl2] and [oxaliplatin] in 95% iaOH 
Stock solution preparations (95% iaOH) 
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• Pt(dach)Cl2 in 95% iaOH (1.0 mM/378 ppm) 
A mass of 15.1 mg of Pt(dach)Cl2 was weighed into a 50 ml polypropylene Greiner 
tube.  To this was added 40.0 ml 95% iaOH (water).  The solution was shaken and 
briefly sonicated whereafter a coated magnetic stirring bar (Teflon) was added.  
The polytop was placed on a Pierce ReactiTherm variable speed stirrer and set to 
position 8.  Sample aliquots (200 µl) were withdrawn from this stirring suspension.  
(Reproducibility of stirring-pot sampling method determined as 2.8% RSD, n=5)  
• tbaox in 95% iaOH (5.0 mM/pH 7) 
Oxalic acid (1.0 g) was weighed into a plastic 15 ml falcon tube. Water (10 ml) was 
added to give a concentration of 0.1 g/ml (1.111 M oxalate). Water (8.0 ml) was 
added to this solution (0.9 ml). To this was added 1.1 ml tbaOH (40%/1.5 M). The 
pH of this solution was 7.0. This solution (1.5 ml) was added to iaOH (28.5 ml) to 
obtain a solution that contained 5 mM tbaox in 95% iaOH. 
• Oxaliplatin 400 ppm/water 
weighed oxaliplatin (CRS, 1.60 mg) into a glass vial and added 4.0 ml water. 
• Pt(dach)Cl2 400 ppm/dmf 
weighed Pt(dach)Cl2 (1.60 mg ) into a glass vial and added 4.0 ml dmf. 
• Y14.2 (Internal standard)/160 ppm/dmf 
weighed Y14.2 (12.8 mg) into a Schott bottle (100 ml) and added 80.0 ml dmf. The 
resultant solution was 80 ml of Y14.2 at a concentration of 160 ppm/dmf. 
 Sample solution preparations 
All reactions were performed in 2 ml glass autosampler vials with Teflon lined 
septa. The reaction solutions were transferred to each vial using a calibrated auto 
pipette with the appropriate sized plastic tip.  The volume of each of the stock 
solutions used is depicted in the Table 2.10. 
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Table 2-10:  Table indicating how the sample solutions were prepared prior to incubation 
and analysis (95% iaOH reaction). 
Reaction of Ptdc with tbaox in 95% iaOH - different ratio's 
  
Volumes (µl) to 2 ml AS vials 
  
1:1.50 1:2.50 1:5.00 
Ptdc (1 mM) 95% iaOH 200 200 200 
tbaox (5 mM) 95% iaOH 60 100 200 
iaOH 95% 140 100 0 
Total volume (µl) 400 400 400 
      
Addition of internal standard     
Y14.2 (160 ppm) dmf 400 400 400 
Total volume 800 800 800 
All samples to be analysed: 47.5% iaOH, 50% dmf , 2.5% H2O 
  
The total number of vials required is given in Table 2.11. 
Table 2-11:  Vial requirements for the reaction in 95% iaOH. 
Ratio 75ºC 80ºC 85ºC 90ºC 
1:1.50 16 16 16 16 
1:2.50 16 16 16 16 
1:5.00 16 16 16 16 
Total 192 
Standard solution preparations 
The methods used to prepare oxaliplatin and Pt(dach)Cl2 standard solutions are 
given in Tables 2.12 and 2.13. 
Table 2-12:  Preparation of calibration standards for oxaliplatin (95% iaOH reaction). 
Oxaliplatin standards preparation 
Stock solutions        [oxaliplatin]  [oxaliplatin] 
oxaliplatin in water (ppm) 400   (ppm) (ppm) 
  stock (µl) H2O (µl) Total in 400 µl in 800 µl 
std1 40 360 400 40 20 
std2 80 320 400 80 40 
std3 120 280 400 120 60 
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std4 160 240 400 160 80 
std5 200 200 400 200 100 
% dmf in 800 µl  50    
% water in 800 µl  50    
Table 2-13:  Preparation of calibration standards for Pt(dach)Cl2 (95% iaOH reaction). 
Ptdc standards prep 
Stock solutions        [Ptdc]  [Ptdc] 
Ptdc in dmf (ppm) 400   (ppm) (ppm) 
  stock (µl) dmf (µl) Total in 400 µl in 800 µl 
std1 40 360 400 40 20 
std2 80 320 400 80 40 
std3 120 280 400 120 60 
std4 160 240 400 160 80 
std5 200 200 400 200 100 
% dmf in 800 µl  100    
% water in 800 µl  0    
• Sample reactions 
The standards and samples were prepared as indicated in the tables above. The 
samples were placed in an oven at the indicated temperature and periodically 
withdrawn. The withdrawn samples were placed in a freezer at -18ºC.  Prior to 
analysis the standards and samples were allowed to equilibrate whereafter 
internal standard was added to all vials (400 µl Y14.2/160 ppm/dmf).  The vials 
were shaken thoroughly.  A homogenous solution was obtained for all standards 
and samples.  The T13, T14 and T15 samples of the 75 and 80ºC batches that 
were monitored for 12 h, were removed from the oven at the end of the day and 
placed at -18ºC overnight.  On the following day the samples were allowed to 
equilibrate to RT before being replaced in the ovens for further reaction.  No 
deviations from the oxaliplatin formation curves were noticed for these samples. 
• Analysis 
Although the analysis method made use of a column as in traditional LC-MS, the 
purpose of the column in this case was not the separation of the components.  
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The C4 column used was merely to provide some backpressure to the system 
pump ensuring that the sample constituents entered the mass spectrometer in a 
tight reproducible band facilitating quantitation.  Some separation was obtained in 
that the composite sample peak was resolved from isobaric non platinum 
components related to tbaox. 
             System Thermo Surveyor autosampler and quaternary HPLC LCQ 
Deca quadrupole ion trap mass spectrometer utilising an 
Electrospray API source 
 Mode   negative ion mode 
 Mass range  m/z300-600 
 Tune file  Ptdc neg 050517 
 Capillary temperature 200ºC 
 Capillary voltage 5.0 kV 
 Probe position  4 
 Flow rate  400 µl/min 
 Column   SGE GL Nucleosil C4 2.0 x 150 mm (5 µm) 
 Mobile phase   45% acetonitrile containing 20 mM ammonium formate 
 Injection volume 2 µl 
 Run time  6 min (Divert to MS from 1 to 3.2 min) 
Table 2.14 depicts the analysis sequence that was followed.  Notice that a 
calibration was performed before each temperature set was analysed. 
Table 2-14:  Table stipulating the sample analysis sequence followed during the 95% 
iaOH study. 
Run # Sample Run # Sample Run # Sample Run # Sample 
1 Ptdc std1 91 Ptdc std1 181 Ptdc std1 271 Ptdc std1 
2 Ptdc std2 92 Ptdc std2 182 Ptdc std2 272 Ptdc std2 
3 Ptdc std3 93 Ptdc std3 183 Ptdc std3 273 Ptdc std3 
4 Ptdc std4 94 Ptdc std4 184 Ptdc std4 274 Ptdc std4 
5 Ptdc std5 95 Ptdc std5 185 Ptdc std5 275 Ptdc std5 
6 oxaliplatin 
std1 96 
oxaliplatin 
std1 186 
oxaliplatin 
std1 276 
oxaliplatin 
std1 
7 oxaliplatin 
std2 97 
oxaliplatin 
std2 187 
oxaliplatin 
std2 277 
oxaliplatin 
std2 
8 oxaliplatin 
std3 98 
oxaliplatin 
std3 188 
oxaliplatin 
std3 278 
oxaliplatin 
std3 
9 oxaliplatin 
std4 99 
oxaliplatin 
std4 189 
oxaliplatin 
std4 279 
oxaliplatin 
std4 
10 oxaliplatin 
std5 100 
oxaliplatin 
std5 190 
oxaliplatin 
std5 280 
oxaliplatin 
std5 
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Run # Sample Run # Sample Run # Sample Run # Sample 
11 75115T00 101 80115T00 191 85115T00 281 90115T00 
12 75125T00 102 80125T00 192 85125T00 282 90125T00 
13 75150T00 103 80150T00 193 85150T00 283 90150T00 
14 75P00 104 80P00 194 85P00 284 90P00 
15 75O00 105 80O00 195 85O00 285 90O00 
16 75115T01 106 80115T01 196 85115T01 286 90115T01 
17 75125T01 107 80125T01 197 85125T01 287 90125T01 
18 75150T01 108 80150T01 198 85150T01 288 90150T01 
19 70P01 109 80P01 199 85P01 289 90P01 
20 75O01 110 80O01 200 85O01 290 90O01 
21 75115T02 111 80115T02 201 85115T02 291 90115T02 
22 75125T02 112 80125T02 202 85125T02 292 90125T02 
23 75150T02 113 80150T02 203 85150T02 293 90150T02 
24 75P02 114 80P02 204 85P02 294 90P02 
25 75O02 115 80O02 205 85O02 295 90O02 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
86 75115T15 176 80115T15 266 85115T15 356 90115T15 
87 75125T15 177 80125T15 267 85125T15 357 90125T15 
88 75150T15 178 80150T15 268 85150T15 358 90150T15 
89 75P15 179 80P15 269 85P15 359 90P15 
90 75O15 180 80O15 270 85O15 360 90O15 
Analytes monitored 
The same analytes as described for the reaction in 95% dmf were monitored (see 
Figure 2.13). 
2.4 .2 Methods ut i l ised in  Chapter  4  
Structural verification of the synthesised N-S platinum complexes was performed by 
infusing a solution of each compound in MeCN (ca. 1 mg/ml) directly into the mass 
spectrometer.  Unique molecular ions were obtained demonstrating that the correct 
structure had been prepared during synthesis and that the energy imparted by the 
instrument during the electrospray process was not excessive.  Samples were also 
dissolved in water and similarly analysed.  In cases where rapid hydrolysis had taken 
place markedly different mass spectra were obtained with prominent hydration 
product ions dominating.  To try and visualize the effect of sustained ionisation over 
time, aliquots of the aqueous samples were heated at 80ºC for at least 18 h and 
reanalysed. 
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To try and characterise the ionisation rate of each individual compound, aqueous 
solutions were prepared and analysed over time.  The formation of the ionisation 
product(s) and the degradation of the original compounds were quantified by 
integration of the peaks produced for each.  As the ionisation rates of the 
individual species varied greatly, two different methods were utilised. 
Method M4.1 Fast loops method 
Some of the transitions occurred very rapidly and in order for the method to be 
applicable, it had to enable sampling at very short intervals.  For such rapid transitions 
a fast loops method was used, typically monitoring transitions between 0.5 and 4 min.  
This required that the sample be dissolved in MeCN at a concentration of 600 µM.  A 
non-aqueous solvent was used.  Use of water was not possible as by the time that 
the sample had dissolved sufficiently to allow for analysis, the transition would have 
been completed.  Immediately prior to the start of the analysis an aliquot of the 
solvent solution (50 µl) was added to water (450 µl) to yield a 10% MeCN solution 
(90% water) containing the analyte at a concentration of 60 µM.  This solution was 
then sampled (5 µl loop) at 20 s intervals to monitor the effect of water on the analyte 
species.  This technique was used to monitor the drop in dihalide concentration.  
However, even though the T0 time for this method was typically 30 s, it is suspected 
that we have only managed to plot the latter part of this very fast reaction and that the 
deduced ionisation T½ times are in fact much shorter.  To compensate for the speed 
of the reaction the T0 concentration was obtained as described above but dilution 
was carried out using MeCN i.e. 60 µM in MeCN. 
Instrument setup 
           System Thermo Surveyor autosampler and quaternary HPLC LCQ 
Deca quadrupole ion trap mass spectrometer utilising an 
Electrospray API source 
 Mode   Pos ion mode 
 Mass range  m/z200-600 
 Tune file  Ptdc 050510 
 Capillary temperature 200ºC 
 Capillary voltage 3.5 kV 
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 Probe position  3 
 Flow rate  200 µl/min 
 Column   No column was used 
 Injection  5 µl stainless steel loop 500 µl Unimetrics HPLC syringe 
Method M4.2 Incubation method 
For transitions occurring less rapidly, the samples were dissolved in MeCN at a 
concentration of 600 µM. Prior to analysis (0.5 min) an aliquot of the MeCN 
solution was diluted with water (37ºC) to produce a solution of 6 µM in 1% MeCN 
(99% water).  The samples were then placed in a heated tray (37ºC) and sampled 
periodically, typically monitoring transitions between 0.5 and 180 min.  The 
difficulty with this technique is that it can be influenced by instrument drift as the 
detector is on for the entire period.  This implies that identical samples analysed 2 
h apart may show differences in the ion intensities and hence the perceived 
concentration of species.  Such differences in ion intensities will detrimentally 
affect ionisation curves leading to false ionisation T½ times.  The relative 
abundance of the species will however be reflected correctly.  Therefore plotting 
the individual ion intensities as a function of the total ion current (TIC) was 
considered as a possible solution.  The general assumption being that all 
ionisation and degradation products are detected and contribute to the TIC (unsafe 
assumption). The best way to compensate for the problem would be through the use 
of a suitable internal standard. In the absence of such a compound all steps were 
taken to ensure that the analysis time was kept to a minimum. The three known 
anticancer compounds were analysed in 100% water (100 µM). 
Instrument setup 
             System Thermo Surveyor autosampler and quaternary HPLC LCQ 
Deca quadrupole ion trap mass spectrometer utilising an 
Electrospray API source 
 Mode   Pos ion mode 
 Mass range  m/z200-600 
 Tune file  Ptdc 050510 
 Capillary temperature 200ºC 
 Capillary voltage 3.5 kV 
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 Probe position  3 
 Flow rate  200 µl/min 
 Column   No column was used 
 Injection  dichlorides 10 µl; dibromides 15 µl and diiodides 20 µl 
    cisplatin 20 µl; carboplatin 10 µl; oxaliplatin 4 µl 
2.4 .3 Methods ut i l ised in  Chapter  5  
Method M5.1 Direct MS infusion 
Structural verification of the synthesised mononitro complexes of platinum(IV) was 
performed by infusing a solution of each compound in water (ca. 0.5 mg/ml) 
directly into the mass spectrometer.  Unique molecular ions were obtained 
demonstrating that the correct structure had been prepared during synthesis.  Due 
to the utilisation of NO2 (g) nitrates were often present in the dried sample material 
tested.  The formation of distinct nitrate adducts in the negative ion mode served 
as additional confirmation of the molecular mass of certain species.  Detection of 
the unique target ions confirmed that the energy imparted by the instrument during 
the electrospray ionisation process was not excessive and that in-source 
ionisation was not compromising compound identification.  
The instrumental conditions used during direct infusion studies are detailed in 
section 2.3.1. 
Method M5.2 HPLC-UV analysis of aqueous sample solutions 
Three very similar methods were selected for routine analysis of synthetic samples 
during this study.  For all three methods the injection volume (5 µl), sample 
concentration (0.5 mg/ml), detection wavelength (210 nm) and eluent (2.5% MeCN) 
was kept constant.  Depending upon the application, the flow rate was adjusted from 
0.8 to 1.2 ml/min and one of 2 columns was selected.  All initial work was performed 
on an YMC Hydrosphere C18 column while later studies were conducted using the 
more polar Phenomenex Curosil PFP (perfluorinated phenyl) column.  These 
columns having different stationary phases and hence selectivities, were similar in 
dimension i.e. 250x4.6 mm, 5 µm particle size. 
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2.4 .4 Methods ut i l ised in  Chapter  6  
Reactant stock solutions were prepared in water.  As the ratio of challenge agent to 
drug was kept constant throughout the study (2:1), aqueous stock solutions of the 
challenge agents were prepared at a concentration of 2.0 mM and drug stocks at 1.0 
mM.  This simplified preparation of reaction solutions and facilitated detection of the 
relevant species well within the linear range of the detector.  Table 2.15 is a typical 
sample preparation outlay used during one such trial. 
Table 2-15:  Table detailing the preparation of sample solutions and appropriate control 
solutions for a typical binding assay involving cysteine. 
Sample 
Volume 
Drug 
(1mM) 
(ml) 
Volume 
Cys 
(2mM) 
(ml) 
Volume 
Buffer 
(10mM) 
(ml) 
Volume 
NaCl 
200mM 
(ml) 
Volume  
Buffer (10 mM) 
NaCl (200 mM) 
(ml) 
Water 
 
 
(ml) 
Sample 0.5 0 0 0 0 1.5 
Sample + buffer 0.5 0 1.0 0 0 0.5 
Sample + Cys 0.5 0.5 0 0 0 1.0 
Sample + buffer + Cys 0.5 0.5 1.0 0 0 0 
Sample + NaCl 0.5 0 0 1.0 0 0.5 
Sample + NaCl + Cys 0.5 0.5 0 1.0 0 0 
Sample + NaCl + Cys + 
Buffer 
0.5 0.5 0 0 1.0 0 
The procedure outlined in Table 2.15 resulted in the following concentrations: Cys 
0.50 mM; Drug 0.25 mM; buffer 5.0 mM and NaCl 100 mM. 
Drug binding assays were followed by monitoring the concentration of the drug in the 
reaction mixture.  This was achieved through direct injection of a fixed volume into the 
mass spectrometer i.e. without prior column separation.  Very short run times are a 
benefit of such determinations.  However, a drawback of this technique is the inability 
to distinguish between actual reaction products and gas phase associations formed in 
the API source.  To compensate for this and where isobaric species were present, the 
sample was injected onto a column to enable separation of the different species.  In 
some cases where new compounds had resulted from the drug and the reactants, 
more advanced separations were performed on higher resolution columns.  The 3 
basic analysis methods utilised are summarised below.  In each case the actual 
instrument settings were similar to those described in section 2.3.1. 
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Method M6.1 Direct injection 
HPLC-MS analysis parameters        
Column  No column was used 
Flow rate  200 µl/min 
Eluent A  1% ACN, 20mM AF 
Eluent B  70% ACN, 10mM AF 
Isocratic  22% A, 78% B 
Run time  4 min 
Injection volume 3 µl 
Probe position 3 
Capillary temp 200ºC 
Method  Ptdc pos no column 060424 
Tune file (Pos) Ptdc 050510 
Scan range  m/z300-1500 
Method M6.2 Gemini column separation 
Method  061006 Bind assay pos 
Column  Gemini C18, 30x2.0 mm, 5 µm 
Flow rate  400 µl/min 
Eluent C  55% MeCN, 12 mM AF 
Run time  3 min 
Probe position 3 
Capillary temp 200ºC 
Injection volume 2 µl 
Scan range  m/z300-1200 
Tray temp  14ºC 
Tune File (Pos) Ptdc 050510 
Method M6.3 Hydrosphere column separation 
Method  060630 Hydrosphere 1 ACN  
Column  Hydrosphere C18, 250x4.6mm, 5µm 
Flow rate  1.0 ml/min (split using red line) 
Eluent   1% MeCN, 20 mM AF, 0.15% FA (pH 3.5) 
Run time  15 min 
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Probe position 3 
Capillary temp 200ºC 
Injection volume 5 µl 
Scan range  m/z300-1200 
Tray temp  Room temperature 
Tune File (Pos) Ptdc 050510 
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Chapter 3:   
Direct l igand exchange reactions 
employed for the novel synthesis 
of oxaliplatin 
3.1 Introduction 
The starting material for any platinum pharmaceutical is either K2PtCl6 or K2PtCl4.  
A neutral platinum(II) chloro complex can be prepared by the reaction of the 
neutral ligand such as trans-ℓ-1,2-diaminocyclohexane (dach) with K2PtCl4 in an 
aqueous medium according to equation 3.1. 
K2PtCl4 + dach  Pt(dach)Cl2 + 2K+ + 2Cl-   eq. 3.1 
When leaving groups (anions) other than Cl- are required the ligand exchange is 
achieved indirectly (without exception), by a two step reaction in which a silver salt 
(such as AgNO3 or Ag2SO4) is employed to remove the Cl- by precipitation as AgCl 
with the resulting formation of for example a diaqua complex, e.g. [Ptdach(H2O)2]2+, in 
the presence of a poorly coordinating anion towards platinum(II), e.g. NO3- or SO42-. 
After filtration of the AgCl the resulting platinum(II) diaqua complex can be reacted 
with an alkali metal salt of the required anion e.g. potassium oxalate to give 
complexes such as Pt(dach)ox (see eq. 3.2 and eq. 3.3). 
Pt(dach)Cl2 + 2Ag+ + 2NO3-  [Pt(dach)(H2O)2]2+ + 2AgCl + 2NO3-         eq. 
3.2 
[Pt(dach)(H2O)2]2+ + ox2-  Pt(dach)ox    eq. 3.3 
The above “silver method” has a number of disadvantages: 
The reaction must be performed in the dark at room temperature and at least 
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below 50ºC in view of the metastability of the diaqua species which is relatively 
active towards hydrolysis and oxidation to platinum(IV).  The precipitation of AgCl 
requires many hours for completion due to the covalent nature of the platinum-Cl 
bonds and the resulting slow ionisation reaction. 
(i) Contamination with Ag+ also occurs and extra steps are required to 
remove excess Ag+. 
(ii) The crude yield is relatively high but recrystallisation of the final 
product is necessary to obtain the high degree of purity required. 
(iii) The multi-step time consuming nature of this method is 
unsatisfactory for large-scale synthesis. 
In view of the above drawbacks and the fact that oxaliplatin is the world’s most 
prescribed  anticancer agent for colorectal cancer, efforts were directed by this 
research unit to develop novel improved synthetic methods for this drug. 
Three different methods were successfully developed utilizing direct ligand 
exchange at elevated temperature, viz. 
(a) The reaction of dach in a buffered aqueous solvent at elevated 
temperature with K2Ptox2; 
(b) The reaction of Pt(dach)Cl2 with excess oxalate in an essentially non 
aqueous solvent, i.e. 95% dmf (water); and 
(c) The reaction of Pt(dach)Cl2 with excess oxalate in another 
essentially non aqueous solvent, i.e. 95% isoamylalcohol (water). 
The complete synthesis using reaction (a) is described in an MSc dissertation;107 
that of reaction (b) in a PhD thesis108 as well as (c) in another PhD thesis.109  
In this chapter results obtained by the techniques described in Chapter 2 will be 
interpreted in order to understand the detailed chemistry involved in the 
abovementioned reactions viz. 
(i) Reaction (a) K2Ptox2/dach 
(ii) Reaction (b) Pt(dach)Cl2 + oxalate in 95% dmf (water) 
(iii) Reaction (c) Pt(dach)Cl2 + oxalate in 95% isoamylalcohol (water) 
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3.2  Reaction (a)  K2Pt(ox)2/dach 
In this method the starting material already contains the oxalate (Pt(ox)22-) and 
one oxalate could be replaced by dach.  Literature describing utilisation of this 
method could not be found and the lack of study in this area is thought to be due 
to two factors, namely the low yield obtained for the production of (Pt(ox)22-) 
(30%),110 and the fear that oxalate will reduce platinum(II) to platinum black at the 
elevated temperatures required for the reaction.  
However studies undertaken by this laboratory showed that successful ligand 
exchange could be achieved and that oxaliplatin could be produced (22% yield)107 
leading to the filing of a patent on this novel synthetic application.1 
Initial applications of this synthetic route employed a molar equivalent of aqueous 
dach which was added to hot (90ºC) aqueous K2Ptox2 under nitrogen.  The solid 
precipitate was filtered, dried and analysed.  Initial results using FAB MS yielded a 
molecular ion at m/z398 and subsequent CHN analysis also indicated that the 
product was oxaliplatin.  However the yellow colour of the product as well as the 
insoluble nature thereof was inconsistent with expectations.  The product was 
further examined using LC and ESI-MS. Chromatographic comparison with an 
oxaliplatin sample synthesised using the silver method (Figure 3.1) revealed that 
there was no oxaliplatin present in the sample.  
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Figure 3-1:  Figure showing an overlay of the 2 chromatograms obtained for the 
oxaliplatin standard solution and that of the sample solution. The sample 
solution does not contain any oxaliplatin (6.43 min) but only an unknown 
peak at 3.50 min. 
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To identify the unknown peak eluting at 3.50 min the sample was analysed by 
direct infusion ESI-MS.  Two platinum ion clusters were detected one in positive 
ion mode at m/z421 and one in negative ion mode at m/z371.  Further structural 
elucidation was performed by examining the fragmentation spectra (MSn) of each 
ion cluster individually.  The data is presented in Figure 3.2a and 3.2b. 
 
 
 
 
 
 
 
 
Figure 3-2a: Positive ion mode fragmentation spectra obtained for the ion cluster at 
m/z421. 
 
 
 
 
 
 
 
 
Figure 3-2b:  Negative ion mode fragmentation spectra obtained for the ion cluster at 
m/z371. 
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From the data obtained it became evident that autoionisation had occurred and 
that the species produced was in fact the autoionisation product [Pt(dach)2][Ptox2] 
as depicted in Figure 3.3. This is plausible as the large lattice energy of the doubly 
charged cationic and anionic species (auto ionised) totally dominates the product 
formed under the above experimental conditions. 
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2- 2+
 
Figure 3-3:  Autoionised product from the reaction between K2Ptox2 and dach. 
The false confirmation supplied by the CHN analysis can be explained by the fact 
that the ratio of C: H: N was the same for the autoionised product as for 
oxaliplatin.  The result obtained by FAB MS is intriguing and more difficult to 
explain.  It is suspected that molecular rearrangement takes place after contact 
with the high energy particle beam (Xe atoms) during ionisation of the sample, to 
yield traces of oxaliplatin.  
With the autoionisation product having been identified, subsequent 
experimentation was directed at limiting the autoionisation reaction.  Steps taken 
to limit autoionisation included decreasing the ratio of dach to K2Ptox2 in the initial 
reaction.  This was achieved by the incremental addition of the dach to the 
K2Ptox2.  Dilute acetic acid was also used to decrease the pH of the dach solution.  
Final reaction conditions involved the incremental addition (8 x 12.5%) of an 
equimolar amount of buffered dach (pH 6.6-7.5) to the K2PtOx2 (aq) at 90ºC.  The 
best yield obtained under these conditions was 22%.  
3.3 Essential ly non-aqueous solvent systems 
3.3 .1 Genera l   
In light of the disadvantages of using an aqueous solution in the case of oxalate, 
which is known to reduce platinum(II) to platinum black at elevated temperatures, 
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and the rapid hydrolysis rate of platinum(II)Cl2 complexes in water, it was decided 
to investigate the use of a different solvent system.  
The purpose was to exchange 2Cl- for one oxalate ion in the square planar 
platinum(II) complex (Figure 3.4). 
NH2
NH2 O
O
O
O
Pt
NH2
NH2 Cl
Cl
Pt
O
O
O-
O-
2Cl-+ +
 
Figure 3-4:  Simplified reaction scheme for the synthesis of oxaliplatin from Pt(dach)Cl2 
and oxalate. 
Requirements for the solvent system 
• A solvent system in which both of the reagents are soluble enough to allow 
for reaction.  Preferably, the oxalate salt must have a greatly different 
solubility property relative to the product (oxaliplatin).  This will facilitate the 
isolation of the oxaliplatin final product. 
• A dielectric constant which will allow enough ionisation to enable ligand 
exchange (part of the driving force for the reaction is the replacement of a 
monodentate ligand (Cl-) with a bidentate one (C2O42-) – thus an entropy 
driven reaction is required). 
• A solvent system in which solvation can occur but preferably not solvolysis. 
The anation (replacement by an anion) of a neutral oxygen donor ligand 
from the coordination sphere of the platinum(II) will readily occur whereas 
that of a solvolysed species will not (i.e. at a neutral pH). 
• A solvent system in which the product (oxaliplatin) is insoluble and all the 
other species remain soluble will be very useful since it will provide 
additional driving force to the reaction and minimise decomposition of the 
oxaliplatin. 
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Ligand exchange using metal oxalates 
The logical source of oxalate for the above purpose would be metal oxalates.  The 
common ones viz. Na2C2O4 and K2C2O4 are insoluble in dmf.  The heavier alkali 
metal oxalates are much more soluble in water for example 283 g of Cs2C2O4 
dissolves in 100 ml of cold water. 
Experiments were subsequently performed using Cs2C2O4 as a source of the 
oxalate.  Pure oxaliplatin could be produced in an overall yield of 25% using a 
reaction time of 4 h at 90°C and a solvent mixture of 83% dmf and 17% H2O. 
The main disadvantage of this system, however was the scarcity and expense of 
Cs2C2O4. 
Tetrabutylammonium as source of oxalate 
After much trial and error and tedious experimentation, a quaternary ammonium 
salt was chosen as the source of oxalate ions for the reaction.  The greater 
organic character endowed by the organic cation and its relatively weak ion-
pairing with oxalate, would enable adequate solubility in the non-aqueous reaction 
medium as well as allowing its subsequent removal from the hydrophilic 
oxalatoplatinum(II) product.  Furthermore, the disparity in size between cation and 
anion was not excessively large to render the salt thermally unstable.  The choice 
of oxalate complex was tetrabutylammonium oxalate since the oxalates of the 
smaller tetraalkyl analogues were not soluble enough in dmf.  This salt was not 
commercially available and was synthesised by reacting tetrabutylammonium 
hydroxide solution with pure oxalic acid in a 2:1 mole ratio. The salt is extremely 
hygroscopic.  Upon heating the solid to 80°C it gradually darkens. 
In light of the previous observation a temperature of 65°C and a solvent mixture of 
~90% dmf and 10% water, was used as initial general starting conditions for the 
reaction. 
The next question was whether to use an excess of oxalate ions.  Chemical 
potential is an important factor in direct ligand exchange reactions and indeed an 
excess of oxalate would be expected to enhance the forward reaction.  However, 
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oxalate is a reducing agent and its ability to reduce platinum(II) to platinum(0) is 
known.111  Thus, from a chemical standpoint, it would make no sense to react an 
excess of a reducing agent with platinum(II) at elevated temperatures.  Indeed, 
this could very well have been the reason why such reactions have been poorly 
studied.  However, our work on the synthesis of bisoxalato complexes of 
platinum(II),1 indicated that a large excess of oxalate, under appropriate 
conditions, can actually enhance the formation of the oxalate product and stabilise 
it, thus overcoming its reducing power.  On this basis, we decided to experiment 
with various oxalate to Pt(dach)Cl2 ratios, viz. 1.5:1, 2.5:1 and 5.0:1.  
Temperature range and kinetics 
Ligand exchange in the silver method was performed at room temperature since 
the driving force in that case is the affinity of Ag+ for halide and the insolubility of 
the silver halides.  In the case of direct ligand exchange of Cl- with oxalate the 
driving force is only the enhanced chemical potential of oxalate by using an 
excess of oxalate and the bidentate nature of oxalate thus resulting in a “chelate 
effect”. Higher temperatures are therefore required to achieve exchange in a 
reasonable time. 
In the experiment with Cs2C2O4 it was noticed that a slight darkening of the 
solution gradually occurred upon heating the reaction to 90°C. This temperature 
was thus set as the upper limit for reactions. 
At this stage it was realised that kinetic data was required to improve our insight 
into the reaction.  The effect of temperature 70-90°C and oxalate concentration 
(varied from 1.5-5.0 mol equivalents) were thus investigated through the use of 
microscale reactions.  Use was made of LC-MS in which the concentrations of 
Pt(dach)Cl2 and oxaliplatin respectively were monitored as a function of reaction 
time, reaction temperature and reagent concentrations. 
3.3 .2 Exper imenta l  
During the course of this study two essentially non-aqueous solvent systems were 
tested and evaluated for the synthesis of oxaliplatin via the reaction of Pt(dach)Cl2 
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with excess oxalate. The first solvent utilised was dmf / (5% water). Thereafter a 
solvent system consisting of iaOH / (5% water) was tested.  
As the focus in this section is on the reaction between tbaox and Pt(dach)Cl2 in 
essentially non-aqueous solvent systems (95% dmf and later 95% iaOH), to yield 
oxaliplatin, specific methods to accurately monitor all aspects of the reaction were 
developed. The requirements and methods utilised are summarised in Figure 3.5. 
Each method is detailed in Chapter 2 under the specific method heading.  
 
tbaox + PtdachCl2  oxaliplatin + 2Cl- + 2tba+ 
Standardisation of 
starting material 
 
●Method (M3.1) for 
the standardisation of 
tbaox in dmf 
Monitoring of reaction 
compounds 
 
●Method (M3.3) for the 
determination of 
[PtdachCl2] and [oxaliplatin] 
in solvent 
Degradation monitoring of reaction compounds 
 
●Method (M3.2) for the determination of [oxalate] in 95% 
dmf 
●Method (M3.3.1) for the determination of [PtdachCl2] and 
[oxaliplatin] in 95% dmf 
●Method (M3.3.2) for the determination of [PtdachCl2] and 
[oxaliplatin] in 95% iaOH 
Standardisation of 
starting material 
 
●No standardisation 
required. Reference 
standards available 
 
Figure 3-5:  Outline of methods used in this section. For a full explanation of these 
methods see Chapter 2.4.1. 
3.3 .3 React ion (b)  Pt (dach)Cl 2  +  oxalate  in  95 % 
dmf/  (w ater )  
Kinetic data 
In Figures 3.6 to 3.9, the normalised concentrations of both Pt(dach)Cl2 and 
oxaliplatin are plotted as a function of time at temperatures of 70°C (Figure 3.6); 
75°C (Figure 3.7), 80°C (Figure 3.8) and 85°C (Figure 3.9).  In each graph the data 
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are plotted for three different Pt(dach)Cl2: tbaox ratios (1:1.5, 2.5 and 5.0). 
Reaction temperature 70C in 95% dmf
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Figure 3-6:  Normalised concentrations of both Pt(dach)Cl2 and oxaliplatin as a function of 
time at 70°C for three different Pt(dach)Cl2: tbaox ratios (1:1.5, 2.5 and 5.0) in 
95% dmf. 
Reaction temperature 75C in 95% dmf
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Figure 3-7:  Normalised concentrations of both Pt(dach)Cl2 and oxaliplatin as a function of 
time at 75°C for three different Pt(dach)Cl2: tbaox ratios (1:1.5, 2.5 and 5.0) in 
95% dmf. 
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Reaction temperature 80C in 95% dmf
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Figure 3-8:  Normalised concentrations of both Pt(dach)Cl2 and oxaliplatin as a function 
of time at 80°C for three different Pt(dach)Cl2: tbaox ratios (1:1.5, 2.5 and 5.0) 
in 95% dmf. 
Reaction temperature 85C in 95% dmf
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Figure 3-9:  Normalised concentrations of both Pt(dach)Cl2 and oxaliplatin as a function 
of time at 85°C for three different Pt(dach)Cl2: tbaox ratios (1:1.5, 2.5 and 5.0) 
in 95% dmf. 
The pronounced increase in reaction rate with increase of temperature is reflected 
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by these curves.  The reaction times required for the formation of ~33% of 
oxaliplatin theoretically are 11.5 h (70°C); 7 h (75°C), 5 h (80°C) and 3.5 h (85°C).  
From Figure 3.6 to Figure 3.9 it can be seen that the increase in the oxalate 
concentration has a relatively small affect on the formation of the oxaliplatin.  In 
Figure 3.10 the rate curves for 70°C and 85°C are compared both in the case of a 
Pt(dach)Cl2 to tbaox ratio of 1:5 to facilitate a more direct observation of the effect 
of temperature.  
 
 
 
Figure 3-10:  Oxaliplatin formation curves at 70 and 85ºC together with the corresponding 
Pt(dach)Cl2 reaction curves for the studies conducted in 95% dmf. 
In Figure 3.10 it is noticeable that the formation of oxaliplatin level’s off at ~65% 
after ~7 h at 85°C. The most obvious explanation for the observation would be that 
due to limited solubility, oxaliplatin has reached a maximum concentration in the 
reaction mixture (95% dmf). To test this hypothesis an experiment was performed 
in which the reactions were repeated at the same ratios of Pt(dach)Cl2 to tbaox 
(1:5.0 at 80ºC in 95% dmf), but the absolute concentration of the reactants were 
diluted to 75, 50 and 25% of the concentration used in the study depicted above.  
The findings showed that the observed decrease in expected oxaliplatin 
concentration was not due to solubility limitations. 
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The leveling off of the oxaliplatin concentration can be interpreted in terms of the 
equilibrium reached for the formation in equation 3.4, since this reaction is 
reversible. 
                           Pt(dach)Cl2 + ox2-  Pt(dach)ox + 2Cl- (eq 3.4) 
It is also noticeable that the Pt(dach)Cl2 concentration at 85°C continues to 
decrease to ~zero after 20 h.  If this is due to the reaction shown in equation 3.4 
then the oxaliplatin formation curve should correspond with the “expected 
oxaliplatin curve” in Figure 3.11 (a replot of the data reported at 85°C seen in 
Figure 3.10).  The oxaliplatin formation curve for the ratio of 1:1.5 is also plotted in 
Figure 3.11. This clearly suggests some degradation of Pt(dach)Cl2 upon 
prolonged heating.  The oxaliplatin formation curve for the ratio of 1:1.5 indicates 
that some decomposition of oxaliplatin also occurs.  These results will be 
reconsidered and compared with data obtained from thermal degradation studies.  
 
Figure 3-11:  Graph displaying the difference between the expected and actual formation 
curves for oxaliplatin and corresponding reaction curves for Pt(dach)Cl2 at 
85ºC in 95% dmf. 
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Thermal degradation studies on Pt(dach)Cl2 
• As a function of solvent 
This study was performed at 70ºC using the following solvents.  
A mixture of 5%   dmf / 95% water 
50% dmf / 50% water 
pure dmf 
The concentration of the neutral Pt(dach)Cl2 species was measured intermittently 
for up to 15 minutes. The results are displayed in Figure 3.12 to Figure 3.14. 
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Figure 3-12: Concentration of Pt(dach)Cl2 at 70ºC in 3 different solvent systems. 
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Figure 3-13:  Concentration of the acetonitrile solvated monochloro species at 70ºC in 3 
different solvent systems. 
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PtdachCl2 degradation at 70C
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Figure 3-14:  Concentration of the dmf solvated monochloro species at 70ºC in 3 different 
solvent systems. 
In Figure 3.12 the “disappearance” of the Pt(dach)Cl2 molecular species is plotted 
against time in each of the three solvent systems at 70°C.  Rapid destruction 
occurs in the 5% dmf 95% H2O system.  The concentration at T0 is already much 
lower than the starting conc. since the reading could not have been made fast 
enough.  The 50% dmf has an intermediate degradation rate whereas no reaction 
occurs in 100% dmf.  
In Figure 3.13 the formation of the most prominent solvated product viz. [M-
Cl+MeCN]+ was plotted as a function of time and solvent system.  In pure dmf no 
reaction had occurred.  The decomposition rate of Pt(dach)Cl2 increases 
significantly with water content.  The mass spectral data revealed that three 
solvated species were found, viz. the mono aqua, mono acetonitrile and mono dmf 
species.  In the 5% dmf system the acetonitrile adduct reached the highest 
concentration.  Figure 3.14 reveals that the dmf adduct reaches the highest 
concentration in the 50% dmf system.  Both this concentration and that of the 
CH3CN adduct reaches a plateau after ~10 min. 
• Interpretation of data 
The first noticeable fact is that no solvation occurs in pure dmf, even at 70°C.  In 
pure water solvation occurs very rapidly (See Figure 3.15). 
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Figure 3-15:  Pt(dach)Cl2 degradation in various solvents at 70ºC. 
In these dmf/H2O mixtures, the mono aquated species always has a low 
concentration.  In our opinion, this can only be interpreted that the coordinated 
water is readily replaced by both CH3CN and dmf.  This could explain why no 
solvation occurs in pure dmf as solvent.  The concentration level of the mono aqua 
complex is kept low by its replacement by the other donor solvents.  The ionisation 
of chloride occurs much more readily in a protic solvent such as water which can 
solvate both cation and anion as compared to the aprotic CH3CN and dmf.  
Coordinated water in platinum(II) can very rapidly be replaced by the CH3CN and 
dmf.  The latter two are in competition.  At low dmf concentration (5% dmf) the 
CH3CN dominates.  At high dmf conc (50%) the dmf adduct dominates.  This is 
demonstrated in Figures 3.16 and 3.17.  Ions at m/z361, m/z384 and m/z416 can 
be ascribed to the monosolvates viz. aqua, methylcyanide and dmf respectively. 
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Figure 3-16:  Time lapse mass spectra showing the decrease in Pt(dach)Cl2 concentration 
together with the increase in concentration of both monosolvates (CH3CN 
and dmf) in 5% dmf. 
 
Figure 3-17:  Time lapse mass spectra showing the decrease in Pt(dach)Cl2 concentration 
together with the increase in concentration of both monosolvates (CH3CN and 
dmf) in 50% dmf. 
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The fact that thermal degradation in pure dmf does not occur to any significant 
extent, even at elevated temperatures, but that the degradation rate increases with 
increasing % water (in the dmf/water mixture) as well as evidence of the formation 
of hydrated chloro species, suggests that the mechanism of the degradation can 
be related to the aqua complex.  This is in agreement with the known metastability 
of platinum(II) aqua complexes.  Although in very dilute solutions as utilised in the 
microscale studies, no visible darkening occurred.  Darkening attributable to the 
formation of platinum black, was however observed in the laboratory scale 
synthetic experiments. 
The aquation of Pt(dach)Cl2 with formation of the monoaqua complex and 
simultaneous ionisation of chloride and its replacement by dmf in excess dmf, can 
almost be seen as the catalytic effect of water facilitating ionisation of the chloride. 
Simultaneously, this facilitates oxalate ligand exchange in the presence of excess 
oxalate through the bidendate entropy benefit of oxalate. 
The aprotic nature of dmf (solvolysis reactions with platinum not possible), and its 
relatively high donor number stabilises the intermediate solvated platinum(II) 
species in the process of ligand exchange.  These arguments are substantiated in 
the data presented. 
• Degradation of Pt(dach)Cl2 in pure water at 70°C 
Figure 3.15 shows the decrease in concentration of the molecular species as a 
function of time.  The formation of hydrolysis products over the 40 min duration is 
shown in Figure 3.18.  The Pt(dach)Cl2 complex can be seen at 2.2 min; and 3 
hydrolysis products at time = 0.8; 1.3 and 1.4 min.  The peak at 1.3 min was found 
to correlate with the monochloro species.   
The degradation at 70°C in a 95% dmf/5% H2O solvent system over the same 
time is only marginal.  Under these conditions, only small amounts of the mono 
aqua species are detectable.  
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Figure 3-18:  LC-UV chromatogram overlays capturing the degradation of Pt(dach)Cl2 
(2.2min) and the formation of degradation products over a 40min period. 
The previous investigation illustrated the stabilising effect that dmf has as part of 
the mixed solvent system on the stability of Pt(dach)Cl2.  It was also possible to 
obtain information of the solvated species present.  
• Degradation as a function of extended time 
Pt(dach)Cl2 degradation was investigated over the full synthetic reaction period.  
The decrease in the concentration of Pt(dach)Cl2 in a 95% dmf/5% H2O solvent 
system over a period of 20 h is presented as a function of temperatures ranging 
from 70°C to 85°C (5°C steps) in Figure 3.19.  The drastic influence of elevated 
temperatures is clearly illustrated.  However, if the decrease of the Pt(dach)Cl2 
concentration in a reaction at 85°C having a 1:5 fold excess of oxalate is also 
plotted (85°C 1:5.0) then a much faster ligand exchange reaction occurs as 
compared to the degradation of Pt(dach)Cl2 alone. 
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Figure 3-19:  Graphs depicting the drop in Pt(dach)Cl2 concentration over time as a 
function of temperature (in 95% dmf) and the drastic decrease in 
concentration caused by the presence of oxalate. 
Thermal degradation studies on oxaliplatin 
The thermal degradation of oxaliplatin in the solvent system employed for the 
ligand exchange reaction was determined. 
The degradation of oxaliplatin in a solution of 95% dmf/5% H2O is plotted against 
time up to 20h at temperatures of 70, 75, 80 and 85°C respectively.  The effect of 
temperature is clearly illustrated in Figure 3.20.   
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Figure 3-20:  Graphs depicting the drop in oxaliplatin concentration over time as a 
function of temperature (in 95% dmf). 
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It is also noticeable that oxaliplatin degrades to a lesser extent than Pt(dach)Cl2.  
This is to be expected in view of the slower kinetics experienced for the 
dicarboxylate as compared to the chlorides and the greater stability of the complex 
containing the bidentate anionic ligand.  
Experiments were conducted to determine the degradation behaviour of oxaliplatin 
in the presence of excess tbaox. The results of this study are depicted in Figure 
3.21.  
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Figure 3-21:  Data indicating the stabilising of oxaliplatin in 88% dmf at 80ºC in the 
presence of excess oxalate. 
It was found that at 80°C (15 h) pure oxaliplatin degrades by 45% in 88% dmf.  In 
the presence of excess tbaox at a ratio of 1:5.0 only 13% degradation occurs.  It 
was also found that the amount of excess tbaox has little influence where the 
platinum to oxalate ratio is ~ 1:2.  This degradation reaction is assumed to be: 
Pt(dach)ox + 2H2O  [Ptdach(H2O)2]2+  +  ox2-   (eq 3.5) 
Clarification of some earlier results 
If we now have a re-look at the curves in Figure 3.10, focusing attention on points 
A, B and C it becomes clear that at a 43.8 mol % formation of oxaliplatin at 85°C 
as compared to 70°C, the concentration ratios of oxaliplatin to Pt(dach)Cl2 is the 
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same in this solvent system in spite of a ~10 h difference in achievement (3.2 h at 
85°C and 13.3 h at 70°C).  This is interesting since it indicates that up to those 
points in each case no significant destructive degradation of oxaliplatin and 
Pt(dach)Cl2 occurred in spite of the 10 h difference in reaching that stage.  
Although the formation reaction is much slower at 70°C the same applies to the 
destructive degradation of Pt(dach)Cl2.  Excess oxalate in the solution protects the 
degradation of oxaliplatin.  These facts thus also suggest that the decrease in 
Pt(dach)Cl2 concentration up to that stage is only due to progress of the reaction 
shifting to the right hand side. 
Pt(dach)Cl2 + tbaox  Pt(dach)ox + 2tbaCl   (eq 3.6) 
The levelling off of the oxaliplatin concentration at ~65% formation must be due to 
reaching equilibrium (ratio of 1:5.0/85°C).  The further rapid decrease in 
Pt(dach)Cl2 concentration can certainly be accounted for by the destructive 
thermal degradation of Pt(dach)Cl2, i.e. after equilibrium has been reached.  The 
formation curve of oxaliplatin for the ratio of 1:5.0 shows little decomposition of 
oxaliplatin due to the large excess of tbaox.  The case for the ratio of 1:1.5 does 
show decomposition since the excess of tbaox is too small to stabilise it.   
When all the above facts are borne in mind we are confident that equilibrium of the 
above reaction is reached at 65% formation of oxaliplatin under these conditions. 
This is also in agreement with the approximately 65% crude yield in the laboratory 
scale synthesis of oxaliplatin in the 95% dmf (water) mixture.108 Preliminary 
studies, in which the solvent system ratio was varied from 70/30 to 95/5% (in steps 
of 5%), indicated that the selected 95% dmf (water) can be regarded as the 
optimum insofar that blackening due to degradation was minimised. 
3.3 .4 React ion (c)  Pt (dach)Cl 2  +  oxalate  in  95 % 
isoamyla lcohol / (water )  
As stated in the general discussion (3.3.1) an ideal synthetic situation would be 
selection of a solvent system from which oxaliplatin could precipitate, with the 
proviso that the reagents are soluble enough to allow reaction and still fulfill the 
basic requirements for a non aqueous solvent system, as stated below. 
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(i) Water miscible;  
(ii) Contains oxygen (lower donor number than nitrogen);  
(iii) Not be a reducing agent - especially as it is know that platinum(II) 
oxalate is susceptible to reduction;  
(iv) Pt(dach)Cl2 must be partially soluble in the solvent;  
(v) Oxalate must be soluble in the solvent and,  
(vi) The boiling point must be higher than the reaction temperature. 
Removal of the product through precipitation would lead to improved efficiency.   
Investigation into the use of alcohols 
Lower alcohols are water miscible but are known to be reducing agents for 
platinum(II). Upon investigating possible mechanisms for Pt reduction, it was noted 
that Pd(II)Cl2 oxidises ethanol by the following mechanism 
PdCl2 + C2H5OH   CH3-CH2-O-PdCl   CH3CHO + H+ + Pd      (eq 3.7) 
It can readily be assumed that platinum(II) will follow a similar path especially at 
elevated temperatures. In such cases the autoionisation of the alcohol (contributing to 
the formation of the alkoxide species) will be an important parameter. It was of 
interest to note that the autoionisation constants of alcohols decrease fairly drastically 
with increasing alkyl bulk of the alcohol, as illustrated in Table3.1. 
Table 3-1:  Physical properties of water and some alcohols. 
 εM 25ºC pK Ion 
HOH 78.54 14 
CH3OH 32.63 16.92 
CH3CH2OH 24.30 19.5 
tetrabutylalcohol 12.4  
εM 25ºC – dielectric constant measured at 25ºC pK Ion – autoionisation constant 
If it is assumed that the above constants define the reducing capabilities of the 
alcohols then the higher alcohols with lower autoionisation constants would be 
less likely to reduce platinum(II).  
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Bearing this in mind some higher alcohols were evaluated as a potential solvent 
system. The dielectric constants for the alcohols are also lower than that of dmf, 
which could possibly lead to the precipitation of oxaliplatin. The ionising capability 
of the solvent system can be controlled through the addition of water. 
The higher alcohols have higher boiling points and facilitate reactions in the same 
temperature range used for the 95% dmf/(water) system. Initially, octanol was 
used as the solvent with varying temperature and % water, similarly to the 
previous system. It was immediately observed that this system resulted in the 
precipitation of oxaliplatin as white crystals with a yield of >80%. Due to the more 
pharmaceutically acceptable nature of isoamylalcohol, this solvent was selected 
and was shown to produce similar yields to that of octanol. 
Thus, following procedures very similar to those outlined for the dmf method, 
microscale reactions were performed to map reaction progress. The same reagent 
ratios (Pt(dach)Cl2: tbaox) were evaluated (1:1.5, 1:2.5 and 1:5.0), but the 
temperature range tested was slightly higher (75 – 90ºC).   
Results (iaOH) 
In Figure 3.22 to Figure 3.25, the normalised concentrations of the molecular 
forms of both Pt(dach)Cl2 and oxaliplatin are plotted as a function of time during 
their reactions for each of temperatures 75°C (Figure 3.22); 80°C (Figure 3.23), 
85°C (Figure 3.24) and 90°C (Figure 3.25).  In each graph, the data are plotted for 
three different Pt(dach)Cl2: tbaox ratios (1.5, 2.5 and 5.0). 
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Figure 3-22:  Normalised concentrations of both Pt(dach)Cl2 and oxaliplatin as a function 
of time at 75°C for three different Pt(dach)Cl2: tbaox ratios (1:1.5, 2.5 and 5.0) 
in 95% iaOH. 
Reaction temperature 80C in 95% iaOH
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Figure 3-23:  Normalised concentrations of both Pt(dach)Cl2 and oxaliplatin as a function 
of time at 80°C for three different Pt(dach)Cl2: tbaox ratios (1:1.5, 2.5 and 5.0) 
in 95% iaOH. 
   
98 
Reaction temperature 85C in 95% iaOH
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Figure 3-24:  Normalised concentrations of both Pt(dach)Cl2 and oxaliplatin as a function 
of time at 85°C for three different Pt(dach)Cl2: tbaox ratios (1:1.5, 2.5 and 5.0) 
in 95% iaOH. 
Reaction temperature 90C in 95% iaOH
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Figure 3-25:  Normalised concentrations of both Pt(dach)Cl2 and oxaliplatin as a function 
of time at 90°C for three different Pt(dach)Cl2: tbaox ratios (1:1.5, 2.5 and 5.0) 
in 95% iaOH. 
What is immediately clear from the data in the curves is the rapid increase in 
oxaliplatin concentration with an good yield >80% for all tests. The increase in 
oxaliplatin is mirrored by the decrease in Pt(dach)Cl2, reflecting an ideal case 
scenario where reagent is converted to product on an almost equimolar basis.  As 
observed in the case of dmf, temperature has a pronounced influence on the 
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reaction rate, while the molar excess of tbaox (in the range tested) does not. This 
is illustrated in Figure 3.26, where the reaction at 75ºC is compared to the reaction 
at 90ºC and where it is shown that a yield of 80% is achieved in just 2 h at a 
temperature of 90ºC while it requires 8 h to obtain the same yield at 75ºC. 
 
 
 
 
 
 
 
Figure 3-26:  Oxaliplatin formation curves at 75 and 90ºC together with the corresponding 
Pt(dach)Cl2 reaction curves for the studies conducted in 95% iaOH. 
The efficiency of the iaOH system is demonstrated in Figure 3.27 where the 
formation of oxaliplatin in 95% dmf at 85ºC is compared to that of the iaOH system 
under similar conditions at the same reagent ratio of 1:5.0 
 
 
 
 
 
 
 
Figure 3-27:  Comparison between formation curves for oxaliplatin in dmf and iaOH 
solvent systems at 85°C. 
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The difference in rate and yield seen in Figure 3.27 can be explained when 
considering the forces driving the reaction. Chemical potential induced through the 
excess of oxalate as well as the additional stability provided by the bidendate 
oxalate ligand versus the two mono chloro atoms, is common to both solvent 
systems. What sets the iaOH solvent system apart from the dmf system is the 
insolubility of oxaliplatin therein. An additional and potent driving force is thus 
present in the iaOH system in that the formed oxaliplatin is removed from the 
reaction in the form of a precipitate. As in the case of the silver method where the 
reaction is driven by removal of the chloro atoms via formation of insoluble AgCl, 
here we have achieved a similar result, but without the addition of a heavy metal. 
The formation of the precipitate was not apparent from the microscale reactions 
due to the very small volumes and low concentrations involved. A 100% yield 
would only produce ≈ 80 µg of oxaliplatin in 0.4 ml of 95% iaOH. However when 
the reaction is performed at typical laboratory scale (5-30 g) the precipitate is 
clearly visible. To ensure that all oxaliplatin was dissolved prior to analysis a 
volume of 400 µl dmf containing the internal standard Y14.2 was added to all 
sample vials. Removal of the oxaliplatin through precipitation also has the added 
benefit of stabilising the product. In the solid form (less degrees of freedom) the 
oxaliplatin is less likely to undergo degradation reactions such as hydrolysis. 
Removal of the product is also facilitated and simple filtration resulted in yields > 
80%. 
Thermal degradation of Pt(dach)Cl2 and oxaliplatin 
As it was found that the oxaliplatin formation curves were mirrored by the 
Pt(dach)Cl2 decline curves in the graphs above, it was expected that no significant 
degradation of either compound would occur during the reaction time allowed. 
Actual results confirmed the expectation.  Degradation monitoring of both species 
at 85ºC and 90ºC over a 6 h period showed no significant change in concentration. 
3.3 .5 Method compar ison 
In comparing the latter (iaOH) method with the current commercial silver method 
used globally, the advantages are obvious. Not only can the reaction be performed 
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under ambient lighting but also at elevated temperatures to obtain much higher 
yields (>80%) of oxaliplatin in reduced time. As the reaction does not proceed via 
the metastable diaqua complex, hydrolysis and oxidation to platinum(IV) is also 
unlikely. This is substantiated by the fact that tests according to the European 
pharmacopoeia methods,106 never indicated levels of the diaqua or dihydroxy 
(indicating oxidation to platinum(IV) species), higher than threshold levels (0.1%). 
These tests were conducted on numerous batches of samples prepared during the 
course of this study and showed not only that the concentrations were within 
specification, but that in the case of the dihydroxy derivative it was below the 
method detection limit in all cases. 
The most obvious advantage is the absence of silver contamination in the 
final product where a limit of 5 ppm is stipulated.106 
In conclusion, the iaOH method presents a faster, cleaner and higher yielding 
method for the preparation of oxaliplatin. An analysis of the current oxaliplatin 
patent landscape reveals that numerous patents are in practice.  However all 
these patents are but slight variations of the silver method. 112 , 113 , 114 115  The 
greatest value of this new method may yet lie in its commercial application as a 
truly novel synthetic method for the preparation of oxaliplatin. 
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CHAPTER 4:  
PLATINUM COMPLXES OF 
NEUTRAL N-S LIGANDS 
4.1 Introduction N-S dihal ides 
The main targets of antitumour active platinum compounds are assumed to be the 
nucleobases of DNA, resulting in so called cross-links.  These cross-links block 
replication and transcription, and ultimately, cell division.  Although it has been 
established that the preferred binding site of platinum is the N7 of guanine in the 
DNA, numerous other compounds, especially those containing sulfur donor atoms, 
will preferentially bind platinum.   
Once in circulation platinum complexes are taken up by the tissue.  They then either 
bind irreversibly to the plasma protein, or undergo metabolism and excretion.  Most 
platinum complexes including cisplatin are heavily bound to protein in the plasma, 
subsequently losing their therapeutic value and causing unwanted toxicity profiles.  A 
study on the drug JM216 found that 93% of the platinum was bound to plasma 
protein, leaving only 7% available for DNA interaction.116  The unbound 7% “free” 
platinum would still have to fend off the unwanted advances from smaller sulfur donor 
entities such as glutathione, cysteine and methionine, which play an important role in 
these “secondary reactions.”14  This can be related to the strong interaction between 
platinum(II) and the “soft” centres of S-donors.   
Kinetic factors play an equally important role in spite of the above thermodynamic 
effect on the platination of S donors, e.g.  thioethers occur in 2 hours whereas that of 
the N7 of guanine takes 15 h under comparable conditions.14  These kinetic 
differences are likely to play a role in the “protective action” of S donors and the 
possibility of creating a “drug reservoir”.  This concept in its simplest form, dictates 
that platinum complexes can interact with the thioether methionine for example, and 
be protected from further metabolic interaction from where at a later stage the 
platinum can be available for interaction with GN7 of DNA.  This point however has 
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been contested and it has been shown in a competitive binding assay with oxaliplatin 
that once bound to Met, the PtL is not “released.”  In fact similar competitive binding 
assays indicated that Met was able to remove Pt bound to the DNA surrogate 5-
GMP.117  However, in vitro binding assays with DNA surrogates can only go so far to 
mimic the natural processes occurring in the cell.  Although progress has been made 
in understanding the various facets of the Pt-S interaction, regarding their anticancer 
behaviour, the simultaneous equilibria involved are numerous and exclusive 
interpretations are not readily reached.118 
Platinum complexes having sulfur and nitrogen heterocyclic ligands are of interest 
from a drug design point of view.  Such ligands possess several binding modes to 
metals.  They can either act as neutral or anionic ligands and can be bound in a 
monodentate manner via the exocylic sulfur atom, the endocyclic nitrogen atom or 
in a chelating fashion.  The formation of a sulfur bridge, between 2 metal atoms, 
through the thione group has also been reported.119,120  Studies regarding relative 
donicities of S-donors suggest that they can be divided into two groups with 
reference to their action on platinum(II) complexes. The first group are those with σ 
donor pi donor capabilities like thiolates (Cys, GSH) and thiourea.49  These ligands 
react irreversiby with platinum(II).  The second group containing σ donor pi acceptor 
S atoms like thioethers (Met), and dimethylsulfoxide is substituted by N7 atoms of 
guanine to give the thermodynamically more stable Pt-nucleobase adduct. 
To broaden our understanding of the action of S-donor ligands on the anticancer 
activity of platinum(II) complexes it was decided to study the properties of 
platinum(II) complexes of a bidentate ligand having an aromatic N donor atom in 
combination with a thioether S atom capable of forming a five-membered ring with 
platinum(II).  In addition the basic structure should allow substitution to be made to 
change the stereochemistry, hydrophobicity and S donor strength of the ligand 
enabling the influence of these parameters to be studied on the outcome of the 
platinum(II) complex species and the anticancer action.  The target molecule 
planned to study this is based on an N-alkyl-2-methylthioalkyl/aryl imidazole 
structure (See Figure 4.1).  The attachment of the –SR group to a potentially 
electron withdrawing group was selected to somewhat weaken the influence of the 
thioethereal S donor capability.  A few pyridine analogues were used to compare 
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the properties of the complexes.  A number of different counterions were studied 
in view of their possible effects on the ligand exchange rate, namely different 
halides and dicarboxylate ions.   
R2
S
R1
N N N
S
R2
 
Figure 4-1:  Structures of the bidendate ligands evaluated during this study, where R1 = 
CH3 to C4H9 and R2 = CH3, C2H5, C3H7, phenyl and benzyl. 
The focus of this chapter is thus on the evaluation of these complexes with the 
main aim being the establishment of a structure activity relationship.  
Thermodynamic aspects such as the relative bond strengths and kinetic aspects 
such as hydrolysis rates were measured to try and obtain a more comprehensive 
overview.  Similar data was obtained for three known anticancer agents to 
facilitate comparisons in characteristics and behaviour.  Based on the differing 
kinetic properties studies of the dihalides will be discribed first followed by a 
discussion of the carboxylate complexes.  
4.2  N-S Dihal ide synthet ic methods 
4.2 .1 Int roduct ion 
From the literature it was noticed that K2Pdox2 could be used for the synthesis of 
monomeric complexes of the type PdL2ox (where L = a monodentate amine) 
through a room temperature ligand exchange reaction.121  The Pd(II) complexes 
were therefore synthesised by this method, using K2PdCl4 and K2Pd(ox)2 
respectively as starting materials.  No record could however be found in the 
literature in which K2Pt(ox)2 had been used in an analogous reaction to prepare 
L2Ptox or PtL-Lox complexes by direct ligand exchange.  In previous work in this 
laboratory, the reaction between K2Pt(ox)2 and dach was extensively studied.  The 
results indicated that a monomeric complex viz. Pt(dach)ox could only be formed 
in a low yield (~20%) by careful control of pH to keep the free ligand concentration 
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low.  This direct ligand exchange reaction at elevated temperatures was therefore 
also investigated.  The results are given below and are compared with those of the 
silver method.  The latter proved to be a much more satisfactory method for this 
purpose.  The reactions used in both these cases are given below:  
Method A 
                           oxKSoxPtN
aqueous
heatSNPtoxK 222 +−>−+  (eq. 4.1) 
Method B 
 
K2PtCl4  +  2I- K2Ptl4 PtN-S2 PtN-S(H2O)22+
2Ag+ + 2NO3-
N-S
AgI  +  PtN-Sox
2Na+
C2O42-
 (eq 4.2)  
 
The various complexes that were studied are shown in Figure 4.2.  In order to 
simplify the notation the code followed is as follows Jx (where x = a number) refers 
to the chloro complex, e.g.  J7 (chloro), J7.1 (oxalate) J7.2 (malonato), J7.3 
(bromo), J7(IV) refers to the platinum(IV) tetrachloride and J7.4 refers to the 
platinum(IV) trichloronitro compound.  The same notation will be used throughout.  
J7.1.4 refers to the oxalato, chloro, nitro platinum(II) analogue of J7.   
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Figure 4-2:  Examples of the various N-S platinum(II) complexes studied in this section.  
   
106 
4.2 .2 Di rect  l igand exchange f rom K 2 Pt(ox) 2  or  
K 2 PtX 4  
Results obtained by using method (a), i.e. for chloro and oxalate species will be 
dealt with firstly.   Direct reaction of all of these ligands with K2PtCl4 produced 
extremely insoluble pink or peach coloured substances.  CHN analysis agreed with 
PtN-SCl2 compounds, but chromatographic and mass spectral data indicated that the 
precipitates were mixtures of PtN-SCl2 and Pt(N-S)2PtCl4, the latter complex being 
the major constituent.  This is illustrated in Figure 4.3 showing the mass spectrum 
(pos ion mode) for a CH3CN solution of the compound J5.   
 
Figure 4-3:  Positive ion mass spectrum obtained for J5 prepared by direct reaction of a 
ligand with K2PtCl4. 
4.2 .3 S i lver  method 
The above-mentioned compounds were not pure and this lead us to investigate 
alternative synthetic methods.  There was some doubt as to whether the silver 
method could be utilised as a possible synthetic route due to the high affinity of 
Ag+ for S donor atoms.  However, other methods did not seem viable and 
therefore experiments were performed using silver nitrate as the means of 
j5 acn 
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removing the halide ions. 
Given in the formation of the auto ionised species, important factors to be considered 
are firstly the extent of the ion pairing between Pt(N-S)22+ and PtX42- (x=Cl or I-) and 
secondly the stabilities of PtX42- which will necessarily differ.  It was thought 
worthwhile to commence studies using the iodo complex.  A further indication that the 
iodo option is advantageous for this purpose was given by the analogous synthesis of 
cisplatin and the known affinity of Ag+ for I- which is much greater than the 
corresponding affinity for for Cl-.  The Ag+ - S interaction is thus less likely.  
K2PtCl4 + 4I-  K2PtI4 + 4Cl- (eq 4.3) 
K2PtI4 + N-S + 2Ag+ + 2NO3- PtN-SI2 + 2AgI + 2K+ + 2NO3-  (eq 4.4) 
The application of this method and the results obtained immediately emphasised 
the difference since only yellow reaction products having very different properties, 
were obtained.  The mass spectrum (pos ion mode) for sample J5 in CH3CN is 
shown in Figure 4.4.  Note the absence of the PtL2 species at m/z532. 
 
Figure 4-4:  Positive ion mass spectrum obtained for a sample prepared by the silver 
method.  
J5Pg133 ACN pos 
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4.3  N-S Dihal ide Ionisation 
4.3 .1 Molecular  species 
Ionisation of the N-S ligands, especially the dichlorides, was found to be very 
quick indeed.  It was noticed that a sample of the dichloride (PtN-SCl2) in CH3CN 
yielded a molecular ion [M+NH4]+ whereas the same sample in water did not, 
producing only the ionisation products.  This led to the development of the so-
called Fast Loop method (See Chapter 2.4.2 Method M4.1) whereby a rapid 
ionising compound is first prepared as a stock solution in CH3CN.  Water is then 
added very quickly and the solution (10% CH3CN) monitored over a short time 
interval (typically 4min).  The effect of the N-S ligands on the ionisation rate of the 
molecular species, i.e. PtLX2 (X= Cl-, Br- and I-) was studied initially by monitoring 
the concentration of the molecular species as a function of time in 10% CH3CN 
aqueous solution at room temperature.   
PtLX2  +  S    PtLXS+  +  X-     (eq 4.5) 
The hydration rate of the dichlorides was found to be extremely fast and 
independent of the non-leaving ligands (Figure 4.5a).  In Figure 4.5b, the 
ionisation curves for the bromo complexes are only marginally different to those of 
their chloro analogues.  They indicate rates of J7.3>J5.3>J12.3.  This is the order 
of increasing alkyl substituent length with increasing hydrophobicity.  The 
ionisation of bromide is slower when compared to ionisation of chloride with 
perhaps the exception of J5.3, which is very similar to J5. 
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Figure 4-5a:  Graphs depicting the drop in concentration of the chloro species in 10% 
CH3CN / (water) at room temperature using the fast loop method. 
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Figure 4-5b:  Graphs depicting the drop in concentration of the bromo species in 10% 
CH3CN / (water) at room temperature using the fast loop method. 
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Figure 4-5c:  Graphs depicting the drop in concentration of the iodo species in 10% 
CH3CN / (water) at room temperature using the fast loop method. 
In Figure 4.5c, the PtN-SI2 complexes again show a spread in their ionisation rates 
J5>J12≥J7 and all the bulkier substituted non leaving groups have slower rates.   
The ionisation rates (X = Cl-, Br- and I-) of PtN-SX2 are directly compared in 
Figures 4.6a to 4.6c.  In all the three instances, those of Cl- and Br- are minute 
whilst the iodides are much slower.  
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Figure 4-6a:  Graphs comparing the difference in ionisation rates of Cl-, Br- and I- species 
(J7, J7.3 and J7a) in 10% CH3CN / (water) at room temperature using the fast 
loop method. 
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Figure 4-6b:  Graphs comparing the difference in ionisation rates of Cl-, Br- and I- species (J5, 
J5.3 and J5a) in 10% CH3CN / (water) at room temperature using the fast loop 
method. 
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Figure 4-6c:  Graphs comparing the difference in ionisation rates of Cl-, Br- and I- species (J12, 
J12.3 and J12a) in 10% CH3CN / (water) at room temperature using the fast loop 
method. 
The marginal differences between chloro and bromo analogues and much bigger 
difference of iodo complexes are typical of differences between Cl, Br and I 
compounds in general. 
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4.3 .2 Ionisat ion of  monocat ionic  species 
Where the ionisation of the molecular chlorides were independent of the non-leaving 
N-S ligand (See Figure 4.5a), the rates for the monocationic chloro species followed 
the following sequence (from faster to slower) J13>J5≥J12≥Lt16>J14>J7.  The 
differences in rate between J13 (S-prop), J5 (S-et) and J7 (S-me) are odd, since J7 
has the slowest rate and the other two the fastest.  The monochloride of J7 is very 
reluctant to ionise further (Figure 4.7a).   
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Figure 4-7a:  Graphs comparing the difference in ionisation rates of the solvated 
monochloro species in 10% CH3CN / (water) at room temperature using the 
fast loop method. 
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Figure 4-7b:  Graphs comparing the difference in ionisation rates of the solvated monobromo 
species in 10% CH3CN / (water) at room temperature using the fast loop method. 
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Figure 4-7c:  Graphs comparing the difference in ionisation rates of the solvated 
monoiodo species in 10% CH3CN / (water) at room temperature using the 
fast loop method. 
The ionisation of the monobromides (Figure 4.7b) corresponds well with the chloro 
results since the S-Et, i.e. J5.3 ionises readily whereas the two S-Me complexes, 
i.e. J7.3 and J12.3 do not seem to ionise further.  The behaviour of J5a is also 
quite different to the other monoiodo species (Figure 4.7c).  It is the only complex 
to ionise readily to produce the dicationic species. 
4.3 .3 Ionisat ion w i th a  constant  non- leaving group 
and var ia t ion in  leaving groups 
In the case of J7 the MLXS+ species seems stable towards further ionisation in 
each of X=Cl, Br and I (See Figure 4.8a). 
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Figure 4-8a: Graphs comparing the difference in ionisation rates of the solvated 
monohalide species in 10% CH3CN / (water) at room temperature using the 
fast loop method (J7 series). 
[M-X+S] Fast loops J5 J5.3 J5a
0
20
40
60
80
100
120
0 1 2 3 4
Time (min)
No
rm
al
is
ed
 
ar
ea
dichloride dibromide diiodide
 
Figure 4-8b:  Graphs comparing the difference in ionisation rates of the solvated 
monohalide species in 10% CH3CN (water) at room temperature using the 
fast loop method (J5 series). 
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Figure 4-8c:  Graphs comparing the difference in ionisation rates of the solvated 
monohalide species in 10% CH3CN / (water) at room temperature using the 
fast loop method (J12 series). 
In the case of the S-Et ligand (J5), there is almost no difference in the rate of the 
three halo compounds.  Even the iodocomplex ionises to a dicationic species, 
being halo anion independent (Figure 4.8b). In the other case the complexes with 
ligand S-Me (J12), only the chloride complex ionises to any extent (Figure 4.8c).   
4.3 .4 Ionisat ion studies over  extended t ime span  
It was of interest to study ionisation rates at 37ºC for a longer period (See Chapter 
2.4.2 Method M4.2).  From the curves in Figure 4.9a to Figure 4.9c it can be seen 
that in the last hydrolysis step, i.e. from monocationic to dicationic species, the 
behaviour of the chloro, bromo and iodo species are very similar. This behaviour can 
possibly be related to the reduced effect of the halide with only one residual ion. 
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Figure 4-9a:   Graphs depicting the last ionisation step for the 3 dichlorides (J7, J5 and 
J12), i.e. formation of the dicationic species. 
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Figure 4-9b:  Graphs depicting the last ionisation step for the 3 dibromides (J7.3, J5.3 and 
J12.3), i.e. formation of the dicationic species. 
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Figure 4-9c:  Graphs depicting the last ionisation step for the 3 diiodides (J7a, J5a and 
J12a), i.e. formation of the dicationic species. 
4.3 .5 Mass spectra l  data  of  tota l  systems 
Although the previous studies on the ionisation of specific species provided useful 
information towards understanding their solution behaviour, it was also necessary 
to investigate the formation of all the species in the solvent system at different 
temperatures.  This would provide a clearer perspective of detailed species 
behaviour.  Three solutions were prepared for each compound.  The mass 
spectral data obtained for J7 (dichloride) are given in Figure 4.10.  The top 
spectrum is that of a fresh acetonitrile solution, the middle spectrum of a freshly 
prepared aqueous solution and the third, that of an aqueous solution after 18h at 
80°C.   
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Figure 4-10:   Mass spectra (pos ion mode) of sample J7 in MeCN, water and the same 
aqueous solution after 18 h at 80°C. 
The acetonitrile solution shows the presence of the molecular (unionised) and 
monocationic species (m/z424 and m/z389 respectively) in approximately equal 
amounts.  The room temperature aqueous solution shows the monocationic 
species and very small quantities of the unionised species.  A similar situation is 
found even after 18 h at 80°C, thus suggesting that one Cl- ionises almost 
immediately in H2O and that this ion is stable towards further ionisation even after 
reaction in water at 80°C for 18 h. 
The bromo (J7.3) and iodo complexes (J7a) show very similar behaviour except 
that the mass spectra of J7a shows a large amount of the dicationic species in 
solution after 18 h at 80°C. 
The behaviour of the J12 and J12.3 complexes are similar to the J7 and J7.3 
analogues, i.e. only monocationic species are formed. The iodo species (at 80°C 
in water for 18 h) is an exception.  
The behaviour of J5 is quite different to the other dichlorides as mass spectra data 
reveals that almost complete hydrolysis to the dicationic species occurs in water 
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(see mass spectra in Figure 4.11).  Even in acetonitrile solution the dicationic 
species almost rivals the molecular species in terms of ion abundance. 
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Figure 4-11:  Mass spectra (pos ion mode) of sample J5 in MeCN, water and the same 
aqueous solution after 18 h at 80°C. 
It is of interest to note the similarity in behaviour of the J7 and J12 complexes as 
compared to that of J5. In an effort to relate this to structural factors it is also 
noticeable that J7 and J12 both have S-CH3 groups whereas J5 has a S-CH2CH3 
group. When the Spartan molecular modelling program is applied to obtain 
structural information, indications were observed that one H atom on C2 of the 
ethyl substituent (J5) appears to have some interaction with the central platinum 
atom. Similar behaviour is found with J13 which has a S-CH2CH2CH3 substituent. 
This structural feature could be responsible for the above behaviour. 
4.3 .6 Compar ison of  ionisat ion w i th commonl y 
used ant icancer  agents  
A comparison of ionisation spectra of the N-S complexes were made with those of 
commonly applied anticancer agents.  The ionisation of three of these complexes 
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were studied and is illustrated in Figure 4.12a (cisplatin), Figure 4.12b 
(carboplatin) and Figure 4.12c (oxaliplatin).  In each of these instances the 
concentration of the molecular species in water was determined as a function of 
time over 4 h at body temperature, viz. 37°C.  When these rates are compared 
with those of the N-S complexes in Figure 4.5 a, b and c which were measured 
over minutes at room temperature, it is clear that the latter ionises almost 
immediately even when compared to cisplatin.  
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Figure 4-12a:  Graph detailing the drop in cisplatin concentration in water (37°C) over time. 
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Figure 4-12b:  Graph demonstrating the stability of carboplatin in water (37°C) over time. 
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Figure 4-12c:  Graph demonstrating the stability of oxaliplatin in water (37°C) over time. 
The strength of the trans effect exerted by the S atom is further demonstrated by 
comparing the hydrolysis rates of a PtN-SCl2 complex (J12) to that of an N-N 
dichloride complex (Pt(dach)Cl2) (see Figure 4.13). As expected J12 undergoes 
hydrolysis at a much faster rate. Note that the x-axis in the graph has a log scale. 
N-S vs N-N ionisation of dichlorides at RT
0
20
40
60
80
100
0.001 0.010 0.100 1.000 10.000
Time (h)
No
rm
al
is
ed
 
co
n
c
J12 (N-S) Ptdc (N-N)
 
Figure 4-13:  Graph detailing the dramatic difference in ionisation rate between N-S and N-
N dichlorides. 
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4.4 Introduction N-S dicarboxylato complexes 
The differences between dicarboxylato platinum(II) (oxalato and malonato) and 
halo complexes (chloro, bromo and iodo) of amine non-leaving groups with 
respect to those aspects relating to their anticancer properties are well known.  
Ligand exchange rates of the former are much slower, e.g. when cisplatin is 
compared with oxaliplatin and carboplatin.   Although the ligand exchange rate is 
only one of many parameters determining anticancer action efficacy, it is a very 
important one.  This is clearly illustrated by the aggressive action of platinum 
amine chloro complexes such as cisplatin and Pt(dach)Cl2 where only a relatively 
small amount reaches the cancer cells (due to secondary reactions) as compared 
to much slower ion exchange resulting in an overall improved action of 
dicarboxylates such as oxaliplatin and carboplatin. 
In the previous section the dramatic increase in the ionisation rate of PtN-SCl2 
when compared to their diamine analogues was clearly illustrated.  This could be 
explained by the enhanced trans effect in replacing a nitrogen donor by a sulfur 
donor atom.  It was therefore of interest to synthesise and study the properties of 
dicarboxylato complexes of the same N-S non-leaving groups and correlate their 
properties with their structural, solid state, thermal and solution behaviour 
including their ionisation and anticancer action. 
4.5 N-S Dicarboxylato synthetic methods 
The methods employed for the synthesis of the oxalato complexes were similar to 
those described for their chloro analogues, i.e. a direct ligand exchange using 
K2Ptox2 and an indirect method using AgNO3 via K2PtI4.  The results obtained 
were also similar to those found for the direct method using K2PtCl4. Thus, 
mixtures of the autoionised complexes (mainly) and molecular species such as 
(PtLox) were obtained as yellow reaction products.107 The silver method produced 
pure molecular cream/white reaction products confirmed by mass spectral 
determinations. 
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4.6  N-S Dicarboxylato ionisation 
In the previous section the dramatic difference in the ionisation of PtN-NCl2 and 
PtN-SCl2 was clearly indicated.  The extent of the ionisation of the former (within 
hours) in aqueous solution was comparable to those of the latter (within 
minutes).  This finding is undesirable for a successful anticancer action and was 
evident by poor cell mortality in four different cancer cell lines.  
The ionisation results obtained for the PtN-Sox complex (J7.1) is represented in 
Figure 4-14. The results are surprising in that the complex barely ionises, even in 
aqueous solution at 80°C for 60 h. The top diagram is for an acetonitrile solution, 
the lower diagrams are for water at room temperature (middle) and at 80°C after 
60h (bottom).  The stability of the molecular species is clearly indicated.  
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Figure 4-14:  Mass spectra (pos ion mode) of sample J7.1 in MeCN, water and the same 
aqueous solution after 60 h at 80°C. 
Significant ionisation occurs for the S-phenyl (J14.1) and S-benzyl (Lt16.1) 
complexes.  The mass spectral data for J14.1 are given in Figure 4.15. The 
increasing extent of ionisation in going from acetonitrile to water to water at 80°C 
is indicated.  
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Figure 4-15:  Mass spectra (pos ion mode) of sample J14.1 in MeCN, water and the same 
aqueous solution after 18 h at 80°C. 
 In a comparative study of the ionisation of the S-alkyl oxalato complexes with 
oxaliplatin in aqueous solution at 80°C after 71 h the results indicated them to be 
similar, e.g. the drop in the concentration of the molecular species were 30% 
(J7.1); 5% (J 5.1)  and  25% (oxaliplatin) respectively. 
This illustrates the ionisation/hydrolyses reactions of the N-S complexes is 
comparable to those of the N-N complexes. 
4.7  Kinetic stabi l i ty vs.  thermodynamic 
stabi l i ty 
Evaluation of the relative bond strengths within the group of N-S compounds was 
accomplished using EV-CAD as described in Section 2.2.5. Ionisation studies 
discussed above have demonstrated that the N-S dihalide compounds undergo 
rapid ionisation in water. The first ionisation step leads to the loss of one or both of 
the halides and is measured as a drop in the concentration of the [M+NH4]+ 
species, using a fast loop method as described in Section 2.4.2, (typically 0.5-
3min). Further ionisation is monitored over a longer period (typically 3 h) by 
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measuring the drop in concentration of the monohalide species typified by the ion 
[M-X+S]+, using an incubation method described in Section 2.4.2. 
The data presented below details the results obtained of the relative bond 
strengths of the two species described above using EV-CAD viz. [M+NH4]+ and 
[M-X+S]+. The method utilised is described in Section 2.2.5. 
4.7 .1 EV-CAD f ragmentat ion of  [M+NH 4 ] +  
For this determination the molecular ion cluster was selected for evaluation. 
Energy was supplied incrementally and the relative abundance of the molecular 
ion cluster was noted in the MS2 spectrum. The amount of energy required to 
reduce the concentration of the molecular species [M+NH4]+ by 50% ([M+H]+ used 
for the oxalates) is listed in Figure 4.16 below. 
 
 
 
Figure 4-16: Tabulated results obtained from the EV-CAD study of the various N-S 
compounds depicting the amount of energy required to cause a 50% 
reduction in signal strength of the molecular species [M+NH4]+ ([M+H]+ in the 
case of the oxalates). 
The following observations can be made from the data: 
• In all cases the amount of energy required for fragmentation follows the 
pattern:dichloride > dibromide > diiodide 
• The amount of energy required for fragmentation of the oxalate derivatives 
%CE J7 J5 J12 J13 J14 Lt16 
dichloride 19.9 19.5 18.8 19.2 18.3 18.0 
dibromide 17.7 17.4 16.8 - - 16.2 
diiodide 15.8 15.6 15.1 15.4 14.8 14.6 
oxalate 19.9 19.5 20.5 19.1 19.3 18.0 
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is generally similar to that of the dichlorides 
• There appears to be a simple inverse relationship between the amount of 
energy required for fragmentation and the molecular mass of the 
compounds, with larger molecules requiring less energy to fragment. This is 
demonstrated in Figure 4.17. 
 
 
 
 
 
 
 
Figure 4-17: Figure demonstrating the relationship between molecular mass and the 
energy required for fragmentation. To enable the inverse molecular masses 
to be displayed on the same graph as the %E values, a factor of 8000 was 
applied. 
4.7 .2 EV-CAD f ragmentat ion of  [M-X+S] +  
To evaluate the fragmentation of the molecular ion cluster [M-X+S]+ was selected 
for study. Sufficient energy was supplied to cause complete fragmentation of the 
molecular species (typically 20-25%) to yield the MS2 spectrum containing the 
target ion cluster [M-X+S]+. This species was then selected and isolated and the 
relative ion abundance monitored as a function of the applied collision energy 
(MS3). The amount of energy required for a 50% reduction in the signal strength of 
the [M-X+S]+ species is listed in Figure 4.18 
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Figure 4-18: Tabulated results obtained from the EV-CAD study of the various N-S 
compounds depicting the amount of energy required to cause a 50% 
reduction in signal strength of the mono solvated species [M-X+S]+ (oxalates 
were not tested). 
The following observations can be made from the data: 
• Determination of the actual E½ values was more difficult for the [M-X+S]+ ion 
cluster than for the [M+NH4]+ ion cluster. This was due (at least in part) to 
the fact that an additional MS step (MS3) was required to force the 
fragmentation, leading to lower signal strength. 
• As in the case of the molecular ion cluster [M+NH4]+ it was found that larger 
molecules (ion clusters) required less energy to fragment. Sample Lt16 was 
an exception to this trend. 
4.7 .3 EV-CAD f ragmentat ion of  know AC agents  
Data obtained from the EV-CAD studies of known AC agents are presented in Table 
4.1.  
Table 4-1:  Table depicting the EV-CAD results of three known AC agents with the 
transition monitored shown in italics. 
Compound Transition %E 
cisplatin [M+NH4] + → [M+H] + → [M-Cl] + 11.5 
 [M+NH4] + → [M+H] + → [M-Cl] → n 24 
M-X+S J7 J5 J12 Lt16 
dichloride 25 35 50 15 
dibromide 19 20 30 18 
diiodide 10 10 30 17 
EV CAD of M-X+S
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Compound Transition %E 
carboplatin [M+H] + → m/z354 + 14, 19 
 [M+H] + → m/z354 + → n 14, 19 
oxaliplatin [M+H] + → m/z353 + 20.7 
 [M+H] + → m/z353 + → n 24 
4.8  Anticancer action 
● N-S Dihalides – Pt(N-S)X2 
None of the PtN-SX2 complexes were found to show any AC action on four 
different cancer cell lines. This behaviour is not surprising when considering 
that the ionisation experiments indicated that the molecular species hardly 
exists in aqueous medium. This can almost certainly be attributed to the 
trans-effect of the sulfur atom. Experiments have shown that even in the 
presence of 4 mM and 100 mM NaCl this ionisation is not retarded (Figure 
4.19a). In the case of cisplatin the presence of NaCl suppresses this 
ionisation (Figure 4.19b). 
J12 in 10% MeCN / 90% solvent
[M+NH4]
0
1
2
3
4
5
6
0 1 2 3 4
B
ill
io
ns
Time (min)
Ar
ea
 
[M
+
NH
4]+
MeCN 100mM NaCl 4mM NaCl Water
Cisplatin degradation at RT
(1mM cisplatin / NaCl)
0.0
20.0
40.0
60.0
80.0
100.0
120.0
140.0
160.0
0.46 2.46 4.46 6.46 8.46 10.46
Time (h)
Pe
ak
 
he
ig
ht
 
(21
0n
m
)
100mM NaCl 4mM NaCl Water
 
Figure 4-19a: Graphs showing the instability of the J12 complex in 10% acetonitrile / 
(water) and the inability of NaCl (aq) to retard this process. 
Figure 4-19b Graphs showing the decline in the hydrolysis rate of 1 mM solutions of 
cisplatin in the presence of NaCl (aq). 
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● N-S Dicarboxylates – Pt(N-S)ox 
Although dicarboxylates of amines have much lower ionisation constants than 
their dichloro analogues, the results of the N-S complexes were expected to be 
different due to the much stronger trans-directing effect of the thioethereal sulfur 
atom. It was however surprising to find that this is not the case. It was found that 
the percentage ionisation of the N-S oxalate was comparable to oxaliplatin. 
Apparently the chelate effect of the dianionic leaving group effectively countered 
the trans-directing power of the sulfur donor atom. It is thus understandable that in 
contrast to the halo analogues, some of these have significant anticancer action. 
For example Lt16.2, although only slightly soluble in water, behaved very 
effectively towards cervical cancer cells. No indications of cellular resistance were 
observed. 
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Chapter 5:   
Mononitro complexes of platinum(IV)  
5.1 Introduction 
Recently much interest has been shown in the mononitro complexes of 
platinum(IV).  This interest is based on claims that certain of these complexes 
showed significant anticancer activity, as described in two US patent 
applications filed in 2005.122,123  Of greater significance was the report that the 
mode of action was not based on “classical” DNA platination, but rather upon 
interference in the STAT3 mechanism.56   
The general structure of the mononitro platinum(IV) complexes described in these 
patents are presented in Figure 5.1.  
L
Cl
Pt
N
N
Cl
NO2
a   and   b
Cl
Cl
Pt
N
N
Cl
NO2
 
Figure 5-1:  General representation of the type of mononitro complexes investigated - 
where N denotes monodendate ammines (NH3) or bidendate amines and L 
denotes a neutral donor ligand.  
The non leaving groups could either be ammines such as NH3 (cisplatin) or 
bidendate amines such as ethylenediamine.  The two chloro atoms (leaving 
groups) in the xy plane were also exchanged with other anions.  STAT3 specific 
tests showed that some of these mononitro complexes were very promising 
anticancer agents.  One compound in particular was of interest (Figure 5.2). 
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Cl
Cl
Pt
H3N
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Figure 5-2:  Structure of the mononitro platinum(IV) complex CPA7, shown to have 
significant anticancer action via STAT3 interference.56 
Numerous compounds of the types represented in Figure 5.1a and 5.1b have 
been studied by the University of Southern Florida (USA).  These compounds are 
difficult to prepare in a high degree of purity as would be required for 
pharmaceutical use.   
5.2  Synthesis of CPA7 using published 
methods  
Our initial approach was to repeat the synthetic method to produce CPA7 
described in the literature.56  This method consists of a reaction between the 
relevant platinum(II) complex, for example cisplatin, with chloride ions (NaCl) in a 
1:1 mole ratio with platinum in an aqueous solution.  NO2 gas (from a gas source) 
was introduced into this solution.  The reaction proceeded as described with the 
formation of a blue intermediate solution which turned yellow after ca.18 h.  Upon 
evaporation of the solution a yellow precipitate was obtained.    
The objective was to determine the nature and quantity of products formed using 
the literature procedure.  It was hoped that the information gained could be utilised 
in making modifications to optimise the formation of CPA7.   
The identification of the major sample components as well as their approximate 
quantitative presence was accomplished by exposing the product to mass 
spectrometric analysis and chromatographic studies.  The mass spectra are 
presented in Figure 5.3. 
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Figure 5-3:  Positive and negative ion mode mass spectra obtained for an infused 
aqueous solution of CPA7 prepared via the published method.56 
The mass spectral data obtained from direct infusion of an aqueous solution of the 
crude product indicated the presence of 4 compounds viz. CPA7, Pt(NH3)2Cl4, 
Pt(NH3)2Cl2(NO2)2 and Pt(NH3)2Cl3(OH).  The relationship between these and the ion 
clusters in the mass spectra is depicted in Figure 5.4. 
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Pt
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379
Tetrachloro
368
Hydroxy
350
Dinitro
390
m/z397 = [M+NH4]+
m/z378 = [M-H]-
m/z414 = [M+Cl]-
m/z424 = [M+HCOO]-
m/z441 = [M+NO3]-
m/z592 = [M+HFBA]-
m/z386 = [M+NH4]+
m/z367 = [M-H]-
m/z413 = [M+HCOO]-
m/z581 = [M+HFBA]-
m/z351 = [M+H]+ m/z408 = [M+NH4]+
m/z389 = [M-H]-
m/z452 = [M+NO3]-
m/z603 = [M+HFBA]-
 
Table 5-1:  Possible structures for the ions present in the mass spectra depicted in 
Figure 5.3.  Note that the monoisotopic masses (194Pt and 35Cl) as detected 
by the mass spectrometer are used. 
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The relative intensities of the spectra suggest that CPA7 constitutes the largest 
percentage of the product.   
After extensive chromatographic studies including the evaluation of numerous 
columns and eluent systems suitable for the separation of these polar compounds, 
a separation was obtained where all 4 major components could be detected in a 
single chromatographic run.  From the chromatogram shown in Figure 5.4 it 
appears that three of the products are present in similar proportion.  However to 
determine the concentrations, the molar extinction coefficients are required, 
assuming Beer’s law holds. Quantitative analysis was further complicated by the 
analogous disparity in signal response from ESI-MS studies, where in pos ion 
mode, the tetrachloro species has a poor response factor and CPA7 is 
overestimated.  
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Figure 5-4:  LC-UV separation of a sample of CPA7 (4.78 min) utilising a YMC 
Hydrosphere C18 column (250x4.6 mm, 5 µm) and an eluent consisting of 
2.5% MeCN at 0.8 ml/min with detection at 210 nm. 
The YMC Hydrosphere column utilised has the ability to retain the integrity of the 
C18 hydrocarbon chains in highly aqueous mobile phases where standard C18 
chains would collapse and lead to altered column separation characteristics.  The 
Hydrosphere column was however unable to provide baseline resolution of the 
sample components.  In an effort to achieve better separation a more polar 
column was sought.  Previous ion pairing systems had been evaluated but without 
success.  Some of the initial mobile phases tested contained NaCl (0.1 M) as it 
was feared that the sample composition could be undergoing on-column ionisation 
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as in the case of the Pt(N-S)X2 complexes (Chapter 4) and it was hoped that the 
excess Cl- would suppress this.  The increase in polarity was achieved through the 
use of a perfluorinated phenyl stationary phase of the Phenomenex Curosil PFP 
column.  These columns have been specially developed to provide improved 
separations in the study of related Taxane samples.124  Figure 5.5 shows the 
improved results obtained with the new column.   
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Figure 5-5:  LC-UV separation of a CPA7 sample utilising a Phenomenex Curosil PFP 
column (250x4.6 mm, 5 µm) and an eluent consisting of 2.5% MeCN at 
1 ml/min with detection at 210 nm.  Peak assignments: see text below. 
Figure 5.5 demonstrates the improved resolution of the different species as 
indicated by the increased number of peaks.  These peaks were then further 
identified by the use of ESI-MS.  In Figure 5.6 the mass spectral results obtained 
for the peaks at 4.98 and 4.08 min indicated that the peak at 4.98 min consists of 
the required product (CPA7) while that at 4.08 min belongs to the major impurity 
Pt(NH3)2Cl4.  The mass spectral data collected of the two peaks at 3.12 and 
6.08 min (Figure 5.7)  revealed that they correspond to Pt(NH3)2Cl3(OH) and 
Pt(NH3)2Cl2(NO2)2 respectively.  The peak at retention time 2.05 min was found 
not to contain any platinum ions and is suspected to be due to NO3-. 
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Figure 5-6:  Positive and negative ion mode mass spectra of the peaks for the tetrachloro 
species and CPA7 in the chromatogram in Figure 5.5. 
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Figure 5-7:  Positive and negative ion mode mass spectra for the hydroxy and dinitro 
species in the chromatogram in Figure 5.5.  
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Integration of the peak areas (UV 210 nm) was used to calculate the relative purity 
of CPA7.  In this case the purity of CPA7 was found to be ± 20%.  Efforts were 
then directed to increase the purity by recrystallisation but this proved to be 
unsuccessful.  The main reason for this was the fact that the Pt(NH3)2Cl4 species 
could not be totally removed.  From the results obtained, it is evident that this 
synthetic method would be unsatisfactory for the production of CPA7 in a high 
yield with a purity greater than 98%. 
The results were somewhat surprising since a large amount of Pt(NH3)2Cl4 was 
formed in spite of the fact that a 1:1 Pt/Cl- mol ratio was used.  This was shown to 
arise from the ionisation behaviour of cisplatin in a high dielectric constant protic 
solvent such as water (see Figure 5.8).  The ionisation process would be further 
enhanced by the presence of other ligands.   
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Figure 5-8:  Graph detailing the ionisation of cisplatin in water (37°C).  
A further indication that significant ionisation had occurred was provided by the 
presence of the Pt(NH3)2Cl(OH) species among the products.  In these preliminary 
studies, the presence of a number of simultaneous equilibria was evident.   
In light of the above observations, the following reactions could be anticipated.   
Pt(NH3)2Cl2  +  NO2(g)  +  Cl- Pt(NH3)2Cl3NO2  +  NO3-
 eq: 5.1 
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Pt(NH3)2Cl2  +  H2O Pt(NH3)2Cl(H2O)+ + Cl-
 eq: 5.2 
Pt(NH3)2Cl2  +  2Na+ Cl-  +  2NO2 Pt(NH3)2Cl4  +  2Na+ NO3-
 eq: 5.3 
Pt(NH3)2Cl(OH)  +  H+Pt(NH3)2Cl(H2O)+
 eq: 5.4 
Pt(NH3)2Cl2  +  2NO2 Pt(NH3)2Cl2(NO2)2
 eq: 5.5  
The synthesis of CPA7 is given by equation 5.1 but due to the high degree of 
ionisation of cisplatin under these experimental conditions, equation 5.2 and 5.4 
would be favoured.  The ionisation of cisplatin then gives rise to an increase of the 
free chloride ion concentration.  This causes the platinum to chloride mol ratio to 
increase above a 1:1 ratio, which then pushes the equilibrium of equation 3 to the 
right forming Pt(NH3)2Cl4.    
5.3 Improvements to CPA7 synthetic procedure 
The formation of all the products formed in equations 5.1 – 5.5 could be related to 
the high degree of ionisation that occurs in an aqueous medium.  The first step 
was then to suppress the ionisation of cisplatin.  This could be done by changing 
to a non-aqueous solvent system.  Three major factors affect the properties of a 
solvent.  These are listed below: 
1. Protic nature – measure of hydrogen bonding.   
2. Donor number – measure of electron donating capability.   
3. Dielectric constant – measure of degree of ionisation and ion pair formation.   
The table below illustrates these values for solvents that could potentially be used 
in the synthesis: 
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Table 5-2:  Table listing the physicochemical properties of certain solvents evaluated 
for the synthesis of CPA7. 
Solvent Donor 
Number 
Dielectric 
Constant 
Type Relative 
Polarity 
Water 18 81.7 Protic 1.000 
Acetonitrile 14.1 37.5 Aprotic 0.460 
Acetone 17 20.7 Aprotic 0.355 
DMF 26.6 36.7 Aprotic 0.404 
THF 20 7.6 Aprotic 0.207 
MeOH 19 32.6 Protic 0.762 
In light of the information in Table 5.2 and arguments made, it was decided to 
change the solvent system to an essentially aprotic solvent viz. acetone with trace 
amounts of water.  All the solvents in Table 5.2 were tested under similar reaction 
conditions, but the choice of acetone produced the best results.  Following the 
method with acetone as solvent a product was produced which only contained 
CPA7 and Pt(NH3)2Cl4.  Efforts to remove Pt(NH3)2Cl4 by solvent washings proved 
to be unsuccessful as demonstrated in Figure 5.9. 
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Figure 5-9:  LC-UV separation of a CPA7 sample produced using acetone as solvent 
and utilising a Phenomenex Curosil PFP column.   
The removal of Pt(NH3)2Cl4 from the reaction was achieved by not adding chloride 
ions (NaCl) to the reaction system.  This method produced a crude product of 
close to 50% CPA7 purity. Further purification to a degree of greater than 90% 
was achieved by selective washing (as depicted in Figure 5.10). 
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Figure 5-10:  LC-UV separation of a CPA7 sample produced using acetone as solvent and 
further cleaned through selective solvent washings.  Separation performed 
utilising a Phenomenex Curosil PFP column.   
Pt(NH3)2Cl4 and Pt(NH3)2Cl2(NO2)2 were not found in the reaction system while the 
production of Pt(NH3)2Cl3(OH) was greatly reduced.  A silica clean-up column 
produced CPA7 of purity greater than 98%.  Even though CPA7 was produced 
with a purity of 98% (Figure 5.11) the overall yield obtained was only 15%.  
Scaling up of this synthetic procedure proved to be very problematic.   
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Figure 5-11:  LC-UV separation of a CPA7 sample of 98.7% purity after further cleaning on 
a silica column.  Separation performed utilising a YMC Hydrosphere C18 
column.  
   
140 
5.4  Studies involving the dicarboxylate 
oxal iplat in  
Since it was the ionisation of the chloro analogous of platinum(II) that greatly 
complicated the reaction, it was decided to study platinum(II) compounds of 
dicarboxylates which are known to have limited ionisation.  This is clearly 
illustrated by the much lower ionisation of platinum compounds like carboplatin 
and oxaliplatin both having dicarboxylate ions as leaving groups (see Figure 4.12b 
and 4.12c).  This study was limited to the use of oxaliplatin as the starting 
complex.    
The reaction was conducted in a mixture of acetone and water (70/30) to which 
chloride ions (NaCl) were added.  The reaction proceeded via a blue intermediate 
species.  The reaction behaved very differently to that of the chloro species 
because the product nitrochlorooxalatoplatinum(IV) or Mar4.1.4, could be obtained 
in a 75% yield in a purity in excess of 90%.  The chromatogram of the product Mar 
4.1.4 is depicted in Figure 5.12.   
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Figure 5-12:  LC-UV separation of a sample of Mar4.1.4 (6.87 min) utilising a YMC 
Hydrosphere C18 column (250x4.6 mm, 5 µm) and an eluent consisting of 
2.5% MeCN at 1.2 ml/min with detection at 210 nm. 
The percentage purity of the product based on the separation depicted in Figure 
5.12 was 97.8%.  However, successes achieved in the further resolution of CPA7 
samples utilising the Phenomenex Curosil PFP column led to the reanalysis of the 
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above sample on this chromatographic system.  The data revealed the presence 
of another species in the sample viz. that of the dichloride named Mar4.1.6.  The 
chromatogram showing the resolution of the dichloride (Mar4.1.6) from the main 
product (Mar4.1.4) is depicted in Figure 5.13. 
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Figure 5-13:  LC-UV separation of a sample of Mar4.1.4 (11.63min) containing Mar4.1.6 
(10.93min) utilising a Phenomenex Curosil PFP column (250x4.6mm, 5µm) 
and an eluent consisting of 2.5% MeCN at 1.0ml/min with detection at 210nm. 
With the improved separation results obtained with the more polar column the 
product purity was 95.9%.  Identification of the impurity profile was achieved using 
LC-ESI-MS. This revealed that the peaks at 6.23 and 7.15 min were due to the 
NO2/OH and Cl/OH derivatives.  Unreacted oxaliplatin eluted at 8.23 min and the 
dichloride (Pt(dach)oxCl2 named Mar4.1.6) eluted just prior to the product at 
10.93 min.  As in the case of CPA7, no platinum ions were detected in the early 
eluting peak at 1.77 min. 
Reanalysis of an aqueous test sample (0.5 mg/ml) after 64 h at 24°C revealed the 
appearance of two new peaks at 2.83 min and 4.98 min and the virtual 
disappearance of the dichloride impurity (90% drop in peak area).  The 
chromatograms in Figure 5.14 compare the fresh and aged sample solutions. 
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Figure 5-14: Chromatograms of a fresh (top) and aged (bottom) aqueous Mar4.1.4 
(0.5 mg/ml) test solution.  Separation performed utilising a Phenomenex 
Curosil PFP column. 
The aged sample was then subjected to analysis by LC-ESI-MS to try and identify 
the newly formed products and possibly shed some light on the ionisation 
pathway.  The results obtained provided more questions than answers.  Firstly the 
peak at 2.83 min was found to be devoid of any platinum ions.  Secondly the peak 
at 4.98 min was found to be an exact mass spectrometric duplicate of the existing 
peak at 7 min (Cl/OH derivative), as demonstrated in Figure 5.15. 
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Figure 5-15:  Positive ion mass spectra of the peaks at retention times 4.98 (top pane) and 
6.98 min (lower pane) in the previous figure.  For structural assignments, see 
text below. 
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No diasteriomers for the suspected structure can be proposed.  The identical 
mass spectra displayed in Figure 5.15 point to the Cl/OH hydrolysis product of 
Mar4.1.4 with the following tentative structural assignments: m/z449 = [Cl/OH+H]+; 
m/z466 = [Cl/OH+NH4]+; m/z562 = [Cl/OH+U114]+ and m/z359 = [Pt(dach)Cl-
2H+H2O]+.  In-source degradation is thought to be responsible for the formation of 
the latter as this species would almost certainly have been resolved from the other 
complexes during column separation.  The unknown cationic adduct with m/z114 
was detected in all other spectra and is thought to be due to column bleed.  This 
adduct however served an invaluable function in the assignment of ion masses 
together with the standard modifiers such as H+, NH4+ and Na+.  
The product obtained from oxaliplatin as starting material produced a crystal of 
nitrochlorooxalato-trans-1,2 diaminocyclohexaneplatinum(IV) (Mar4.1.4) having 
two molecules of water of crystallisation (Figure 5.16).   
 
Figure 5-16:  Crystal structure of Mar4.1.4 showing two molecules of water of 
crystallisation.  
An exciting aspect of Mar4.1.4 is its anticancer profile when tested on the three 
cell lines routinely used (HeLa, HT29 and MCF7) at this facility.  These results 
have shown that Mar4.1.4 is superior to both cisplatin (considered the benchmark) 
and oxaliplatin.  Studies discussed in Chapter 6 allude to this compound acting as 
an oxaliplatin pro-drug in that reactions with certain biological reducing agents 
such as glutathione and cysteine resulted in the formation of oxaliplatin.  In a 
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STAT3 bioassay this compound has also shown superior performance compared 
to CPA7, thus confirming that it possesses STAT3 inhibition potential.  To our 
knowledge this is the only platinum drug to show significant anticancer ability in 
both intercalation and STAT3 inhibition bio assays. 
As described in Chapter 1, the benefits of an anticancer platinum(IV) drug are 
numerous.  Foremost among these is the possibility of oral administration, a 
benefit currently not shared by any of the prescribed platinum drugs and only 
envisaged for drugs still in clinical trials (JM216).  Further studies are currently 
underway and the synthesis of Mar4.1.4 as well as its application as anticancer 
agent has resulted in the filing of a patent application.125   
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Chapter 6:   
Binding assays 
6.1 Introduction 
A primary objective of this study was to establish a link between anticancer 
activity, based on cell line tests, and the unique structural characteristics of test 
compounds.  Establishing such a link would provide a crucial clue in the 
chemotherapeutic structure-activity model and would lead to the development of 
tests better able to evaluate new drug candidates.  This chapter investigates the 
binding behavior of novel platinum complexes with endogenous sulfur containing 
molecules and a DNA surrogate.  Comparisons are made with known anticancer 
compounds.   
The assays discussed here were limited to reactions between small sulfur 
molecules (two amino acids and one tripeptide).  Under in vivo conditions, 
platinum drugs are “mopped-up” efficiently by proteins.  A study on the early 
biotransformation of oxaliplatin, after intravenous administration (130 mg/m2) to 
cancer patients, found that after only 1 hour, 40% of the platinum was bound to γ-
globulins and another 40% was bound to albumin.126  The interaction of platinum 
complexes with proteins such as the ones listed above and metallothioneins 
(MT’s) were not studied in this thesis.  However, the ability of these proteins to 
bind platinum is largely based on the availability of (multiple) thiol groups from 
cysteine residues.  Cys residues account for up to 30% of the total amino acids in 
these low molecular weight MT proteins.  Studies with cisplatin have shown that 
one protein molecule can bind as many as 7 platinum molecules.127  It has also 
been shown that glutathione can efficiently remove platinum from platinum(II) – 
protein adducts.128  
6.2  Platinum sulfur interaction 
One of the parameters tested was the interaction of test complexes with certain 
endogenous sulfur containing low molecular weight compounds such as 
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methionine, cysteine and glutathione present in the plasma and the cytosol.  A 
conventional hypothesis is that sulfur containing nucleophiles initially bind to the 
platinum atom and then convert to thermodynamically mores stable platinum DNA 
complexes.  The ability of a compound to avoid irreversible complexation with any 
of these would be regarded as a positive characteristic, while rapid irreversible 
complexation would render the complex inactive and therapeutically useless.  As 
discussed in Chapter 4, these entities present an additional obstacle to the 
platinum complex on its way to the DNA target and interaction with thiols such as 
GSH and Cys is thought to result in irreversible complexation, while interaction 
with Met may be reversible.129  The interaction of platinum with thioether and thiol 
containing cytosol constituents is summarised in Figure 6.1.    
 
Figure 6-1:  Summary of intracellular thioether and thiol activity on platinum(II) 
complexes.130 
The concentration levels of three biologically active small sulfur containing 
molecules is listed in Table 6.1 together with inter and intracellular pH and NaCl 
content. 
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Table 6-1:  Table listing the concentrations and pH levels of certain plasma and cytosol 
constituents. 
 Intercellular Intracellular 
pH 7.424 7.4 (non cancerous)
24
 
6.0 (cancerous)24 
NaCl (mM) 10012 412 
Cys (µM) 10-25130 33130 
Met (µM) 13-33130 32130 
GSH (µM) 2-2012 5000-1000012 
6.3   Plat inum GN 7  interaction 
The ability of a candidate compound to platinate DNA is even more important than 
the ability to avoid irreversible complexation with any of the listed biothio 
molecules and larger thiol containing proteins.  Numerous factors (discussed in 
Chapter 1) such as stereochemistry and configuration can aid or disrupt DNA 
platination.  An example of such a factor was recently demonstrated by a group at 
Lund University in Sweden.131  They demonstrated that the DNA platination rate 
could be reduced by addition of the polyamines spermine and spermidine.  They 
hypothesized that despite the structural diversity of current platinum based 
anticancer drug candidates a common theme can still be observed with a cationic 
metal complex as the biologically active species.  Attraction between the 
polyanionic backbone of the DNA molecule and the cationic platinum compound 
was disrupted by the presence of cationic spermine and spermidine molecules.132  
DNA binding assays have been performed in an attempt to gauge the relative 
binding efficiencies of various platinum complexes and to pinpoint the actual 
mechanism so as to facilitate further drug design improvements.132,133  Competitive 
binding assays involve the reaction of these complexes with DNA or DNA 
surrogates after reaction with, or in the presence of the biothio compounds.131  
Various forms and lengths of DNA have been used for this purpose.  Calf thymus 
DNA has been used where intercalation was monitored by absorption and circular 
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dichroism (CD) spectroscopy. 134 , 135   Various other researchers have utilised 
shorter lengths of DNA, so called single or double stranded oligodeoxynucleotides 
or oligomers.136,137,138  By far the most widely used DNA surrogate is guanosine 5’-
monophosphate or 5-GMP, the structure of which appears in Figure 
6.2.117,131,133,139  This compound is in essence the DNA monomer containing the 
preferred GN7 binding site of platinum (see 1.3.5.1).   
OH
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Figure 6-2:  Structure of the DNA surrogate most commonly used for binding assays 
guanosine 5’-monophosphate (5-GMP). 
6.4  Binding assays 
Simple comparative assays were performed at room temperature or at 37ºC in 
water or in buffer (5.0 mM/Bistris acidified with formic acid) at pH ranging from 6.0 
to 7.5 in the presence or absence of NaCl (100 mM).  The ratio of small molecule 
concentration to that of the drug was kept constant at 2:1.  In some cases, the 
compounds Cys, GSH and Met were per-mixed to provide a competitive binding 
assay versus GMP, which was prepared separately.  Reaction solutions were 
monitored by LC-UV, LC-MS or infusion MS.  The results obtained from a typical 
study with oxaliplatin against GMP (19.5 h/37ºC/water) are displayed as an 
example.  Table 6.2 lists the raw data and demonstrates the reproducibility of the 
method (%RSD<2.5%) for each of the double triplicate samples.  The data can 
also be summarised in the form of a bar graph (Figure 6.3). 
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Table 6-2:  Table detailing the raw data obtained from the study of oxaliplatin with GMP 
at 37°C. 
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Figure 6-3:  Bar graph summarising the data obtained from the study of oxaliplatin with 
GMP at 37°C. 
Filename Peak area 
  
Blank_18_1 2,947,195,084   
Blank_18_2 3,151,650,743   
Blank_18_3 3,001,476,575  Blank (-18ºC) 
Blank_18_4 3,101,792,379 3,056,566,456 Average 
Blank_18_5 3,090,851,480 73,975,074 SD 
Blank_18_6 3,046,432,474 2.42 %RSD 
Blank_37_1 2,939,197,004   
Blank_37_2 2,869,096,922   
Blank_37_3 2,932,850,232  Blank (37ºC) 
Blank_37_4 2,869,847,011 2,894,546,002 Average 
Blank_37_5 2,932,835,256 47,411,791 SD 
Blank_37_6 2,823,449,584 1.64 %RSD 
Sample_2_1 1,753,780,815   
Sample_2_2 1,785,982,367   
Sample_2_3 1,852,929,525  GMP (37ºC) 
Sample_2_4 1,833,661,207 1,812,328,551 Average 
Sample_2_5 1,840,852,455 37,603,316 SD 
Sample_2_6 1,806,764,934 2.07 %RSD 
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The average oxaliplatin concentration in the blank samples stored at -18ºC was 
normalised and equated to 100%.  The normalised concentration of oxaliplatin in 
the blank samples incubated at 37ºC showed a 5% drop due to ionisation (-18ºC 
versus 37ºC).  After 19.5 h at 37 º C, about 40% of the oxaliplatin had reacted with 
GMP.  Positive ion mode mass spectra of the GMP samples revealed the 
presence of two complexes at m/z654 and 1001.  These are expected to be [M-
Ox+GMP-H]+ and [M-Ox+2GMP-H]+ respectively.  The bar chart provides 
information regarding the reactivity of oxaliplatin toward GMP at a glance.   
To facilitate discussion of the results obtained, the compounds evaluated will be 
divided into five basic structural groups.  The reactions of each group will be 
treated in turn and compared with data related to a known AC agent (s) belonging 
to that group.   
Group 1 consists of a platinum(II) complex with 2 monodendate ligands (non-
leaving groups) and 2 monodendate leaving groups.  A typical example from 
this group would be cisplatin. 
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Figure 6-4:  Typical examples of group 1 complexes consisting of a platinum(II) with 2 
monodendate ligands (non leaving groups) and 2 monodendate leaving 
groups. 
Group 2 consists of a platinum(II) complex with 2 monodendate ligands (non-
leaving groups) and 1 bidendate leaving group.  A typical example from this 
group would be carboplatin. 
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Figure 6-5:  Typical examples of group 2 complexes consisting of a platinum(II) with 2 
monodendate ligands (non leaving groups) and 1 bidendate leaving group. 
Group 3 consists of a platinum(II) complex with 1 bidendate ligand (non leaving 
group) and 2 monodendate leaving groups.  A typical example from this group 
would be Yol25. 
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Figure 6-6:  Typical examples of group 3 complexes consisting of a platinum(II) with 1 
bidendate ligand (non leaving group) and 2 monodendate leaving groups.    
Group 4 consists of a platinum(II) complex with 1 bidendate ligand (non leaving 
group) and 1 bidendate leaving group.  A typical example from this group would 
be oxaliplatin. 
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Figure 6-7:  Typical examples of group 4 complexes consisting of a platinum(II) with 1 
bidendate ligand (non leaving group) and 1 bidendate leaving group. 
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Group 5 consists of the platinum(IV) compounds.  A typical example from this 
group would be JM216. 
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Figure 6-8:  Typical examples of group 5 complexes consisting of a platinum(IV) 
compound with various ligands and leaving groups. 
6.4 .1 Group 1  binding assays  
Reactions of cisplatin and JMy1a (water/37°C/2h) with Cys, Met, GSH and GMP 
are summarised in Figure 6.9a and 6.9b. 
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Figure 6-9a:  Reactivity chart of cisplatin in water at 37°C after 2 h in the presence of the 
challenge agents. 
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Reactivity chart: JMy1a
Time 2h
0.0
20.0
40.0
60.0
80.0
100.0
120.0
100.0
JM
y1
a 
co
n
c.
 
(no
rm
al
is
ed
)
JMy1a
Cys
GMP
GSH
Met
 
Figure 6-9b:  Reactivity chart of JMy1a in water at 37°C after 2 h in the presence of the 
challenge agents. 
A similar study showed that after 15 h all cisplatin had been depleted when 
challenged with a mixture of MGC (Met, GSH and Cys).  However, 15% of the 
cisplatin remained in the solution challenged with GMP. 
Reactions of ZD0473 with the individual challenge agents (water/37°C) monitored 
at various time intervals revealed the formation of Met and GMP related products.  
No Cys or GSH related products were detected which is unexpected as the latter 
species have thiol groups and these are expected to readily bind with the 
platinum(II) centre.  The species formed are listed in Table 6.3 below.   
Table 6-3:  Table listing the ions detected in the reactions of ZD0473 with various 
challenge agents.  Possible structural assignments have been made. 
 Met Cys GSH GMP M GC + GMP 
ZD0473 [M+Met+H] + m/z524 
[M-Cl-NH3+Met]+ 
m/z471 
[LPt+Met-H]+  
m/z435 
- - [LPtNH3+GMP-H]+ 
m/z650 
[LPtNH3-H+guanine]+ 
m/z454 
Unknown m/z437 
[M-Cl-NH3+Met]+ 
m/z471 
[LPt+Met-H]+  
m/z435 
The time lapse mass spectra for the reaction of ZD0473 and Met are displayed in 
Figure 6.10. 
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Figure 6-10:  Time lapse positive ion mass spectra for the reaction of ZD0473 with 
methionine (Met) in water at 37°C, indicating the formation of a platinum-Met 
species at m/z435. 
Examination of the relative rates of formation revealed that both GMP and Met 
related species formed linearly over time.  Although the Met species were 
detected at the start of the reaction, the GMP species formed at an increased rate 
and at a much higher concentration.  Reaction of ZD0473 with all 4 small 
molecules (MGCG) resulted in formation of Met and GMP species only. 
6.4 .2 Group 2  binding assays  
The known AC agent in this group, carboplatin (Figure 6.5), proved to be very 
resilient to attack by the challenge agents and this characteristic has been linked 
to its lower nephrotoxicity.131  Evidence for this is shown in Figure 6.11a to 6.11c 
where the results of tests carried out in water at 37°C are depicted. 
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Reactivity chart: Carboplatin
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Reactivity chart: Carboplatin
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Reactivity chart: JMy39
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   Figure 6-11a:          Figure 6-11b:   Figure 6-11c: 
Figure 6-11: Time based Reactivity charts for carboplatin in water at 37°C in the presence 
of the individual challenge agents Cys, GSH and Met. 
Under similar conditions, (water/37°C) reaction with GMP for 15 h only resulted in a 
30% drop in the carboplatin concentration.  Compound JMy39 showed a significant 
drop in concentration after just 2 h under identical conditions (Figure 6.12).   
 
 
 
 
 
Figure 6-12:  Reactivity chart of JMy39 in water at 37°C after 2 h in the presence of the 
challenge agents. 
The pH of the reactions was not adjusted by buffer and was found to be between 5 
and 6.  Analysis of these solutions by LC-MS after 18 h produced the results 
portrayed in Figure 6.13.   
   
156 
 
RT: 0.00 - 15.00 SM: 7B 
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 
Time (min) 
0 
50 
100 
0 
50 
100 
0 
50 
100 
 
0 
50 
100 
0 
50 
100 5.65 
2.83 2.87 2.56 4.04 2.32 4.51 12.93 6.47 5.09 7.70 8.70 9.00 11.66 9.83 13.00 14.34 1.77 7.40 11.20 0.48 
5.70 
2.95 
3.08 10.66 3.88 2.67 4.32 9.97 6.74 10.73 7.01 7.78 4.71 8.89 12.48 13.82 13.39 9.63 2.34 14.74 1.97 0.78 
11.19 11.29 
6.73 6.70 
5.65 3.71 3.75 2.94 
4.52 12.33 2.69 9.52 13.01 9.04 10.09 8.50 7.70 5.42 13.96 0.04 1.92 14.67 0.97 
4.91 4.94 
7.33 
5.65 
4.38 
2.97 8.39 11.06 0.03 0.85 14.68 6.75 13.50 13.17 12.26 9.48 9.75 8.81 3.65 2.67 2.12 
5.66 8.68 
9.15 
4.67 4.21 
9.64 2.95 7.21 3.22 9.96 2.53 10.48 7.94 0.90 13.08 14.20 6.79 11.42 12.14 1.99 5.32 0.11 
NL: 
1.20E7 
Base Peak  
F:   MS  
Carboplat_1 
8Hr 
NL: 
1.30E7 
Base Peak  
F:   MS  
carboplat_cy 
s18hr 
NL: 
5.08E7 
Base Peak  
F:   MS  
carboplat_g 
mp18hr 
NL: 
4.33E7 
Base Peak  
F:   MS  
carboplat_gs 
h18hr 
NL: 
1.14E7 
Base Peak  
F:   MS  
carboplat_m 
et18hr 
Carboplatin 18h / 37ºC 
Carboplatin + Cys 18h / 37ºC 
Carboplatin + GMP 18h / 37ºC 
Carboplatin + GSH 18h / 37ºC 
Carboplatin + Met 18h / 37ºC 
Carboplatin 
GMP 
GSSG 
GSH 
Non Pt 
m/z491 
 
Figure 6-13:  LC-MS positive ion mode chromatograms obtained for the reaction of 
carboplatin with individual challenge agents in water at 37°C after 18 h.   
The data in Figure 6.13 indicates that Cys has very little effect on carboplatin.  
GMP and GSH do cause a drop in the carboplatin concentration, but no related 
platinum species are formed.  From the GSH chromatogram, the presence of 
oxidised GSH (GSSG) can be seen at 7.33 min (m/z613, [GSSG+H]+), indicating 
that the carboplatin may have been reduced.  The reaction with Met produced 
platinum-Met species in the form of 2 chromatographic peaks at 8.68 and 
9.15 min.  MS evaluation of these peaks indicate that they have the same mass 
viz. m/z491, thought to be due to the formation of [Pt(Met)2-H]+.  It is not known 
why there are two peaks for this complex.  It may be due to the racemic Met used, 
which could have led to the formation of a diastereomeric complex.  Tests 
performed at a pH ranging from 6.0 to 7.5, with or without NaCl (100 mM) present, 
also indicated that carboplatin was very stable.  Figure 6.14 demonstrates this by 
way of comparison with oxaliplatin.  Buffered samples without Cys showed both 
drugs to be stable in the studied pH range over 18 h implying that the drop in drug 
concentration was due to interaction with Cys and not due to ionisation (data not 
shown).  The absence of platinum(II)/GSH and platinum(II)/Cys adducts is in 
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accordance with data published by Liu et al.140 
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Figure 6-14:  Graph demonstrating the stability of carboplatin toward Cys at different pH 
by way of comparison to oxaliplatin. 
Figure 6.15 further demonstrates the resistance of carboplatin to the challenge 
agents at physiological pH in the presence of 100 mM NaCl.   
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Figure 6-15:  Graph demonstrating the stability of carboplatin towards the challenge 
agents at physiological pH, in the presence of 100 mM NaCl.  
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6.4 .3 Group 3  binding assays  
This group, consisting of a bidendate ligand and 2 monodendate leaving groups 
(typically halides), does not have a known AC agent (Figure 6.5).  A study of Yol25 
in water at 37°C showed that Met and GMP – platinum products are formed.  No 
such adducts were detected for the 2 thiols (Cys and GSH).  The reaction with Met 
is especially dominant and when Yol25 is reacted with MGCG, only the Met 
derivative [LPt+Met-H]+ is detected at m/z511.  The time lapse mass spectra of 
Yol25 and Met are shown in Figure 6.16.  In the top pane it is noticed that there is 
no molecular species i.e.  [M+NH4]+ at m/z451 but rather formation of [M-Cl+H2O]+ 
at m/z416.  This is due to the rapid ionisation of the Pt(N-N)Cl2 complexes, which 
although fast, is considerably slower than the Pt(N-N)Cl2 complexes described in 
Chapter 4.   
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Figure 6-16:  Time lapse positive ion mass spectra for the reaction of Yol25 with 
methionine (Met) in water at 37°C, indicating the formation of a platinum-Met 
species at m/z511. 
Figure 6.17 shows the ionisation curves for Yol25 compared to the analogue 
Pt(dach)Cl2, with calculated hydrolysis T½ times of 1.0 and 0.4 h respectively. 
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Figure 6-17:  Graphs depicting the drop in concentration of the molecular species 
([M+NH4]+) and the rise in concentration of the ionisation products ([M-
Cl+S]+), for 2 N-N dichlorides (Pt(dach)Cl2 and Yol25) in water at 37°C.  
Reaction of a series of Pt(N-S)X2 complexes (J12 = dichloride; J12.3 = dibromide 
and J12a = diiodide) with the challenge species (water/37°C/15h) showed a strong 
correlation to ionisation behavior, where the reactivity followed the sequence: J12 
> J12.3 > J12a (Figure 6.18a to Figure 6.18c). 
 
 
 
 
 
        Figure 6-18a   Figure 6-18b           Figure 6-18c 
Figure 6-18: Reactivity charts for a series of dihalides with a common N-S bidendate 
ligand (J12) indicating highest reactivity for the dichloride (6.18a), followed 
by the dibromide (6.18b) and the diiodide (6.18c). 
Due to the rapid ionisation of the first halogen atom from the platinum complex, 
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the mono halo species was monitored viz. [M-X+S]+, where X = H2O or MeCN.  
From the graphs it is clear that after the test period, the dichloride was completely 
depleted by both MGC and GMP.  The dibromide was depleted by MGC but not by 
GMP and the diiodide still had some unreacted platinum complex in both the MGC 
and GMP reaction.   
ESI-MS analysis of the reaction solutions revealed the presence of a common 
dominant platinum-Cys product, the first seen in this study, at m/z498 [M-2X+Cys-
H]+.  
6.4 .4 Group 4  binding assays  
This group consisting of a bidendate ligand (N-N or N-S) and a bidendate leaving 
group (oxalate, malonate or cyclobutylmalonate), contains the AC active 
compound oxaliplatin (Figure 6.7).  Owing to the bidendate chelate effect this 
group is much more stable in aqueous solution and consequently ionisation times 
are much longer than for groups 1-3 with the exception of carboplatin. 
 Reactions of oxaliplatin (water/37ºC) with individual challenge agents are shown 
in Figures 6.19a to Figure 6.19c.  From this data, it is clear that oxaliplatin, 
although having a bidendate ligand, is more susceptible to attack than carboplatin 
having two ammine ligands.  It can also be seen that the concentration drop is 
most severe when oxaliplatin is reacted with Met, where 80% is depleted after 6 h. 
   
 
 
 
 
Figures 6.19a          Figures 6.19b   Figures 6.19c 
Figure 6-19: Time based Reactivity charts for oxaliplatin in water at 37°C in the presence 
of the individual challenge agents Cys, GSH and Met. 
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The time lapse mass spectra for the reaction between oxaliplatin and Met are 
depicted in Figure 6.20 and show the formation of the complex [M-Ox+Met-H]+ at 
m/z456.  Further investigation showed that the formation of this complex 
proceeded linearly over the period monitored. 
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Figure 6-20:  Time lapse positive ion mass spectra for the reaction of oxaliplatin with 
methionine (Met) in water at 37°C, indicating the formation of a platinum-Met 
species at m/z456. 
It is interesting to note how quickly oxaliplatin looses the oxalate leaving group when 
forming the Met complex.  Ionisation studies have shown that oxaliplatin is stable in 
aqueous solution for hours (Figure 4.12c), indicating that the reaction is not 
dependant upon the ionisation of oxaliplatin but that the oxalate is actively displaced 
by Met.  Due to the high stability of the platinum-dach moiety, a release caused by the 
trans effect of sulfur resulting in the formation of different mixed ligand adducts, as 
observed in the case of carboplatin ([Pt(Met)2-H]+), does not occur.131  Similar 
reactions with the thiol GSH was observed.  Two GSH complexes were detected and 
separated by LC.  The oxaliplatin molecule again loses the oxalate moiety and is 
shown to accommodate two and three GSH molecules.  Figure 6.21 shows the 
gradient LC separation of the GSH complexes ([LPt+3GSH+H]+ m/z921 at 8.08 min 
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and [LPt+2GSH+H]+ m/z1228 at 10.92 min) from unreacted GSH and oxidised 
GSSG.  The elution order follows the expected hydrophobicity profile dictated by 
reversed phase HPLC, with the more polar entities eluting first. 
 
Figure 6-21:  LC-MS chromatograms demonstrating the formation of two different 
platinum-GSH species in the reaction of oxaliplatin with GSH in water at 37°C 
after 18 h. 
Similar studies utilising Cys did not reveal the presence of any platinum-Cys 
adducts, which was unexpected in view of the GSH data.  The reaction with Cys 
was however found to be pH dependant as is shown in Figure 6.22 where 50% of 
the oxaliplatin was depleted by Cys at pH 6.0 vs.  100% depletion at pH 7.5 
(T=18 h).  The pKa value for the thiol group of Cys is 8.33,141 and at a pH of 7.5 a 
small portion of the Cys may be present as the reactive thiolate anion.   
As shown in Figure 6.3, about 40% of the oxaliplatin had reacted 
(water/19.5 h/37ºC) with GMP.  Positive ion mass spectra of the GMP samples 
revealed the presence of two complexes at m/z654 and 1001.  These correlate 
with the structures [M-Ox+GMP-H]+ and [M-Ox+2GMP-H]+ respectively.  In a 
competitive binding assay with MGCG the preference of oxaliplatin for Met over 
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GMP is clearly demonstrated (Figure 6-22).   
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Figure 6-22:  Positive ion mode time lapse mass spectra denoting the reaction between 
oxaliplatin and an equimolar mixture of the challenge agents.  The dominant 
product at m/z456 can be attributed to the platinum-Met species [LPt+Met-
H]+. 
Extended monitoring of this reaction (64 h) did not indicate that the more 
thermodynamically stable GMP complex formed from the Met complex as would 
be expected based upon the drug reservoir hypothesis. 
The reaction profile (pH 7.4/100 mM NaCl/24ºC) obtained for the N-N oxalate - 
Yol25.1 correlated with oxaliplatin.  However the profiles for the N-S oxalates were 
vastly different.  Even though ionisation studies had indicated that these species 
were stable in aqueous solution (80ºC/60 h, Figure 4.14) they were rapidly 
depleted by Cys leading in all cases to the formation of the platinum – Cys product 
[LPt+Cys-H]+.  The data indicated that elevated pH alone was in part responsible 
for the depletion of J7.1 and that the presence of NaCl (100 mM) enhanced this 
degradation.  The addition of Cys, at this pH and salt content, resulted in complete 
depletion of the drug even before the first analysis could be made (T = 5 min).  
Figure 6.23a shows the chromatograms obtained for J7.1 at 4 different pH levels 
(6.0, 6.5, 7.0 and 7.5) after 18 h.  This is to be contrasted with data shown in 
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Figure 6.23b where NaCl (100 mM) is present in the reaction mixture. 
 
 
 
 
 
 
 
 
 
 
Figure 6-23: (a) (top) and (b) (bottom): Overlay of LC-UV chromatograms demonstrating 
the drop in concentration (J7.1) at pH levels 6.0, 6.5, 7.0 and 7.5 (6.23a).  The 
complete absence of sample is noted when NaCl (100 mM) is present in the 
same solutions (6.23b). 
LC-MS investigations into reactions of the AC active oxalate, Lt16.1, indicated the 
presence of platinum complexes with all 4 challenge agents.  Figure 6.24 shows 
the time lapse LC-MS chromatograms of Lt16.1 vs.  Cys (water/37ºC/18 h).  In 
these, the formation of the final product ([M-Ox+Cys-H]+ eluting at 6.55 min occurs 
after formation of an intermediate eluting at 5.43 min, thought to be [M+Cys+H]+.  
No such complexes have been shown with any of the compounds not having a 
bidendate N-S ligand.   
The analogous reaction of Lt16.1 with Met forms only one single complex viz. [M-
Ox+Met-H]+ (m/z560).  There is no indication of an intermediate as in the case of 
Cys.  The reaction with GSH (Figure 6.25) shows the formation of two complexes: 
[M+GSH+H]+ and [M-Ox+GSH-H]+, both eluting at 5.14 min.  These two species 
could not be separated under the conditions applied.  However after a reaction 
time of 90 min the concentration of these two species had decreased by more 
   
165 
than 75% and after 18 h no more platinum species are detected.  An excess of 
GSH (3.17 min) remained after 18 h.  A similar study by Liu et al.140 found that 
thiolate bridged complexes can be readily formed during the reaction of 
platinum(II) complexes and thiol containing ligands and that these high molecular 
mass polymeric species are difficult to characterise.  
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Figure 6-24:  Time lapse LC-MS chromatograms reflecting the reaction between Lt16.1 
and Cys in water at room temperature and at 37°C after 18 h.   
   
166 
 
 
RT: 0.00 - 15.00 SM: 7B 
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 
Time (min) 
0 
20 
40 
60 
80 
100 
0 
20 
40 
60 
80 
100 
0 
20 
40 
60 
80 
100 
 
0 
20 
40 
60 
80 
100 3.30 5.17 
8.65 
9.24 8.35 9.52 5.83 8.08 10.13 6.87 10.76 2.85 11.74 12.45 13.05 13.85 2.48 4.76 1.87 3.84 14.35 1.48 0.48 
3.33 
5.14 
8.71 8.80 2.87 
5.87 8.14 9.45 8.03 10.10 6.34 1.78 2.61 12.07 13.01 11.21 14.13 1.42 4.34 1.19 
3.33 
5.16 
2.87 5.86 8.78 6.35 2.61 9.12 1.84 8.12 9.77 7.86 7.24 1.55 4.83 13.59 14.35 4.28 10.17 12.68 10.85 11.94 0.59 
3.31 
2.83 1.86 1.68 11.91 0.80 14.41 10.10 13.24 12.41 9.06 11.53 4.29 7.12 7.99 4.93 5.74 8.26 6.67 
NL
: 2.66E7
Base Peak 
F:   MS 
Lt16_1gsh0H
r 
NL
: 2.38E7
Base Peak 
F:   MS 
lt16_1gsh0hr 
_061025162
956
NL
: 2.23E7
Base Peak 
F:   MS 
lt16_1gsh0hr 
_061025171
634
NL
: 1.67E7
Base Peak 
F:   MS 
lt16_1gsh0hr 
_061026084
127
Lt16.1 T=0min / RT 
Lt16.1 T=45min / RT 
Lt16.1 T=90min / RT 
Lt16.1 T=18h / 37ºC 
Lt16.1 
GSH 
[M-Ox+GSH-H] + and [M+GSH+H] + 
 
 
Figure 6-25:  Time lapse LC-MS chromatograms reflecting the reaction between Lt16.1 
and GSH in water at room temperature and at 37°C after 18 h. 
The reaction of Lt16.1 with GMP produced a number of platinum related species 
some of which included the purine group separate from the sugar phosphate.  The 
chromatograms showing progress of the reaction are depicted in Figure 6.26 
together with possible structures of the formed species (Figure 6.27). 
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Figure 6-26:  Time lapse LC-MS chromatograms (positive ion mode) reflecting the reaction 
between Lt16.1 and GMP in water at room temperature and at 37°C after 18 h.  
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Figure 6-27:  Possible structures for the ions detected in the reaction of Lt16.1 with GMP 
in water at 37°C after 18 h.  
6.4 .5 Group 5  binding assays  
This group consisting of platinum(IV) compounds included JM216 (satraplatin) and 
two novel complexes each having a chloro and a nitro group on the platinum z-axis 
(Figure 6.8).  Of these two, Mar4.1.4 has shown considerable promise in cell line 
tests, outperforming its congener oxaliplatin on all three of the cell lines tested (HeLa, 
HT29 and MCF7).  Reaction of JM216 (37ºC/45 h) with GSH showed only a 30 and 
15% drop in concentration (water and buffer pH 7.0 respectively).  No platinum 
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related products were detected.  The reduction of the trans analogue of JM216 (trans, 
cis, cis – Pt(NH3)(c-C6H11NH2)Cl2(OOCCH3)2) and the oxidation of GSH to GSSG 
was noted by Reedijk et al. under similar conditions.142  The stability of JM216 in 
water is known and this property had been ascribed to the higher oxidation state of 
the platinum.  It was thus unexpected that both of the novel platinum(IV) compounds 
showed significant interaction with some of the challenge molecules as well as a 
difference in behaviour to that of JM216. 
Under elevated pH conditions (24ºC/18 h) Yol25.1.4 was reduced to Yol25.1.  This 
reduction, which was more extensive with increasing pH (7.5 > 7.0 > 6.5 > 6.0), was 
not influenced by the addition of NaCl (100 mM).  The addition of Cys however had a 
dramatic effect and brought about a much more rapid reduction.  Figure 6.28a and 
Figure 6.28b show the chromatograms obtained for the reactions of Yol25.1.4 in 
buffer solutions with NaCl (a) and with NaCl and Cys (b) shortly after preparation. 
 
 
 
 
 
 
 
 
Figure 6-28: (a) (top) and (b) (bottom): Overlay of LC-UV chromatograms demonstrating 
the drop in concentration (Yol25.1.4) at pH levels 6.0, 6.5, 7.0 and 7.5 (6.28a).  
Under similar conditions but in the presence of Cys, the rate of the reduction 
is increased (6.28b). 
In contrast to Yol25.1.4, sample Mar4.1.4 was shown to be stable at the tested pH 
ranges for >18 h.  This observation can be rationalised by comparing the two 
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ligands.  Both compounds have bidendate diamine ligands but in the case of 
Yol25.1.4 a six membered chelate ring is formed while Mar4.1.4 forms the more 
stable 5 membered ring with platinum.  The ligand associated with Yol25.1.4 also 
contains other electron withdrawing moieties such as the imidazole ring and the 
carboxylate group, decreasing the electron density of the amine donors.  In 
contrast to this, the donor amines of the dach group of Mar4.1.4 experience a 
positive inductive effect, increasing the electron density on the donors, thus 
stabilising the platinum(IV) complex.   
Upon addition of Cys to Mar4.1.4, a similar reduction pattern to that of Yol25.1.4 
was observed, with oxaliplatin being formed.  This is clearly demonstrated in 
Figure 6.29, where the positive ions attributed to Mar4.1.4 (m/z478 and 495) are 
completely replaced by those of oxaliplatin (m/z397).  This observation implies that 
the AC activity observed in the cell line tests may well be due to the in-situ 
formation of oxaliplatin from Mar4.1.4, and can thus be considered as an 
oxaliplatin prodrug.  
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Figure 6-29:  Positive ion mass spectra comparing Mar4.1.4 (water/37°C/18 h) in the 
absence (top) and presence (bottom) of Cys.  
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6.5  Binding assay conclusions 
The currently applied dosage regimen for Eloxatin™ (oxaliplatin) can result in a 
maximum plasma concentration of 76 µM (85 mg/m2 dose applied to a 70 kg 
individual with a total blood volume of 5 l over a 3 h period).143 For reasons stated 
in sections 6.2 and 6.3 the oxaliplatin concentration will never be quite as high. 
Even at half this concentration, an intercellular ratio of approximately 1:1 to the 
endogenous challenge agents at average concentrations12,130 is realised. This 
ratio differs from that of the utilised test scenario where the ratio was 2:1 in favour 
of the challenge agents. The intracellular ratio is expected to further favour the 
challenge agents as diffusion of the platinum compound (active or passive) has to 
occur and intracellular thiol concentrations are higher (GSH – 10 mM vs. 20 µM). 
For this reason a fixed ratio of 2:1 was used for all tests conducted. A more 
accurate indication could have been obtained through the utilisation of plasma or 
even whole blood samples. However this was beyond the scope of the current 
study.   
As stated at the outset of this study a structure activity relationship was sought 
and to this end certain relationships were noted - albeit with the very simplified 
physiological model described.  
The first observation was that platinum – Cys derivatives were not readily formed. 
In fact such adducts were only readily and rapidly formed, especially at pH 7.4, in 
platinum complexes with bidendate N-S ligands. These derivatives formed so 
efficiently that the complex non leaving group had little effect in retarding the 
irreversible complexation with the thiol. Thus Pt(N-S)ox complexation was as 
extensive as that of Pt(N-S)Cl2 . This finding is attributed to the trans effect of the 
thioether in the ligand weakening the trans platinum – oxygen bond. The only 
other confirmation of formation of a platinum(II) – thiol bond was found for the 
complexes formed between oxaliplatin and GSH (Figure 6.21). No evidence of 
platinum(IV) – thiol bond formation was observed.  
Another interesting finding was the instability of the Pt(N-S)ox complexes at 
physiological pH and especially in the presence of NaCl (100 mM) as 
demonstrated in Figure 6.23a and 6.23b. These compounds had been found to be 
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stable in water at 80ºC for 18 h and the rapid drop in concentration at room 
temperature under these conditions was unexpected.  
Reduction of the tested platinum(IV) compounds without formation of thiol 
derivatives was a welcome finding, especially as this reduction led to the formation 
of a known AC agent in the case of Mar4.1.4. In this modality the thiol reducers 
now facilitate reduction of the prodrug with the subsequent formation of the active 
species. 
The use of binding assays, have thus helped elucidate some basic questions as to 
why certain platinum complexes have performed better than others in cell line 
assays. In future, further studies will be undertaken to elaborate on the currently 
applied model and make it more representative of the actual physiological 
conditions.  
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Chapter 7:   
Conclusions 
(i) The application of mass spectral and chromatographic methods have 
been applied to elucidate the chemistry involved in two novel processes 
used to synthesise oxaliplatin. 
(a)  The formation of an autoionised species, viz. (Ptdach2)2+Ptox22- 
could be shown in the synthesis whereas common analytical 
methods failed to do so. 
(b) A reaction mechanism, that included the role of small amounts 
of water in each of the two essentially non-aqueous synthetic 
methods used for the second novel synthetic process for 
oxaliplatin, was proposed.  
(c) The reaction rates at different temperatures could be obtained 
which greatly facilitated the understanding of the chemistry 
involved, indicating how ligand exchange could be facilitated 
without hydrolysis and reduction of the platinum(II). 
(ii) In the novel Pt(N-S)X2 and Pt(N-S)ox chelate complexes the analytical 
methods were applied. 
(a) The data revealed how the trans effect of the S-atom in Pt(N-
S)X2 led to greatly increased ionisation of the halide ions as 
compared to the Pt(N-N)X2 analogues.  
(b) The data enabled the study not only of the ionisation of the 
molecular species but also those of the monocationic species.  
This suggested why these compounds are ineffective as 
anticancer agents.  
(c) The application of EV-CAD studies illustrated the relative bond 
strength of Pt(N-S)X2 complexes.  The data also illustrated the 
difference between thermodynamics and kinetics – since the 
least stable (iodo complexes) were the most stable kinetically 
(slowest ligand exchange).  
(iii) In the study of the mononitroplatinum(IV) complexes the combination of 
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the two analytical methods showed how the PtLCl2 (L=ligand) produced 
numerous products which greatly complicated purification of the 
required mononitroplatinum(IV)-trichloro species.  In the case of the 
PtLox (L=ligand) reaction with NO2 the required platinum(IV) complex 
could be obtained in high purity.  
(iv) The application of these techniques to binding studies of S-containing 
biomolecules with platinum anticancer agents resulted in generalities 
which seem to be significant in anticancer action. 
(a) Cys-derivatives were only readily and rapidly formed with Pt(N-
S)Cl2.  The Pt(N-S)ox species which are kinetically stable 
towards water even at 80°C also formed complexes like their 
chloro analogues in contact with Cys, especially in the presence 
of NaCl at pH 7.4. 
(b) Reduction of platinum(IV) compounds occurs readily in the 
presence of thiol derivatives, e.g. Mar4.1.4 is readily reduced to 
oxaliplatin.  
(c) Dicarboxylic anions which were screened, like malonate in the 
case of carboplatin, are surprisingly inert towards bioderivatives 
of thiols.  
 
   
174 
References 
    
 
1
  Du Preez, J.G.H.  Platinum(II) Complexes, Preparation and Use, Platco Technologies 
(Pty) Ltd.  Patent WO2005/051966  (2005).  
2
  Du Preez, J.G.H.  Preparation of Platinum(II) Complexes, Platco Technologies (Pty) 
Ltd. Patent WO06024897 (2006). 
3
   Du Preez, J.G.H.  Preparation of Platinum(II) Complexes, Platco Technologies (Pty) 
Ltd. Patent (141088pct) (2007). 
4
   Diamandopoulus G.T. Cancer: An historical perspective.Anticancer Res 1996, 
16:1595-1602. 
5
  World Health Organization: Cancer. http://www.who.int/cancer/en/ (accessed January 
2007). 
6
  Jakupec, M.A.; Galanski, M.; Keppler, B.K.; Tumour-inhibiting Platinum Complexes-
State of the Art and Future Perspectives. Rev. Physiol. Biochem. Pharmacol.  2003, 
146, 1-53. 
7
  Kauffman, G.B.; Cowan, D.O., cis- and trans-Dichlorodiammineplatinum(II). In 
Inorganic Syntheses; Kleinberg, J., Ed.in Chief; McGraw-Hill Book Co., Inc.: New York, 
1963, 7, 239-244. 
8
  McAuliffe, C.A., Sharma, H.L.; Tinker, N.D. Cancer Chemotherapy Involving Platinum 
and Other Platinum Group Complexes. In: Chemistry of the Platinum Group Metals–
Recent Developments; Hartley F.R., Ed.; Elsevier: New York, 1991; 546-593. 
9
  Desoize, B.; Madoulet, C. Particular Aspects of Platinum Compounds Used at Present 
in Cancer Treatment. Crit. Rev. in Onc./ Hem. 2002, 42, 317-325. 
10
  Rosenberg, B.; Van Camp, L; Krigas, T. Inhibition of Cell Division in Eschericia coli by 
Electrolysis Products from a Platinum Electrode. Nature 1965, 205, 698-699. 
11
 Rosenberg, B.; Van Camp, L; Trosko, J. E.; Mansour, V. H. Platinum Compounds: a 
 New Class of Potent Antitumor Agents.  Nature 1969, 222, 385-386. 
12
  Fuertes, M. A.; Castilla, J.; Alonso, C. and Perez, J. M. Novel Concepts in the 
Development of Antitumor Drugs. Curr. Med. Chem. – Anti Cancer Agents, 2002, 2, 
539-551. 
13
  Online Medical Dictionary:  www.cancerweb.ncl.ac.uk/cgi-
bin/omd?action=Home&query= (accessed June 2007) 
14
  Reedijk, J. Why Does Cisplatin Reach Guanine-N7 with Competing S-donor Ligands 
Available in the Cell? Chem. Rev., 1999, 2499-2510. 
15
  Farrell, N.; Qu, Y.; Bierbach, U.; Valsecchi, M.; Menta, E. Structure-Activity 
   
175 
 
Relationships within Di- and Trinuclear Platinum Phase-I Clinical Anticancer Agents. In 
Cisplatin. Chemistry and Biochemistry of a Leading Anticancer Drug; Lippert, B., Ed.; 
Verlag Helvetica Chimica Acta: Zurich; Wiley-VCH: Weinheim, 1999; 479-496. 
16
  Reedijk, J. Improved Understanding in Platinum Antitumour Chemistry. Chem. 
Commun. 1996, 801-806. 
17
  Pil, P., Lippard, S. J. In Encyclopedia of Cancer, J. R. Bertino, Ed. Academic Press: 
San Diego, CA, 1997, Vol. 1, pp. 392-410. 
18
  Kelland, L.R.; Sharp, S.Y.; O’Neill, C.F.; Raynaud, F.I.; Beale, P.J.; Judson, I.R. 
 Mini-review: Discovery and Development of Platinum Complexes Designed to 
 Circumvent Cisplatin Resistance. J. Inorg. Biochem. 1999, 77, 111-115. 
19
  Cleare, M.J.; & Hoeschele, J.D. Studies on the Antitumor Activity of Group VIII 
Transition Metal complexes. Part 1. Platinum Complexes. Bioinorg. Chem. 1973; 2, 
197-210. 
20
  Cleare, M.J.; & Hoeschele, J.D. Antitumor Platinum Compounds. Relation Between 
Structure and Activity. Plat. Met. Rev. 1973; 17, 2-13. 
21
  Radulovic, S.; Testic, Z.; Manic, S. Trans-platinum Complexes as Anticancer Drugs: 
Recent Developments & Future Prospects. Curr. Med. Chem. 2002, 9, 1611-1618. 
22
  Giandomenico , C.M.; Abrams, M.J.; Murrer, B.A.; Vollano, J.F.; Barnard, C.F.J.; 
Harrap, K.R.; Goddard, P.M.; Kelland, L.R.; Morgan, S.E. Synthesis and Reactions of a 
New Class of Orally Active Pt(IV) Antitumor Complexes. In: Platinum and other metal 
coordination complexes in cancer chemotherapy, 1st Ed.; Howell, S.B., Ed.; Plenum 
Press: New York, 1991; 93-100. 
23
  Farrell, N. Polynuclear Charged Platinum Compounds as a New Class of Anticancer 
Agents. In: Platinum-Based Drugs in Cancer Chemotherapy. Kelland, L.R.; Farrell, 
N.P., Eds.; Humana Press Inc.: Totawa, NJ, 2000; 321-338. 
24
  Galanski, M.; Arion, V. B.; Jakupec, M. A. and Keppler, B. K. Recent Developments in 
the Field of Tumor-Inhibiting Metal Complexes. Current Pharmaceutical Design, 2003, 
9, 2078-2089. 
25
  Radulovic, S.; Testic, Z.; Manic, S. Trans-platinum Complexes as Anticancer Drugs: 
Recent Developments & Future Prospects. Curr. Med. Chem. 2002, 9, 1611-1618. 
26
  Bierbach, U.; Qu, Y.; Hambley, T.W.; Peroutka, J.; Nguyen, H.L.; Doedee, M.; Farrell, 
N. Synthesis, Structure, Biological Activity, and DNA Binding of Platinum(II)complexes 
of the type trans-[PtCl2(NH3)L] (L=planar nitrogen base). Effect of L and Cis/Trans 
Isomerism on Sequence Specificity and Unwinding Properties Observed in Globally 
Platinated DNA. Inorg. Chem. 1999, 38, 3535-3542. 
   
176 
 
27
  Coluccia, M.; Boccarelli, A.; Mariggio, M.A.; Cardellicchio, N.; Caputo, P.; Intini, F.P.; 
Natile, G. Platinum(II) Complexes Containing Iminoethers: A Trans Platinum Antitumor 
Agent. Chem. Biol. Int. 1995, 98, 251-266. 
28
  Montero, E.I.; Diaz, S.;Gonzalez-Vadillo, A.M.; Perez, J.M.; Alonso, C.; Navarso-
Ranninger, C. Preparation and Characterisation of Novel Trans-
[PtCl2(amine)(isopropylamine)] compounds: Cytotoxic Activity and Apoptosis Induction 
in ras-Transformed Cells. J. Med. Chem. 1999, 42, 4264-4268. 
29
  Hambley, T.W. The Influence of Structure on the Activity and Toxicity of Pt Anti-cancer 
Drugs. Coord. Chem. Rev. 1997, 166, 181-223. 
30
 Yoshida, M.; Khokar, A.R.; Siddik, Z.H. Axial Ligands and Alicyclic Ring Size Modulate 
the Activity and Biochemical Pharmacology of Ammine/ Cycloalkylamine-Platinum(IV) 
Complexes in Tumor Cells Resistant to cis-Diamminedichloroplatinum(II) or trans-
1R,2R-1S,2S-Diaminocyclohexanetetrachloroplatinum(IV). Cancer Res. 1994, 54, 
4691-4697. 
31
  Scheeff, E.D., Briggs, J.M., Howell, S.B. Molecular Modelling of the Intrastrand 
Guanine-Guanine DNA Adducts Produced by Cisplatin and Oxaliplatin. Mol. 
Pharmacol. 1999, 56, 633-643. 
32
  DiFrancesco, A.M.; Ruggiero, A.; Riccardi, R. Cellular and Molecular Aspects of Drugs 
of the Future: Oxaliplatin. Cell. Mol. Life Sci. 2002, 59, 1914-1927. 
33
  Woynarowski, J.M.; Faivre, S.; Herzig, M.C.; Arnett, B.; Chapman, W.G.; Trevino, A.V.; 
Raymond, E.; Chaney, S.G.; Vaisman, A.; Varchenko, M.; Juniewicz, P.E. Oxaliplatin-
Induced Damage of Cellular DNA. Mol. Pharmacol. 2000, 58, 920-927. 
34
  Yamada, M.; O’Regan, E.; Brown, R.; Karran, P. Selective Recognition of a Cisplatin-
DNA Adduct by Human Mismatch Repair Proteins. Nucl. Acid. Res. 1997, 25, 491-495. 
35
  Vaisman, A.; Varchenko, M.; Umar, A.; Kunkel, T.A.; Risinger, J.I.; Barrett, J.C.; 
Hamilton, T.C.; Chaney, S.G. The Role of hMLH1, hMSH3, and hMSH6 Defects in 
Cisplatin and Oxaliplatin Resistance: Correlation with Replicative Bypass of Platinum-
DNA Adducts. Cancer Res. 1998, 58, 3579-3585. 
36
  Chen, Y.; Guo, Z.; Parkinson, J.A.; Sadler, P.J. Kinetic Control of Reactions of a 
Sterically Hindered Platinum Picoline Anticancer Complex with Guanosine 5’-
monophosphate and Glutathione. J. Chem. Soc., Dalton Trans. 1998, 3577-3585. 
37
  Wong, E.; Giandomenico, C.M. Current Status of Platinum-based Antitumor Drugs. 
Chem. Rev. 1999, 99, 2451-2466. 
38
  Dedon, P.C.; Borch, R.F. Characterisation of the Reactions of Platinum Antitumor 
Agents with Biologic and Nonbiologic Sulfur-containing Nucleophiles. Biochem. 
   
177 
 
Pharmacol. 1986, 36, 1955-1964. 
39
  Tobe, M.L. Substitution at Four-coordinate Planar Reaction Centres. In Inorganic 
Reaction Mechanisms, 1st Ed; Thomas Nelson & Sons LTD: London, 1972; 42-68. 
40
  Knox, R.J.; Friedlos, F.; Lydall, D.A.; Roberts, J.J. Mechanism of Cytotoxicity of 
Anticancer Platinum Drugs: Evidence that cis-Diamminedichloroplatinum(II) and cis-
Diammine(1,1-cyclobutanedicarboxylato)platinum(II)  Differ Only in the Kinetics of 
Their Interaction with DNA. Cancer Res. 1986, 46, 1972-1979. 
41
  Johnson, N. P.; Butour, J. L.; Villani, G.; Wimmer, F. L.; Defais, M; Pierson, V. and 
Brabec, V. Metal antitumor compounds: the mechanism of action of platinum 
complexes. Prog. Clin. Biochem. Med. 1998, 10, 1-24. 
42
  Arpalahti, J. Reactivity and Inertness of Pt-Nucleobase Complexes. In Cisplatin. 
Chemistry and Biochemistry of a Leading Anticancer Drug; Lippert, B., Ed; Verlag 
Helvetica Chimica Acta: Zurich; Wiley-VCH: Weinheim, 1999; 207-209. 
43
  Lippert, B. Platinum Nucleobase Chemistry. In Progress in Inorganic Chemistry;  
Lippard, S.J., Ed.; John Wiley & Sons: New York, 1989; Vol. 37, 13-15. 
44
  Jaganath, Y. Non-classical Platinum Anticancer Complexes. Master’s Dissertation, 
Port Elizabeth: Nelson Mandela Metropolitan University, 2005. 
45
  Reedijk, J. The Relevance of Hydrogen Bonding in the Mechanism of Action of 
Platinum Antitumor Compounds.  Inorg. Chim. Acta 1992, 198-200, 873-881. 
46
  Martin, R.B. Nucleoside Sites for Transition Metal Ion Binding. Acc. Chem. Res. 1985, 
18, 32-38. 
47
  Martin, R.B. Dichotomy of Metal Ion Binding to N1 and N7 of Purines. Metal Ions Biol. 
Syst. 1996, 32, 61-89. 
48
  Martin, R.B. Platinum Complexes: Hydrolysis and Binding to N(7) and N(1) of Purines. 
In Cisplatin. Chemistry and Biochemistry of a Leading Anticancer Drug; Lippert, B., Ed; 
Verlag Helvetica Chimica Acta: Zurich; Wiley-VCH: Weinheim, 1999; 196-204. 
49
  Bierbach, U.; Roberts, J.D.; Farrell, N. Modifications of Platinum(II) Antitumor 
Complexes with Sulfur Ligands.2. Reactivity and Nucleotide Binding Properties of 
Cationic Complexes of the Types [PtCl(diamine)(L)]NO3 and [{PtCl(diamine)}2(L-
L)](NO3)2 (L=monofunctional thiourea derivative; L-L= bifunctional thiourea derivative) 
in Relation to the Cytotoxicity. Inorg. Chem. 1998, 37, 717-723. 
50
  Soldatovic, T and Bugarcic, Z.D. Study of the reactions between platinum(II) 
complexes and L-methionine in the presence and absence of 5-GMP. J. Inorg. 
Biochem.  2005, 99, 1472–1479. 
51
  Reedijk, J., Teuben, J.M. Platinum-sulfur Interactions Involved in Antitumor Drugs, 
   
178 
 
Rescue Agents and Biomolecules. In Cisplatin. Chemistry and Biochemistry of a 
Leading Anticancer Drug; Lippert, B., Ed; Verlag Helvetica Chimica Acta: Zurich; 
Wiley-VCH: Weinheim, 1999, 204-105. 
52
  Jamieson, E.R.; Lippard, S.J. Structure, Recognition, and Processing of Cisplatin-DNA 
Adducts. Chem. Rev. 1999, 99, 2467-2498. 
53
  Huang, H.; Woo, J.; Alley, S.C.; Hopkins, P.B. DNA-DNA Interstrand Cross-linking by 
cis-Diamminedichloroplatinum(II): N7(dG)-to-N7(dG) Cross-linking at 5’-d(GC) in 
Synthetic Oligonucleotides. Bioorg. Med. Chem. 1995, 3, 659-669 
54
  Farrell, N. DNA Binding and Chemistry of Dinuclear Platinum Complexes. Comm. 
Inorg. Chem. 1995, 16, 373-389. 
55
  Kasparkova, J.; Vrana, O.; Farrell, N. and Brabec, V. Effect of the geometry of the 
central coordination sphere in antitumor trinuclear platinum complexes on DNA 
binding. J. Inorg. Biochem. 2004, 98, 1560-1569. 
56
  Turkson J, Zhang S, Palmer J, Kay H, Stanko J, Mora LB, Sebti S, Yu H, Jove R. 
Inhibition of constitutive signal transducer and activator of transcription 3 activation by 
novel platinum complexes with potent antitumor activity. Mol. Cancer. Ther. 2004, 3, 
1533-42. 
57
  Turkson J, Zhang S, Mora LB, Burns A, Sebti S, Jove R. A novel platinum compound 
inhibits constitutive Stat3 signaling and induces cell cycle arrest and apoptosis of 
malignant cells. J. Biol. Chem. 2005, 280, 32979-88. 
58
  Wikipedia, the free encyclopaedia: JAK-STAT signalling pathway.  
http://en.wikipedia.org/wiki/JAK-STAT_signaling_pathway (accessed January 2007). 
59
  Yu, H. and Jove, R. The STATS of cancer-new molecular targets come of age. Nat. 
Rev. Cancer. 2004, 4, 97-105. 
60
  Niu, G., et al. Role of Stat3 in Regulating p53 Expression and Function. Mol. Cell. Biol., 
2005, 25, 7432-7440. 
61
  Niu, G., et al. Constitutive Stat3 activity up-regulates VEGF expression and tumor 
angiogenesis. Oncogene. 2002, 21, 2000-8. 
62
  Diaz, N. et al., Activation of Stat3 in Primary Tumors from High-Risk Breast Cancer 
Patients Is Associated with Elevated Levels of Activated Src and Survivin Expression. 
Clin. Cancer Res. 2006, 12, 20-28. 
63
  Kelland, L.R.; Mistry, P.; Abel, G.; Loh, S.Y.; O’Neill, C.F.; Murrer, B.A.; Harrap, K.R. 
Mechanism-related Circumvention of Acquired cis-Diamminedichloroplatinum(II) 
Resistance Using Two Pairs of Human Ovarian Carcinoma Cell lines by Ammine/ 
Amine Platinum(II) Dicarboxylates. Cancer Res. 1992, 52, 3857-3864. 
   
179 
 
64
  Zutphen, S. and Reedijk, J. Targeting platinum anti-tumour drugs: Overview of 
strategies employed to reduce systemic toxicity. Coord. Chem. Rev. 2005, 249, 2845-
2853. 
65
  Vail, D.M. et al., STEALTH liposome-encapsulated cisplatin (SPI-77) versus 
carboplatin as adjuvant therapy for spontaneously arising osteosarcoma (OSA) in the 
dog: a randomized multicenter clinical trial. Can. Chemother. Pharmacol.  2002, 50, 
131-136. 
66
  Boulikas, T. Low toxicity and anticancer activity of a novel liposomal cisplatin 
(Lipoplatin) in mouse xenografts. Oncol. Rep. 2004, 12, 3-12. 
67
  Paschke, R. et al., Cholic acid–carboplatin compounds (CarboChAPt) as models for 
specific drug delivery: synthesis of novel carboplatin analogous derivatives and 
comparison of the cytotoxic properties with corresponding cisplatin compounds. J. 
Inorg. Biochem, 2003, 94, 335-342. 
68
  Tromp, R.A. et al.,  The b-glucuronyl-based prodrug strategy allows for its application 
on b-glucuronyl-platinum conjugates. Med. Chem. Lett. 2004, 14, 4273-4276. 
69
  Farrell, N., Almeida, S. and Yun, Q. Complex salts of platinum with ethylenediamine 
and propanediamine [PtCl(diamine)L][PtCl3L] Inorg. Chim. Acta, 1990, 178, 209-211. 
70
  Cai, L.S. et al.  Synthesis and in vitro antitumor activity of oligonucleotide-tethered and 
related platinum complexes. J. Med. Chem. 2001, 44, 2959-2965. 
71
  C. Zimmer, K.E. Reinert, G. Luck, U. Wahnert, G. Lober and H. Thrum. Interaction of 
the oligopeptide antibiotics netropsin and distamycin A with nucleic acids. J. Mol. Biol. 
1971, 58, 329-348. 
72
  Stubbs, M. Veech, R.L. Griffiths, J.R. Tumor metabolism: The lessons of nuclear 
magnetic resonance spectroscopy. Adv. Enzyme Regul. 1995. 35, 101-115. 
73
  Stewart, D.J.  Mechanisms of resistance to cisplatin and carboplatin. Critical reviews in 
Oncology / Hematology. 2007, 63, 12-31. 
74
  Raghunand N, Gillies RJ. pH and drug resistance in tumors. Drug Resist. Update. 
2000, 3, 39-47. 
75
  Prescott, D.M. et al.  The relationship between intracellular and extracellular pH in 
spontaneous canine tumors. Clin. Cancer Res.  2000, 6, 2501-5. 
76
  Popovic, P. et al.,  Pressure-tuning infrared spectra of cisplatin sensitive and resistant 
human ovarian cancer cells exposed to cisplatin. Proc. Am. Assoc. Cancer Res. 1993, 
34, 404. 
77
  Popovic, P. et al., Membrane fluidity and lipids in cisplatin resistant cells with low 
cisplatin uptake. Proc. Am. Assoc. Cancer Res. 1994, 35, 440. 
   
180 
 
78
  Stewart, D.J. et al., Effect of cations on cisplatin uptake and efficacy in lung cancer cell 
lines. Proc. Am. Assoc. Cancer Res. 1995, 36, 399. 
79
  Higashimoto M, Kanzaki A, Shimakawa T, et al. Expression of copper-transporting P-
type adenosine triphosphatase in human esophageal carcinoma. Int. J. Mol. Med. 2003, 
11, 337-41. 
80
  Miyashita H, Nitta Y, Mori S, et al. Expression of copper-transporting P-type adenosine 
triphosphatase (ATP7B) as a chemoresistance marker in human oral squamous cell 
carcinoma treated with cisplatin. Oral Oncol.  2003, 39, 157-62. 
81
 Perego P, et al. Ovarian cancer cisplatin resistant cell lines: multiple changes including 
collateral sensitivity to Taxol. Ann. Oncol. 1998, 9,  423-30. 
82
  Masters, J.R. et al., Sensitivity of testis tumour cells to chemotherapeutic drugs: role of 
detoxifying pathways. Eur. J. Cancer.  1996, 32A, 1248-53. 
83
  Fokkema, E., Groen, H.J., Helder M.N., de Vries E.G., Meijer C. JM216-, JM118-, and 
cisplatin-induced cytotoxicity in relation to platinum–DNA adduct formation, glutathione 
levels and p53 status in human tumour cell lines with different sensitivities to cisplatin. 
Biochem. Pharmacol. 2002, 63, 1989-96. 
84
  Bose Girigoswami K, Bhaumik G, Ghosh R. Induced resistance in cells exposed to 
repeated low doses of H2O2 involves enhanced activity of antioxidant enzymes. Cell. 
Biol. Int.  2005, 29, 761-7. 
85
  Byun, S.S., Kim, S.W., Choi, H., Lee, C., Lee, E. Augmentation of cisplatin sensitivity in 
cisplatin-resistant human bladder cancer cells by modulating glutathione 
concentrations and glutathione-related enzyme activities.  BJU Int. 2005, 95, 1086-90. 
86
  Siddik Z.H. Cisplatin: mode of cytotoxic action and molecular basis of resistance. 
Oncogene 2003, 22, 7265-79. 
87
  Reed E. Platinum–DNA adduct, nucleotide excision repair and platinum based anti-
cancer chemotherapy. Cancer Treat. Rev. 1998, 24, 331-44. 
88
  Dabholkar, M., Vionnet, J., Bostick-Bruton, F., Yu, J.J., Reed, E. Messenger RNA 
levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to 
platinum-based chemotherapy. J .Clin. Invest. 1994, 94, 703-8. 
89
  Dabholkar, M. et al., ERCC1 and ERCC2 expression in malignant tissues from ovarian 
cancer patients. J. Natl. Cancer Inst. 1992, 84, 1512-7. 
90
  Henderson, W. and McIndoe, J.S. Mass Spectrometry of Inorganic and Organometallic 
Compounds: Tools Techniques Tips, 1st Ed.; John Wiley & Sons, Inc.: New York, 2005; 
6-7. 
91
  Yamashita, M. and Fenn, J. B. J. Phys. Chem. 1984, 88, 4451-4671. 
   
181 
 
92
 Aleksandrov, M. L., Gall, L. N., Krasnov, V. N.; Nikolaev, V. I.; Pavlenko, V. A. and 
Shkurov, V. A. Dokl. Akad. Nauk. SSSR. 1984, 277, 379. 
93
  Dole, M.; Mack, L. L.; Hines, R. L.; Mobley, R. C.; Ferguson, L. D. and Alice, M. B. J. 
Chem. Phys. 1968, 49, 2240. 
94
  Jayaweera, P., Blades, A.T., Ikonomou, M.G. and Kebarle, P.J. J. Am. Chem. Soc. 
1990, 112, 2452-2453. 
95
  Blades, A.T., Jayaweera, P., Ikonomou, M.G. and Kebarle, P.J. Int. J. Mass Spectrom. 
Ion Processes 1990, 101, 325-336. 
96
  Blades, A. T., Jayaweera, P., Ikonomou, M.G. and Kebarle, P.J. Int. J. Mass Spectrom. 
Ion Processes 1990, 102, 251. 
97
  Blades, A.T., Jayaweera, P., Ikonomou, M.G. and Kebarle, P.J. J. Chem. Phys.  1990, 
92, 5900-5906. 
98
  Katta, V., Chowdhury. S.K. and Chait, B.T. J. Am. Chem. Soc. 1990, 112, 5348-5349. 
99
  Schaaff, T.G., Qu, Y., Farrel, N. and Wysocki, V.H. Investigation of the TRANS Effect 
in the Fragmentation of Dinuclear Platinum Complexes by Electrospray Ionisation 
Surface-induced Dissociation Tandem Mass Spectrometry. J. Mass Spectrom. 1998, 
33, 436-443. 
100
 Poon, G.K. and Mistry, P. Electrospray Ionisation Mass Spectrometry of Platinum 
Anticancer Agents. Biol. Mass Spectrom. 1991, 20, 687-92. 
101
 Thermo Electron Corp. CD. Center for Proteomics excellence 1438_CPE. 
102
 Paul, W.,  Reinhardt, H. and Zahn, V.Z. Z. Phys. 1959, 156, 1. 
103
 Bertani, R.; Seraglia, R.; Favretto, D.; Michelin, R. A.; Mozzon, M.; Sbovata, S. M. and 
Sassi, A. Electrospray mass spectrometry of Pt(II) amidine complexes of the type cis- 
and trans-[PtCl2{NH=C(R)NR’R”}2] and trans-[PtCl2(RCN){NH=C(R)NR’R”}] Inorg. 
Chim. Acta, 2003, 356, 357-364. 
104
 Cole, R. B. Electrospray Ionisation Mass Spectrometry: Fundamentals, Instrumentation 
& Applications, 1st Ed.; John Wiley & Sons, Inc.: New York, 1997; 6-7. 
105
 Siuzdak, G. Mass Spectrometry for Biotechnology, 1st Ed.; Academic Press. San 
Diego, 1996, 136-139. 
106
 Monographs: Oxaliplatin. European Pharmacopoeia. 2002, 4.4, 3491-3493. 
107
 Vidalis, J. The study of the coordination chemistry of platinum(II) to develop anticancer 
agents. Master’s Dissertation, Nelson Mandela Metropolitan University, 2004. 
108
 Bouwer, Y. The Development of Novel Pt(II) Anticancer Complexes.  Unpublished PhD 
Thesis, Nelson Mandela Metropolitan University, 2008. 
109
 Jaganath, Y. The Development of Platinum Coordination Complexes for Potential 
   
182 
 
Anticancer Agents.  Unpublished PhD Thesis, Nelson Mandela Metropolitan University, 
2008. 
110
 Miller, J.S. Electrochemical growth of Highly Conducting Inorganic Complexes.  
Science.  1976, 194,189. 
111
 Orts, J.M., Feliu, J.M, Aldaz, A, Clavilier J, and Rodes A. J. Electroanalytical Chem. 
1990, 281, 199-219. 
112Kidani, Y., Inagaki, Y. Cis-Platinum(II) Complex of Trans-ℓ-1,2- diaminocyclo-hexane. 
US4169846, October 2, (1979). 
113
 Nakanishi, C. et al., US5338874, August 16, (1994). 
114
 Okamoto, K. et al.  US5420319. May 30, (1995). 
115
 Ibrahim, H., Mauvernay, R-Y. US5716988, February 10, (1998). 
116
 Poon, G. K.; Raynaud, F. I.; Mistry, P.; Odell, D. E.; Kelland, L. R.; Harrap, K. R.; 
Barnard, C. F. J. and Murrer, B. A. Metabolic studies of an orally active anticancer drug 
by liquid chromatography – electrosopray ionisation mass spectrometry. J. Chrom. A, 
1995, 712, 61-66 
117
 Strickmann, D.B., Kung, A. and Keppler, B.K. Application of capillary Electrophoresis-
mass spectrometry for the investigation of the binding behavior of oxaliplatin to 5’-GMP 
in the presence of of the sulfur containing amino acid L-methionine. Electrophoresis 
2002, 23, 74-80. 
118
 Wang, X. and Guo, Z.  The role of sulfur in platinum anticancer chemotherapy, Anti-
cancer Agents in Med. Chem., 2007, 7, 19-34. 
119
 Zhang, L. et al., Modulation of the coordination environment of silver(I) in 
bis(diphenylphosphino)methane complexes by selection of heterocyclic thiolato ligands 
Inorg. Chim. Acta. 2003, 355, 49-56. 
120
 Liu, Q.; Wei, H.; Lin, J.; Zhu, L. and Guo, Z. Novel polynuclear platinum adducts 
detected during the reactions of [Pt(Met-S,N)Cl2] with γ-glutathione and L-cysteine. J. 
Inorg. Biochem. 2004, 98, 702-712. 
121
 Van Kralingen, C.G., de Ridder, J.K. and Reedijk. Coordination compounds of Pt(II) 
and Pd(II) with imidazole as ligand. New synthetic procedures and characterization. J. 
Inorg. Chim. Acta. 1979, 36, 69-77. 
122
 Kay, H., Palmer, J.W. Stanko, J.A. and Sebtis, S.M.. U.S. 20050288365. January 6, 
(2005).  
123
 Turkson, J., Jove, R., Palmer, J.W., Kay, H. and Hua, Y. WO/2005/023824.  March 17, 
(2005).  
124Lanina, S.A.et al.  Reversed-phase high-performance liquid chromatographic method 
   
183 
 
using a pentafluorophenyl bonded phase for analysis of tocopherols. J. Chrom A. 1994, 
1, 75-80. 
125
 Du Preez, J.G.H. US Provisional Application.  In process. Platco Technologies (Pty) 
Ltd. June 18, (2007).  
126
 Allain, P., Heudi, O., Cailleux, A., Le Bouil, A., Larra, F., Boisdron-Celle, M and 
Gameli, E. Early biotransformations of Oxaliplatin after its intravenous administration to 
cancer patients. DMD 2000, 28, 1379-1384. 
127
 Esteban-Fernandez, D. et al.,, SEC-ICP-MS and ESI-MS as tools to study the 
interaction between cisplatin and cytosolic biomolecules. J. Anal. At. Spectrom., 2007, 
22, 1113-1121. 
128
 Peleg-Schulman, T. Najajreh, Y and Gibson, D. Interactions of cisplatin and transplatin 
with proteins. Comparison of binding kinetics, binding sites and reactivity of the Pt-
protein adducts of cisplatin and transplatin towards biological nucleophiles. J. Inorg. 
Biochemistry. 2002, 91, 306-311. 
129
 Barnham, K.J. et al. Ring-Opened Adducts of the Anticancer Drug Carboplatin with 
Sulfur Amino Acids. Inorg Chem. 1996, 35, 1065-1072. 
130
 Soldatovic, T. and Bugarcic, Z.D. Study of the reactions between platinum(II) 
complexes and L-methionine in the presence and absence of 5-GMP. J. Inorg. 
Biochem,   2005, 99, 1472-1479. 
131
 Snygg, Å, S., Hung, M. and Elmroth, S.K.C . The polyamines spermidine and spermine 
retard the platination rate of single-stranded DNA oligomers and plasmids. J. Inorg. 
Biochem., 2007, 101, 1153-1164 
132Kung, A.; Strickmann, D. B.; Galanski, M. and Keppler, B. K. Comparison of the binding 
behavior of oxaliplatin, Cisplatin and analogues to 5’-GMP in the presence of sulfur-
containing molecules by means of capillary electrophoresis and electrospray mass 
spectrometry. J. Inorg. Biochem. 2001, 86, 691-698 
133 Hagemeister, T and Linscheid, M. Mass spectrometry of cis-diamminedichloro-
platinum(II) adducts with the dinucleosidemonophosphates d(ApG), d(GpG) and 
d(TpC) in an ion trap. J. Mass Spectrom.  2002, 37, 731-747. 
134
 A. Küng et al., Reaction of (SP-4-2)-dichlorobis(2-hydroxyethylamine)platinum(II)with 
5’-GMP under simulated physiological conditions, a CZE-ESIMS study. Inorg. Chim. 
Acta.  2002, 339, 9 -13. 
135
 Kurosaki, H.; Yamakawa, N.; Sumimoto, M.; Kimura, K. and Goto, M. Interaction of 
Binuclear Xylylthiolato(2,2’,2’-terpyridine)platinum(II) Complexes with DNA. Bioorg. 
Med. Chem. Lett. 2003, 13, 825-828. 
   
184 
 
136
 Moradell, S.; Lorenzo, J.; Rovira, A.; Robillard, M. S.; Aviles, F. X.; Moreno, V. de 
Llorens, R.; Angeles Martinez, M.; Reedijk, J. and Llobet, A. Platinum complexes of 
diaminocarboxylic acids and their ethyl ester derivatives: the effect of the chelate ring 
size on antitumor activity and the interactions with GMP and DNA. J. Inorg. Biochem. 
2003, 96, 493-502. 
137
 Wan, K.X. and Gross, M.L. Gas-Phase Stability of Double Stranded 
Oligodeoxynucleotides and their Noncovalent Complexes with DNA-Binding Drugs As 
Revealed by Collisional Activation in an Ion Trap. J. Am. Soc. Mass Spectrom. 2000, 
11, 450-457. 
138
 Reyzer, M, L.; Brodbelt, J, S.; Kerwin, S, M. and Kumar, D. Evaluation of complexation 
of metal-mediated DNA-binding drugs to oligonucleotides via Electrospray ionisation 
mass spectrometry. Nucleic Acids Research, 2001, 29, 21 e103. 
139
 Zollner, P.; Zenker, A.; Galanski, M.; Keppler, B. K. and Linder, W. Reaction 
monitoring of platinum(II) complex-5’-guanosine monophosphate adduct formation by 
ion exchange liquid chromatography/electrospray ionisation mass spectrometry. J. 
Mass Spectrom. 2001, 36, 742-753. 
140
 Liu, Q., Wei, H., Lin, J., Zhu, L. and Guo, Z. Novel polynuclear platinum adducts 
detected during the reactions of [Pt(Met-S,N)Cl2] with γ-glutathione and L-cysteine. J. 
Inorg. Biochem. 2004, 98, 702-712. 
141
 Edsall, J.T., Wyman and Jeffries, Biophysical Chemistry. Academic Press, Inc., New 
York, 1958. 
142
 Talman, E, G. Bruning, W., Reedijk, J., Spek, A. L and Veldman, N. Crystal and 
molecular structures of asymmetric cis- and trans-Platinum(II/IV) Compounds and 
Their Reactions with DNA Fragments. Inorg. Chem. 1997, 36, 854-861. 
143
 Sanofi-Synthelabo Inc. Eloxatin (oxaliplatin) solution, concentrate label. Manufactured 
for Sanofi-Synthelabo Inc. by Ben Venue Laboratories Bedford, OH 44146-0568. 
Printed in USA. Rev. May 2005. 
